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“The endless questioning finally ended.  
My psychiatrist looked at me, there was no uncertainty in his voice.  
“Manic-depressive illness.” I admired his bluntness. I wished him locusts on his 
lands and a pox upon his house. Silent, unbelievable rage.  
I smiled pleasantly. He smiled back.  
The war had just begun.” 
 
Kay Redfield Jamison 
“An Unquiet Mind” (1995) 
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Abstract 
 
Petri Arvilommi. Treatment, Adherence, and Disability in Bipolar Disorder. 
 
This study is part of a collaborative bipolar research project between the Unit of 
Mental Health of the National Institute for Health and Welfare, Helsinki (the 
former Department of Mental Health and Alcohol Research of the National Public 
Health Institute, Helsinki) and the Department of Psychiatry, Jorvi Hospital, 
Helsinki University Central Hospital (HUCH), Espoo, Finland. The Jorvi Bipolar 
Study (JoBS) is a prospective, naturalistic cohort study of 191 secondary-level care 
psychiatric in- and outpatients with a new episode of DSM-IV bipolar disorder 
(BD). 
Overall, the study involved screening 1,630 adult patients (aged 18-59 years) 
using the Mood Disorder Questionnaire (MDQ) for symptoms of bipolar disorder 
in the Department of Psychiatry, Jorvi Hospital, from January 1, 2002, to 
February 28, 2003, for a possible new episode of bipolar disorder. A clinical 
diagnosis of ICD-10 schizophrenia was an exclusion criterion for screening. The 
490 consenting patients were interviewed with a semi-structured interview (SCID-
I/P). Thereby, 191 patients were diagnosed with an acute phase of DSM-IV BD and 
included in the study.  
The patients participating were interviewed again 6 and 18 months after 
baseline.  The course of the disease, with timing and durations of different phases, 
was examined by gathering all available data, which were then combined in the 
form of a graphical life chart. Observer- and self-reported scales were included at 
baseline and at both follow-up assessments. Also, the treatments provided were 
investigated at baseline and at both follow-up interviews.  
The aim in the first study was to investigate the adequacy of acute phase 
pharmacotherapy received by psychiatric in- and outpatients with a research 
diagnosis of BD I or BD II, including patients with and without a clinical diagnosis 
of BD. Information about treatments received during the index acute episode was 
gathered in the interview and from psychiatric records. Definitions of adequate 
acute-phase pharmacotherapy were based on published treatment guidelines. Only 
42% of all 191 patients and 65% of those diagnosed with bipolar disorder received 
adequate treatment for the acute index phase. Clinical diagnosis of bipolar 
disorder was the factor most strongly independently associated with adequate 
treatment. In addition, rapid cycling, polyphasic index episode, or depressive 
index phase independently predicted inadequate treatment. Outpatients received 
adequate treatment markedly less often than inpatients. Lack of attention to the 
longitudinal course of the illness was another major problem area of treatment. 
Next, our aim was to investigate the adequacy of the maintenance-phase 
pharmacotherapy received during the first maintenance phase after an acute 
episode, following the same patients as in the first study. We defined adequate 
maintenance-phase pharmacotherapy based on published treatment guidelines. Of 
5 
 
the patients with a maintenance phase in follow-up, adequate maintenance 
treatment was received by 75% for some time, but by only 61% throughout the 
maintenance phase and for 69% of the total maintenance time. Having adequate 
maintenance treatment throughout the maintenance phase was most strongly 
independently associated with having a clinical diagnosis of BD. In addition, 
inpatient treatment, rapid cycling, and not having a personality disorder predicted 
receiving adequate maintenance treatment throughout the maintenance phase. 
In addition, we investigated the continuity of attitudes toward and adherence 
to various types of psychopharmacological and psychosocial treatments among 
psychiatric in- and outpatients with BD I or II. During the 18-month follow-up, a 
quarter of the patients using mood stabilizers or atypical antipsychotics 
discontinued medication by their own decision, and of the medications continued, 
a third were not used regularly enough to provide a benefit. Overall, more than 
half of BD patients either discontinued pharmacotherapy or used it irregularly. 
The highest risk for discontinuing pharmacotherapy was present when the 
patients were depressed. Also, a quarter of the patients receiving psychosocial 
treatments did not adhere to the treatment. The main reasons patients gave for 
nonadherence toward pharmacological treatment were side-effects, lack of 
motivation, and a negative attitude toward the offered treatment; for 
individual/supportive psychotherapy, the reasons included practical barriers to 
coming to sessions and lack of motivation. Rates of nonadherence to mood 
stabilizers and antipsychotics did not differ, but the predictors did.  
Last, we investigated the prevalence and clinical factors predicting the 
granting of a long-term disability pension for patients with BD. We used register 
data to gather precise information on the pensions granted and their timing. 
During the 18-month follow-up after an acute episode, a quarter of the patients 
belonging to the labor force were granted a disability pension. Higher age, male 
gender, depressive index episode, comorbidity with generalized anxiety disorder 
(GAD) or avoidant personality disorder, and a higher number of psychiatric 
hospital treatments all independently predicted the granting of a disability 
pension. Moreover, patients’ subjective estimations of their vocational ability were 
surprisingly accurate in forecasting the granting of a future disability pension. In 
addition, the depression-related cumulative burden and the proportion of time 
spent in depression during the follow-up were important predictors. However, the 
predictors may vary depending on the subtype of illness, gender, and age group of 
the patient. 
 
Keywords:  bipolar disorder, treatment, maintenance, adherence, disability, 
disability pension 
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Tiivistelmä 
 
Petri Arvilommi. Treatment, Adherence, and Disability in Bipolar Disorder. 
 
Tämä tutkimus on osa Terveyden ja Hyvinvoinnin Laitoksen Mielenterveysyksikön 
ja Uudenmaan sairaanhoitopiirin Jorvin sairaalan psykiatrian tulosyksikön 
kaksisuuntaisen mielialahäiriön seurantatutkimusta (Jorvi Bipolar Study, JoBS), 
jossa seurattiin 191 ajankohtaisesta (DSM-IV) mielialajaksosta kärsivää 
psykiatrisen erikoissairaanhoidon avohoito- ja sairaalapotilasta. Tutkimusta 
varten Jorvin psykiatrisessa erikoissairaanhoidossa seulottiin 1.1.2002 alkaen 
28.2.2003 saakka 1630 potilasta (iältään 18-59 vuotta), kaksisuuntaisen 
mielialahäiriön oireiden suhteen. Kliininen ICD-10 skitsofreniadiagnoosi oli 
poissulkukriteeri seulontaan. Tutkimushaastatteluun suostui 490 potilasta, jotka 
haastateltiin puolistrukturoidulla haastattelumenetelmällä (SCID-I/P).   
Tutkimukseen otettiin 191 potilasta, joilla oli diagnosoitu akuutissa vaiheessa oleva 
kaksisuuntainen mielialahäiriö. 
Potilaat haastateltiin uudelleen 6- ja 18- kuukautta tutkimukseen ottamisen 
jälkeen. Taudin kulku, vaiheiden ajoitus ja kesto tutkittiin keräämällä kaikki 
käytettävissä oleva tieto, joka koottiin yksityiskohtaiseksi graafiseksi kuvaajaksi, 
oirekortiksi. Sekä alku- että seurantahaastatteluihin kuului tutkijan ja potilaan 
täyttämiä tutkimuslomakkeita. Myös määrätyt hoidot tutkittiin sekä alku- että 
seurantahaastatteluissa. 
Tutkimuksen ensimmäinen tavoite oli selvittää miten asianmukaista akuutin 
vaiheen lääkehoitoa saavat psykiatriset sairaala- ja avohoitopotilaat, joille on 
asetettu tutkimusdiagnoosiksi kaksisuuntainen mielialahäiriö tyyppi I tai II, 
mukaan lukien ne potilaat joilla ei ole kliinistä kaksisuuntaisen mielialahäiriön 
diagnoosia.  Asianmukaisen lääkehoidon määritelmät perustuivat 
hoitosuosituksiin. Vain 42% kaikista 191 potilaasta ja 65% niistä, joilla oli kliininen 
kaksisuuntaisen mielialahäiriön diagnoosi, saivat asianmukaista hoitoa 
akuuttivaiheessa. Kliininen diagnoosi oli tärkein asianmukaista hoitoa itsenäisesti 
ennustava tekijä. Sen lisäksi asianmukaista hoitoa itsenäisesti ennustivat 
tiheäjaksoisuus, monivaiheinen jakso, ja masennusvaihe. Avohoidossa olevat 
potilaat saivat asianmukaista hoitoa merkittävästi harvemmin kuin 
sairaalahoidossa olevat potilaat. Puuttuva huomio taudin pitkittäiseen kulkuun oli 
merkittävä ongelma-alue. 
Seuraavaksi tavoitteena oli selvittää, miten asianmukaista on hoito 
ensimmäisessä ylläpitojaksossa akuutin vaiheen jälkeen, seuraten samoja potilaita 
kuin ensimmäisen tutkimuksen akuuttivaiheessa. Asianmukaisen lääkehoidon 
määritelmät perustuivat hoitosuosituksiin. Niistä joilla oli ylläpitojakso 
seurannassa, sai 75% asianmukaista lääkehoitoa jonkin aikaa, mutta vain 61% 
koko ylläpitovaiheen ajan ja 69% ylläpitovaiheen kokonais ajasta.  Kliininen 
diagnoosi ennusti itsenäisesti vahvimmin asianmukaisen lääkehoidon saamista 
koko ylläpitovaiheen ajan. Kliinisen diagnoosin puuttumisen lisäksi 
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epäasianmukaista ylläpitovaiheen lääkitystä ennustivat sairaalahoito, 
tiheäjaksoisuus ja persoonallisuushäiriö. 
Seurannan aikana tutkittiin myös eri psykofarmakologisten ja 
psykososiaalisten hoitojen jatkuvuutta, sekä asenteita ja hoitoon sitoutumista 
näihin hoitoihin, psykiatrisilla sairaala- ja avohoitopotilailla, joilla oli 
kaksisuuntainen mielialahäiriö tyyppi I tai II.  Neljäsosa niistä potilaista joilla oli 
mielialaa tasaava tai epätyyppillinen psykoosilääke käytössä, lopetti lääkityksen 
omalla päätöksellään ja niistäkin jotka jatkoivat kolmasosa ei käyttänyt lääkkeitä 
riittävän säännöllisesti saadakseen siitä hyötyä. Yhteensä yli puolet 
kaksisuuntaista mielialahäiriötä sairastavista potilaista joko lopetti lääkityksen tai 
käytti sitä epäsäännöllisesti 18 kuukauden seuranan aikana. Suurin riski lääkkeen 
lopettamiseen liittyi masennusvaiheisiin. Myös neljäsosa niistä potilasta jotka 
saivat psykososiaalista hoitoa olivat huonosti hoitoon sitoutuneita. Tärkeimmät 
potilaiden ilmaisemat syyt huonoon lääkehoitoon sitoutumiseen olivat 
sivuvaikutukset, puutteellinen motivaatio ja negatiiviset asenteet tarjottua hoitoa 
kohtaan. Tärkeimmät potilaiden ilmaisemat syyt huonoon yksilö- tai 
supportiivisen hoitoon sitoutumiseen olivat käytännön esteet ja motivaation 
puute. Mielialaa tasaavaan tai antipsykoottiseen lääkitykseen sitoutuneiden osuus 
ei eronnut toisistaan, mutta syyt erosivat. 
Lisäksi tutkittiin pitkäaikaiselle työkyvyttömyyseläkkeelle jäämisen syitä ja 
esiintyvyyttä kaksisuuntaista mielialahäiriötä sairastavilla potilailla. 
Tutkimuksessa käytettiin rekisteritietoja, jotta saatiin tarkka tieto eläkkeistä ja 
niiden ajoituksesta. Akuuttia vaihetta seuranneiden 18 kuukauden aikana 
neljäsosalle työvoimaan kuuluvista potilaista myönnettiin työkyvyttömyyseläke. 
Työkyvyttömyyseläkkeelle jäämistä ennustivat korkeampi ikä, miessukupuoli, 
masennus tutkimuksen alkuvaiheessa, samanaikainen yleistynyt 
ahdistuneisuushäiriö tai estynyt persoonallisuus, sekä suurempi psykiatristen 
sairaalahoitojen lukumäärä. Lisäksi potilaiden omat arviot työkyvystään 
alkuhaastattelussa olivat yllättävän tarkkoja ennustamaan 
työkyvyttömyyseläkkeen myöntämistä. Myös masennuksen osuus seurannan 
aikana oli tärkeä ennustava tekijä.  Ennustavat tekijät kuitenkin vaihtelivat 
sairauden tyypistä, sukupuolesta ja iästä riippuen. 
 
Avainsanat: kaksisuuntainen mielialahäiriö, hoito, ylläpitohoito, hoitoon 
sitoutuminen, työkyvyttömyys, työkyvyttömyyseläke 
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1.  Introduction 
 
 
Bipolar manic-depressive disorder is arguably both the youngest and possibly also 
one of the oldest forms of mental illness, and medical conceptions of mania and 
depression are as old as medicine itself (Goodwin & Jamison, 2007), two of the 
earliest described human diseases (Angst & Marneros, 2001). From ancient times 
to the present, an extraordinary consistency has characterized descriptions of 
these conditions. Few maladies have been represented with such unvarying 
language.  However, while the essential features are recognizable in the medical 
literature across the centuries, the boundaries that define mania and depression 
and the relationship between them have changed over time (Goodwin & Jamison, 
2007). 
Hippocrates (460-337 BC) was the first to systematically describe mania and 
melancholia (Angst & Marneros, 2001), but these early conceptions were broader 
than those of today. The medical writers of ancient Greece conceived of mental 
disorders in terms that sound remarkably modern. They believed that melancholia 
was a psychological manifestation of an underlying biological disturbance, 
specifically, a perturbation in brain function (Goodwin & Jamison, 2007). This 
essentially biological explanation of the cause of melancholia, which survived until 
the Renaissance, was part of the prevailing understanding of all health as an 
equilibrium of the four humors – blood, yellow bile, black bile, and phlegm – and 
all illness as a disturbance of this equilibrium. An excess of black bile was seen as 
the cause of melancholia, a term that literally means black bile (melas means black 
and chole means bile). Depression, the clinical term for melancholy, is much more 
recent in origin and derives from the Latin deprimere (press down or sink down). 
Mania, in contrast, was usually attributed to an excess of yellow bile (Goodwin & 
Jamison, 2007). The origin of the term mania is less clear because of its roots in 
the mytologian area (Angst & Marneros, 2001).  Arateus of Cappadocia, who lived 
in the second century AD, appears to have been the first to bring together the 
syndromes described in Greek medicine and proposed that mania and melancholia 
belong together and that mania was a worsening of melancholia, a view that 
prevailed for centuries (Angst & Marneros, 2001; Goodwin & Jamison, 2007). 
Aretaeus described a group of patients who “laugh, play, dance night and day, and 
sometimes go openly to the market crowned, as if victors in some contest of skill” 
only to be “torpid, dull, and sorrowful” at other times (Burton N., 2012).  
From classical Greece until the Middle Ages, mental and physical afflictions 
were primarily the concern of medical doctors. As illness gradually became the 
responsibility of priests, the above early insights were submerged. The period that 
followed was, in retrospect, a dark age, when mental illness was generally 
attributed to magic, sin, or possession by the devil. Empirical clinical observations 
without religious overtones did not reappear until the beginning of the 
seventeenth century (Goodwin & Jamison, 2007). 
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The explicit conception of manic-depressive illness as a single disease entity dates 
from the mid-nineteenth century. The French “alienists,” Falret and Baillager, 
independently and almost simultaneously formulated the idea that mania and 
depression represent different manifestations of a single illness (Angst & Sellaro, 
2000; Goodwin & Jamison, 2007). In 1854, Falret described a circular disorder, 
“la folie circulaire,” which for the first time expressly defined an illness in which 
”this succession of mania and melancholia manifests itself with continuity and in a 
manner almost regular,” with episodes separated by symptom-free intervals 
(Angst & Sellaro, 2000; Goodwin & Jamison, 2007). In both French diagnoses, the 
prognosis was considered to be “desperate, terrible and incurable” (Angst & 
Sellaro, 2000). 
In the early 1900s, German psychiatrist Emil Kraepelin (1856–1926) studied 
the natural course of the disorder and found it to be punctuated by relatively 
symptom-free intervals. On this basis, he distinguished the disorder from 
dementia praecox (schizophrenia) and coined the term manic–depressive 
psychosis to describe it. Kraepelin emphasized that, in contrast to dementia 
praecox, manic–depressive psychosis had an episodic course and a more benign 
outcome (Angst & Sellaro, 2000; Goodwin & Jamison, 2007).  
However, the distinction between patients with only depressive episodes and 
those with both manic and depressive episodes was not made before 1957 when 
Leonhard proposed a classification system that went beyond clinical description 
alone. Leonhard observed that, within the broad category of manic-depressive 
illness (i.e., recurrent affective illness), some patients had histories of both 
depression and mania, whereas others had depression only. He then noted that 
patients with a history of mania (whom he termed bipolar) had a higher incidence 
of mania in their families than those with recurrent depression only (whom he 
termed monopolar) (Goodwin & Jamison, 2007). This distinction can be seen as 
fundamental for the modern emphasis on bipolarity. The work of Leonhard, Angst, 
Perris, and Winokur led to broad acceptance of the concept of bipolar disorder 
(BD) by the late 1960s. The bipolar-unipolar distinction was formally incorporated 
into the American diagnostic system, DSM, third edition (DSM-III) in 1980 (Yildiz 
et al., 2015).  
Although mild cases of mania had been described by earlier observers, 
Mendel (1881) was the first to define hypomania (Goodwin & Jamison, 2007). 
Ewald Hecker (1898) was among the first to describe what is now diagnosed as BD 
II, emphasizing its chronic, fluctuating, ambulatory course characterized by 
depressions with occasional hypomanic periods. Later, Kraepelin described 
hypomanic episodes in the course of manic-depressive illness, and Dunner et al. 
(Dunner et al., 1976) described a specific course pattern in which hypomanic 
episodes were interspersed with major depressive episodes. Despite the early and 
seemingly prescient advances, the modern concept of BD II was only defined in 
the 1970s by Dunner and his colleagues (Judd et al., 2003). In 1976, Dunner, 
Gershon, and Goodwin suggested the classification of bipolar patients into the 
categories bipolar I and bipolar II, but it was not until 1994, with the fourth 
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edition of DSM (DSM-IV), that bipolar disorder type II was included in the official 
diagnostic system (Yildiz et al., 2015).  
So, even though manic-depressive illness has been known for more than 
2,000 years, the modern concept of BD is only of some decades. Bipolar disorder 
poses a challenge in research, and the effort to evaluate and integrate the results of 
research is filled with difficulties, as nothing could be further from a static 
condition than bipolar disorder. Whereas most psychiatric conditions vacillate 
within a single register between symptom exacerbation and various degrees of 
recovery, those attempting to fully understand bipolar disorder must contend with 
the fact that exacerbations come in two distinct flavors – manias and depressions 
– and that often these exacerbations take any of a nearly infinite number of 
combinations of these two mood disturbances (Maletic & Raison, 
2014).  Unfortunately, Kraepelins’ view of a benign course of BD has proven to be 
too optimistic and for many patients BD is still a chronic disease with major 
functional disabilities. So far, new treatments have not changed the picture 
markedly. 
However, with the rapidly increasing number of diverse studies in BD and 
evolving scientific methods, more than 2,000 years after the discovery of the 
disease and some decades after the modern concept of BD emerged, we may be 
nearing a breakthrough in our knowledge of the etiology of BD, which could start a 
new era in the treatment of this difficult disease. 
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2.   Review of the literature 
 
 
2.1.  Definition of bipolar disorder   
 
Bipolar disorder, or manic depressive illness as it was previously named, is a 
mental disorder characterized by recurrent episodes of mania, hypomania, mixed 
states, and depression.  Bipolar disorder is divided into type I and II disorders.   
 
 
2.1.1.  Diagnosis of bipolar disorder 
 
Currently, two major classification systems are in use, the DSM-5 (American 
Psychiatric Association., 2013) and ICD-10 (World Health Organization, 1992), the 
latter one used in clinical practice in Finland. However, practically all the research 
has been done according to the former DSM classifications (DSM-III and DSM-
IV). The DSM-IV was also used in this thesis.  DSM-5 bipolar and related disorders 
include bipolar I disorder, bipolar II disorder, cyclothymic disorder, 
substance/medication-induced bipolar and related disorder, bipolar and related 
disorder due to another medical condition, other specifier bipolar and related 
disorder, and unspecified bipolar and related disorder. 
 The bipolar I disorder criteria represent the modern understanding of the 
classic manic-depressive disorder or affective psychosis described in the 
nineteenth century, differing from that classic description only to the extent that 
neither psychosis nor the lifetime experience of a major depressive episode is a 
requirement. Bipolar II disorder, requiring the lifetime experience of at least one 
episode of major depression and at least one hypomanic episode, is no longer 
thought to be a ”milder” condition than bipolar I disorder, largely because of the 
amount of time individuals with this condition spend in depression and because 
the instability of mood experienced by individuals with bipolar II disorder is 
typically accompanied by serious impairment in work and social functioning  
(American Psychiatric Association., 2013).  
 
 
2.1.2.  Manic episode (DSM-5) 
 
According to DSM-5 (American Psychiatric Association., 2013), a manic episode is 
defined by a distinct period during which there is an abnormally and persistently 
elevated, expansive, or irritable mood and abnormally and persistently increased 
goal-directed activity or energy. This period must last at least one week (or less if 
hospitalization is required).  The mood disturbance and increased energy or 
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activity must be accompanied by at least three (or four if the mood is irritable) of 
the following symptoms, which have been present to a significant degree and 
represent a noticeable change from usual behavior: inflated self-esteem or 
grandiosity, decreased need for sleep, more talkative than usual or pressure to 
keep talking, flight of ideas or subjective experience that thoughts are racing, 
distractibility, increase in goal-directed activity or psychomotor agitation, or 
excessive involvement in pleasurable activities that have a high potential for 
painful consequences. The mood disturbance must be sufficiently severe to cause 
marked impairment in social or occupational functioning or to necessitate 
hospitalization to prevent harm to self or others, or psychotic features are present.   
 
 
2.1.3.  Hypomanic episode (DSM-5) 
 
A hypomanic episode differs from a manic episode in that a duration of only four 
days is required. In addition, in contrast to a manic episode, a hypomanic episode 
is not severe enough to cause marked impairment in social or occupational 
functioning or require hospitalization, and there are no psychotic features. Still, 
the episode must be associated with an unequivocal change in functioning that is 
uncharacteristic of the individual when not symptomatic and the disturbance in 
mood and change in functioning must be severe enough to be observable by 
others. Otherwise, the criteria for hypomanic episode are the same as for manic 
episode (American Psychiatric Association., 2013).  
 
  
2.1.4.  Major depressive episode (DSM-5) 
 
The criteria for a major depressive episode in BD are the same as for a major 
depressive episode in major depressive disorder (MDD). The essential feature of a 
major depressive episode is a period of at least two weeks during which there is 
either depressed mood or the loss of interest or pleasure in nearly all activities. 
The individual must also experience four (or three if both of the aforementioned 
essential features are fulfilled) of the following symptoms during the same two-
week period that represent a change from previous functioning: significant weight 
loss or gain, decrease or increase in appetite, insomnia or hypersomnia, 
psychomotor agitation or retardation, fatigue or loss of energy, feeling of 
worthlessness or excessive or inappropriate guilt, diminished ability to think or 
concentrate or indecisiveness, recurrent thoughts of death, and recurrent suicidal 
ideation or suicide attempt or a specific plan for committing suicide. The 
symptoms must also be severe enough to cause clinically significant distress or 
impairment in social, occupational, or other important areas of functioning 
(American Psychiatric Association., 2013).   
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2.1.5.  DSM-IV vs. DSM-5  
 
To enhance the accuracy of diagnosis and facilitate earlier detection in clinical 
settings, the main Criterion A for manic and hypomanic episodes in the DSM-5 
includes an emphasis on changes in activity and energy as well as mood.   
The DSM-IV diagnosis of “mixed episode” is replaced in the DSM-5 with a 
mixed-features specifier that can be applied to episodes of major depression, 
hypomania, or mania. In DSM-IV, a diagnosis of mixed episode required an 
individual to simultaneously meet all criteria for an episode of major depression 
and an episode of mania. During its review of the latest research, the DSM-5 Mood 
Disorders Work Group recognized that individuals rarely meet the full criteria for 
both episode types at the same time. To be diagnosed with the new specifier in the 
case of major depression, the new DSM-5 specifier will require the presence of at 
least three manic/hypomanic symptoms that don’t overlap with symptoms of 
major depression. In the case of mania or hypomania, the specifier will require the 
presence of at least three symptoms of depression in concert with the episode of 
mania/hypomania (American Psychiatric Association., 2013).  
In the chapter on bipolar and related disorders and the chapter on depressive 
disorders, a specifier for anxious distress is delineated. This specifier is intended to 
identify patients with anxiety symptoms that are not part of the bipolar diagnostic 
criteria (American Psychiatric Association., 2013). 
 
 
 
2.2.  Epidemiology of bipolar disorder  
 
The lifetime prevalence of BD I is generally assumed to be about 1% (Merikangas 
et al., 2011). The lifetime prevalence of BD II is estimated to about the same as BD 
I, even though no reliable population estimates exist because of the challenge of 
diagnosis of hypomania in general population surveys. An international review of 
both DSM-IV BD I and BD II population studies yielded an aggregate cross-study 
lifetime prevalence estimate of 1.2%, ranging from 0.1% in Nigeria to 3.3% in the 
U.S. (Merikangas et al., 2011). The European College of 
Neuropsychopharmacology (ECNP)/ European Brain Council (EBC) report 2011 
(Wittchen et al., 2011) summarized European studies and found the prevalence of 
BD to be 0.7% (0.2-1.1%). In a comprehensive nationwide study of all Danish 
residents, the cumulative incidence at 50 years of age was 0.76% for males and 
1.07% for females and lifetime risk was 1.32% for males and 1.84% for females 
(Pedersen et al., 2014).  
The lifetime prevalence of BD I in the recent epidemiological studies has 
ranged from 0.6% to 3.3%, and the 12-month prevalence from 0.6% to 2.0% 
(National Epidemiologic Survey on Alcohol and Related Conditions [NESARC], 
National Comorbidity Study Replication [NCS-R], World Mental Health [WMH] 
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Survey Initiative) (Grant et al., 2005; Merikangas et al., 2007; Merikangas et al., 
2011). In a recent systematic review and meta-analysis of population studies, the 
pooled lifetime prevalence of BD I was 1.06% (95%CI 0.81-1.31) and the pooled 12-
month prevalence was 0.71% (95%CI 0.56-0.86) (Clemente et al., 2015). 
Estimation of the prevalence of BD II is difficult due to low reliability of the 
diagnosis of BD II in population studies. In recent studies, the lifetime prevalence 
has been 0.4%-1.1% and the 12-month prevalence 0.3%-0.8% (Merikangas et al., 
2007; Merikangas et al., 2011). In the systematic review and meta-analysis by 
Clemente et al. (Clemente et al., 2015), the pooled lifetime prevalence of BD II was 
1.57% (95%CI 1.15-1.99) and the 12-month prevalence was 0.50% (95%CI 0.35-
0.64). 
In Finnish studies, the prevalence of BD has been estimated to be lower than 
the international prevalence (Suvisaari et al., 2009). The Psychoses in Finland 
(PIF) Study, based on the Health 2000 Study, found that the lifetime estimate of 
BD I was 0.24%, increasing to 0.42% if the register diagnoses of BD I were 
included (Perala et al., 2007). In the Mental Health in Early Adulthood in Finland 
(MEAF) (N=1963), another study based on the Health 2000 study, the authors 
found that lifetime prevalence for Finns aged 19 to 34 years was 1.27% (BD I 
0.38%, BD II 0.51%, and BD NOS (not otherwise specified) 0.37%) (Suvisaari et 
al., 2009). 
 
 
Table 1. Prevalence of bipolar disorder 
 
 
a 11 countries 
 
12-month prevalence of bipolar disorder (I and II) 
ECNP/EBC 0.7% Wittchen et al. 2011 Europe  
Lifetime prevalence of bipolar I disorder 
NESARC 3.3 % Grant et al., 2005 United States N=43093 
NCS-R 1.0 % Merikangas et al., 2007 United States N=9282 
WMH 0.6 % Merikangas et al., 2011 Americas, Europe, Asiaa  N=61392 
PIF 0.2 % Perälä et al., 2007 Finland N=8028 
MEAF 0.5 % Suvisaari et al., 2009 Finland N=546 
12-month prevalence of bipolar I disorder  
NESARC 2.0 % Grant et al., 2005 United States N=43093 
NCS-R 0.6 % Merikangas et al., 2007 United States N=9282 
WMH  0.4 % Merikangas et al., 2011 Americas, Europe, Asiaa  N=61392 
Lifetime prevalence of bipolar II disorder 
NCS-R 1.1 % Merikangas et al., 2007 United States N=9282 
WMH  0.4 % Merikangas et al., 2011 Americas, Europe, Asiaa  N=61392 
MEAF 0.7 % Suvisaari et al., 2009 Finland N=546 
12-month prevalence of bipolar II disorder  
NCS-R 0.8 % Merikangas et al., 2007 United States N=9282 
WMH  0.3 % Merikangas et al., 2011 Americas, Europe, Asiaa  N=61392 
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2.3.  Comorbidity of bipolar disorder 
 
Comorbidity refers to the co-occurrence of two or more distinct disorders in one 
person over a defined period of time. Comorbidity of BD may be with another 
psychiatric disorder or with a disorder from other diagnostic groupings (Angold et 
al., 1999). Comorbidity in BD is the rule rather than the exception (Goodwin & 
Jamison, 2007) and is associated with worse outcomes than bipolar disorder alone 
(NCCMH, 2014) 
 
2.3.1.   Psychiatric comorbidity 
 
The coexistence of other Axis I disorders complicates psychiatric diagnosis and 
treatment. Conversely, symptom overlap in DSM-IV diagnoses hinders definition 
and recognition of true comorbidity (Krishnan, 2005). Comorbidity also 
substantially contributes to the disease burden and economic costs of mood 
disorders. Numerous studies have shown that comorbidity is associated with 
earlier onset of bipolar symptoms, greater functional and psychosocial 
impairment, poor adherence and treatment response, prolonged recovery time, 
increased risk of suicide attempts and completed suicides, increased utilization of 
health services, and higher morbidity and mortality (Krishnan, 2005; Lam et al., 
2012). The total Axis I lifetime comorbidity has been estimated to range from 60% 
to 80% (McElroy et al., 2001; Simon et al., 2004; Suppes et al., 2001) to as low as 
31% (Vieta et al., 2001).  
Simon et al. (Simon et al., 2004) reported the comorbidity rates among the 
first 1,000 patients entering the STEP-BD study. They found that of the 656 
patients 72% met criteria for at least one comorbid disorder, 20% met criteria for 
two, 15% for three, and 17% for four or more comorbid disorders. In the Stanley 
Foundation Bipolar Treatment Outcome Network (SFBN) study (McElroy et al., 
2001), 65% of the patients met DSM-IV criteria for at least one lifetime comorbid 
disorder, and 33% met criteria for at least one current comorbid disorder; 42% 
had two or more and 24% had three or more lifetime comorbid disorders. BD I and 
BD II patients showed no differences regarding rates of lifetime or current 
comorbid disorders. Anxiety (42%) and substance use disorders (42%) were the 
most common comorbid lifetime disorders, followed by eating disorders (6%).  
Axis I comorbidity was associated with earlier age at onset of affective symptoms, 
rapid cycling, and worsening severity of episodes over time. 
In Finland, Mantere et al. (Mantere et al., 2006) reported that 70% of the 
patients with BD I and BD II had a current comorbid disorder; on Axis I 60%, Axis 
II 43%. Anxiety disorders were currently present in 45%, substance use disorders 
in 20%, and eating disorders in 8% of patients with BD. BD I and BD II did not 
differ significantly in terms of comorbidity profile. On the basis of the National 
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Hospital Discharge Register in Finland, Sorvaniemi and Hintikka (Sorvaniemi & 
Hintikka, 2005) studied the recorded prevalence of psychiatric comorbidity among 
psychiatric inpatients. Of the 2,687 hospital stays in 1998, psychiatric comorbidity 
was recorded in 18%. Substance-related disorders (11%) were the most commonly 
recorded comorbid disorder; personality disorders accounted for 6% and anxiety 
disorders for 1%. The authors concluded that comorbidity in BD in psychiatric 
hospitals in Finland goes largely undetected and may have a deteriorating impact 
on the course of the illness. 
Two recent reviews (Nabavi et al., 2015; Pavlova et al., 2015) have estimated 
the lifetime prevalence of anxiety disorder comorbidity among patients with BD. 
Anxiety disorders are one of the most common comorbidities in BD and the 
lifetime prevalence of any anxiety disorder among patients with BD is three times 
greater than for people without BD (Pavlova et al., 2015). The pooled estimation of 
any lifetime anxiety disorder was 45% (from 10% to 80%-90%) (Pavlova et al., 
2015) and 43% (Nabavi et al., 2015), respectively. The most common anxiety 
disorders were panic disorder (19% and 17%), generalized anxiety disorder (20% 
and 14%), social anxiety disorder (20% and 13%), and post-traumatic stress 
disorder (17% and 11%). The lifetime prevalence of any anxiety disorder did not 
differ between people with BD I or BD II, but social phobia was more common in 
those with BD II (Pavlova et al., 2015). Patients with BD also commonly have had 
more than one lifetime anxiety disorder (Ketter, 2015). In patients with BD, 
comorbidity with anxiety disorders is associated with more frequent relapses of 
mood episodes, more severe depressive episodes, a higher prevalence of substance 
abuse, and an increased risk of suicide attempts, impaired role functioning, and 
reduced quality of life. It is also associated with earlier onset age as well as 
treatment resistance (Ketter, 2015). Moreover, anxiety disorders often do not 
remit with the mood episode and continue to cause functional impairment, even 
during periods of euthymia (Pavlova et al., 2015). 
The lifetime prevalence of substance use disorder in BD is higher than in any 
other psychiatric illness, with lifetime rates in epidemiological and clinical samples 
ranging from 40% to 60% (Ostacher et al., 2010) or 19% to 60% (McElroy et al., 
2001; Simon et al., 2004; Suppes et al., 2001; Vieta et al., 2000; Vieta et al., 2001). 
In a recent systematic review and meta-analysis (Di Florio et al., 2014), the overall 
pooled lifetime prevalence of alcohol use disorders was 35%. Comorbid substance 
use disorder has been associated with a variety of negative outcomes among BD 
patients, including greater risk of treatment nonadherence, increased rates of 
psychiatric hospitalization,  low rates of recovery, greater risk of aggression and 
violence, increased rates of attempted and completed suicide, a less favorable 
response to conventional treatment (Levin & Hennessy, 2004; McIntyre, Nguyen 
et al., 2008; Rakofsky & Dunlop, 2013), and all-cause mortality (Hjorthoj et al., 
2015).  
Comorbidity of attention deficit hyperactivity disorder (ADHD) with BD in 
adulthood has been estimated at 5% to 20%, and even up to more than 30% if 
childhood onset ADHD that remitted in adulthood was determined (Brus et al., 
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2014; Skirrow et al., 2012), higher than in the general population (2%-5%). In 
more narrowly defined BD I, comorbidity with ADHD is reported in 5.9% to 8% of 
cases (Skirrow et al., 2012). Patients with ADHD and BD may present with similar 
symptoms, including increased energy, distractibility, disorganization, impulsivity, 
hyperactivity, and rapid speech. Determining whether the patient has either, or 
possibly both, of these syndromes can be a complex task (Brus et al., 2014; Skirrow 
et al., 2012). ADHD symptoms are chronic and traitlike and refer to differences 
from developmental norms, whereas BD symptoms are conceptualized as changes 
from an individual’s usual premorbid state and are episodic in nature (Brus et al., 
2014; Skirrow et al., 2012). Comorbidity of BD and ADHD is associated with an 
earlier age at onset and more chronic and disabling course of BD, as well as more 
psychiatric comorbidity (Brus et al., 2014).  
Fan and Hassel (Fan & Hassell, 2008) reviewed the comorbidity of 
personality disorder in BD. They found that the prevalence of comorbid 
personality disorder is highly variable, ranging from 12% to 84% in outpatient 
studies, and depends on the methodology used, patients included, and the 
presence of a current mood state. The studies using Structured Clinical Interview 
for DSM-IV Personality Disorders (SCID-II) for patients with BD I or II in 
euthymic state have found prevalence rates of personality disorder comorbidity 
from 25% to 50%. Comorbid personality disorder has been associated with a lower 
medication adherence rate, lower rate of clinical recovery, lower functional level, 
higher rates of suicidality, and higher rates of substance abuse (Fan & Hassell, 
2008). In the Finnish JoBS study, total Axis II comorbidity was 41%, borderline 
personality disorder and obsessive-compulsive personality disorder being the most 
common (Mantere et al., 2006). 
 
 
2.3.2.  Medical comorbidity 
 
Patients with BD experience a high incidence of medical comorbidities. These 
comorbidities contribute to major degrees of morbidity and premature mortality 
(Post et al., 2015). Traditionally, the high prevalence of medical illness in those 
with mental health problems has been viewed as a consequence of psychotropic 
medications and an unhealthy lifestyle. However, recent research has suggested 
that exposure to psychotropic medication does not necessarily worsen mortality 
risk in patients with psychiatric illness (Forty et al., 2014). Often it is unclear 
whether a medical disorder is truly comorbid, a consequence of treatment, or a 
combination of both (Krishnan, 2005). 
Forty et al. (Forty et al., 2014) examined the rates of medical illness in 
patients with BD (n=1720) to examine the clinical course of BD according to 
lifetime medical illness burden.  The most prevalent medical conditions in the BD 
sample were migraine headache (24%), asthma (19%), elevated lipids (19%), 
hypertension (15%), thyroid disease (13%), and osteoarthritis (11%). The authors 
also compared the rates of medical illness among patients with BD, patients with 
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MDD (n=1737), and healthy controls (n=1340). They reported that in the logistic 
regression models patients with BD had asthma and elevated lipids significantly 
more often than patients with MDD, patients with BD more often had type 2 
diabetes, epilepsy, or kidney disease than the control group, patients with  BD or 
MDD had gastric ulcers, hypertension, and osteoarthritis more often than the 
control group, patients with MDD had multiple sclerosis more often than patients 
with BD and the control group, and patients with BD had thyroid diseases more 
often than patients with MDD, who had them more often than the control group. 
A recent study by Post et al. (Post et al., 2015) found that of the 876 patients 
with BD recruited in the SFBN only 21% had no medical comorbidities, while 53% 
had one to three comorbidities, and the remaining 26% had four or more medical 
conditions. The most common comorbidities were allergies (38%), migraine 
headaches (35%), head injury without loss of consciousness (22%), high blood 
pressure (16%), chronic menstrual irregularities (16%), hypothyroidism (15%), 
head injury with loss of consciousness (15%), irritable bowel syndrome (13%), 
arthritis (13%), asthma (13%), and hypotension (11%). Having experienced 
adversity in childhood (Post et al., 2013), an early age of onset, and a lifetime 
diagnosis of anxiety disorder remained independently related to the number of 
medical comorbidities in adulthood. 
In the Swedish National Cohort Study of 6,587,036 Swedish adults, including 
6,618 with BD, Crump et al. (Crump et al., 2013) reported that after adjusting for 
age and other sociodemographic factors, patients with BD had an increased risk of 
diagnosis with influenza or pneumonia, chronic obstructive pulmonary disease 
(COPD), diabetes, cardiovascular disease, and specifically stroke. In contrast, in 
this study, patients with BD had no increased risk of diagnosis with ischemic heart 
disease, hypertension, lipid disorders, or cancer. Also, after additional adjustment 
for substance use disorders, the association between BD and either stroke or 
COPD diagnosis among men was no longer statistically significant 
Thus, the available evidence indicates that several general medical disorders 
(cardiovascular, metabolic, infectious, neurological, and respiratory) differentially 
affect the bipolar disorder population (McIntyre et al., 2007). It has been proposed 
that BD should be viewed as a multisystem disorder, or even a multisystem 
inflammatory disease (Frank et al., 2015). According to this view, the presence, for 
example, of medical conditions such as asthma, childhood obesity, and early signs 
of cardiovascular disease may simply be other manifestations of a multisystem 
disorder involving both psychiatric and non-psychiatric comorbidities. Also, 
different disorders may share common genes and comorbidity may be the result of 
these common genes between disorders (Goh et al., 2007). Moreover, BD has been 
proposed to be an illness of accelerated aging, with early mortality and risk of 
developing physical diseases that are more typically seen in the elderly, such as 
cardiovascular disease, stroke, dementia, cancer, obesity, and type II diabetes 
mellitus (Lindqvist et al., 2015; Rizzo et al., 2014). 
 
 
28 
 
2.4. Etiology and pathogenesis of bipolar 
disorder   
 
2.4.1. Heredity 
 
The predisposition to fall ill in BD is highly hereditary and often runs in families. 
In patients with established disease, a family history of mood or psychotic illness is 
common. Furthermore, a family history of bipolar disorder is an important clinical 
predictor of a likely bipolar course in patients who present with one or more 
episodes of depression even before their first episode of mood elation (Craddock & 
Sklar, 2013). Classical genetic epidemiology with family, twins, and, to a lesser 
extent, adoption studies has produced overwhelming evidence that genes affect 
predisposition to bipolar disorder. Indicative figures for the lifetime risks in 
narrowly defined bipolar disorder in relatives of a bipolar proband are: unrelated 
member of the general population 0.5%-1.5%; first degree relative 5%-10% 
(relative risk roughly 8 compared with the risk in the general population); and 
monozygotic co-twin 40%-70% (relative risk roughly 60) (Craddock & Sklar, 
2013). If one identical twin has BD, the other has about an 80% chance of falling ill 
with a mood disorder. The estimates of heritability of BD are usually around 60% 
to 90%. Slightly lower estimates of genetic risk have been suggested based on 
family studies and large population cohorts (Kerner, 2014). The high heritability 
estimates and high monozygotic concordance rate are convincing indicators of the 
importance of genetic factors affecting bipolar susceptibility. However, the fact 
that monozygotic concordance is substantially less than 100% shows that genes 
alone are not the whole story (Craddock & Sklar, 2013). 
Searches for common variants with moderate effect in candidate gene studies 
of BD have not produced consistent results. Moreover, genome-wide association 
studies (GWAS) with thousands of samples have not provided evidence that such 
moderate effect exists. However, common variants of a small effect (Odds Ratio 
[OR] <1.2) have been demonstrated and replicated (Nurnberger et al., 2014). In 
these studies, many single nucleotide polymorphisms (SNPs) of genes (e.g., ANK3, 
CAGNA1C, SYNE1, ODZ4, TRANK1) have emerged as promising candidate genes 
for BD (Craddock & Sklar, 2013; Kerner, 2014).  
Using genes with consistent evidence of association in multiple GWAS, 
Nurnberger et al. (Nurnberger et al., 2014) identified biological pathways that 
contribute to risk for bipolar disorder. They found that pathways involved in the 
genetic predisposition to BD included hormonal regulation, calcium channels, 
second messenger systems, and glutamate signaling. In addition to these 
functions, gene expression studies implicated neuronal development pathways as 
well.  
Models of illness are most consistent with multifactorial inheritance 
(Nurnberger et al., 2014). BD is probably a heterogeneous disease that connects to 
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many genes, and different genetic deviations can lead to the same kind of disorder 
phenotypically. Most cases of bipolar disorder involve the interplay of several 
genes or more complex genetic mechanisms, together with the effects of non-
genetic (environmental) risk factors and stochastic factors (Craddock & Sklar, 
2013). 
 
 
2.4.2.  Neurobiology 
 
For a complete understanding of the pathophysiology of BD, its neurobiology must 
be addressed at different physiological levels: molecular, cellular, systems, and 
behavioral. BD arises from the interaction of multiple susceptibility genes. These 
genes (and the proteins they code) are undoubtedly related much more closely to 
specific biochemical processes and thus specific symptoms than to BD as defined 
by the DSM (Goodwin & Jamison, 2007). Many new methods, new domains, and 
new results have been found, but their significance is still partly uncertain. Many 
theories have been developed to integrate the results from different areas, but so 
far many parts of them have not been proved. From a neurobiological perspective, 
there is no such thing as bipolar disorder. Rather, almost certainly, many 
somewhat similar, but subtly different, pathological conditions produce a disease 
state that we currently diagnose as bipolarity (Maletic & Raison, 2014).  
Historically, following the path set by MDD studies, BD was thought to result 
from an imbalance in monoaminergic neurotransmitter systems. Accordingly, 
these systems have been investigated in biological and pharmacological studies, 
and hypotheses involving the noradrenergic, dopaminergic, serotonergic, and 
cholinergic systems have been developed (Goodwin & Jamison, 2007; Grande et 
al., 2015). The evidence of monoamine involvement in the etiology of bipolar 
disorder is for the most part indirect, inconsistent, and lacking replication in larger 
scale studies (Maletic & Raison, 2014), and despite evidence showing that these 
circuits are likely to play a part, no singular dysfunction of these neurotransmitter 
systems has been identified (Grande et al., 2015). However, the monoaminergic 
hypothesis has not been totally forgotten. Berk et al. (Berk, Dodd et al., 2007) 
utilized cumulative pharmacological and imaging evidence to put forth the 
hypothesis of dopaminergic dysfunction in bipolar illness. Cousins et al. (Cousins 
et al., 2009) also reported that multiple lines of evidence suggest that the 
dopaminergic system may play a central role in BD. Additionally, van Enkhuizen 
et al. (van Enkhuizen et al., 2015) recently updated the hypothesis of 
catecholaminergic-cholinergic balance with recent findings from human and 
animal studies. They reported that evidence from neuroimaging studies, 
neuropharmacological interventions, and genetic associations support the notion 
that increased cholinergic functioning underlies depression, whereas increased 
activation of catecholamines (dopamine and norepinephrine) underlie mania.  
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The GABAergic and glutamatergic systems, the major inhibitory and excitatory 
systems, respectively, are also receiving greater attention and interest (Newberg et 
al., 2008). Multiple, consistent, and convergent evidence from genetic, 
postmortem, biochemical, and imaging studies points to a principal role of 
glutamatergic dysregulation in the etiopathogenesis of bipolar disorder (Maletic & 
Raison, 2014).  
Although traditionally viewed exclusively as a neurochemical disorder, recent 
evidence suggests that the pathophysiology of BD may involve alterations of 
signaling cascades, rather than specific alterations in particular neurochemicals 
per se (Newberg et al., 2008) and it is becoming increasingly evident that current 
mood-stabilizing agents have actions that extend beyond binding to neuronal 
membrane surface receptors. Therapeutic actions of psychotropic medications 
utilized in the treatment of bipolar disorder most likely rely on an interface with 
intracellular signaling cascades and eventual enduring changes in gene expression, 
accompanied by alterations in neurotransmission and neuroplasticity (Maletic & 
Raison, 2014). On the other hand, modulation of synaptic and neural plasticity 
seems to be important in the circuitry regulating affective and cognitive functions 
(Grande et al., 2015). Neurotrophins, such as the brain-derived neurotrophic 
factor, are a family of regulatory factors that mediate the differentiation and 
survival of neurons, as well as the modulation of synaptic transmission and 
synaptic plasticity (Newberg et al., 2008).  Dendritic spine loss has been noted in 
post-mortem brain tissue of patients with BD (Grande et al., 2015).  
Also, alterations in the hypothalamic, pituitary, adrenal (HPA) axis function 
in bipolar disorder have been well substantiated. BD is associated with a 
significant degree of HPA axis hyperactivity, which is most prominent in the manic 
phase but also persists in remission (Belvederi Murri et al., 2016). Exaggerated 
release of the corticotropin-releasing factor (CRF) contributes to greater 
adrenocorticotropic hormone (ACTH) secretion and a subsequent elevation of 
circulating glucocorticoids (i.e., cortisol) (Maletic & Raison, 2014). Overall, the 
available evidence suggests that HPA axis abnormalities should not be considered 
an etiological factor or endophenotype of BD, but rather a pathogenetic and 
pathophysiological mechanism that contributes to shape BD clinical presentation, 
while increasing the risk of clinical relapses and cognitive deterioration (Belvederi 
Murri et al., 2016). The cumulative impact of impaired HPA regulation combined 
with compromised glucocorticoid and insulin receptor activity, aggravated by 
inflammatory cytokines, might explain the high rate of metabolic syndrome, 
diabetes, dyslipidemia, and osteoporosis in the bipolar population (Maletic & 
Raison, 2014; Rosenblat et al., 2014). 
Other pathways that can affect neuronal interconnectivity are also under 
study, including mithochondrial dysfunction and endoplasmic reticulum stress, 
neuroinflammation, oxidation, apoptosis, and epigenetic changes, particularly 
histone and DNA methylation (Grande et al., 2015). Convergent evidence from 
imaging, neurochemical, and genetic studies points to disturbances in 
bioenergetics and mitochondrial function in the context of bipolar illness (Maletic 
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& Raison, 2014).  BD is also associated with abnormalities in glial cells (Hercher et 
al., 2014; Maletic & Raison, 2014; Muneer, 2016; Schroeter et al., 2010), whereas 
the data supporting a role for a primary neuronal pathology in the condition are 
less convincing (Maletic & Raison, 2014).  
Accumulating evidence implicates inflammation as a critical mediator in the 
pathophysiology of mood disorders (Bhattacharya et al., 2016; Muneer, 2016; 
Rosenblat et al., 2014), and it has been proposed that BD can be conceptualized as 
a multi-systemic inflammatory disease (Leboyer et al., 2012). Several studies have 
reported elevated levels of peripheral inflammatory cytokines in bipolar depressed 
and manic patients compared with healthy controls (Maletic & Raison, 2014; 
Muneer, 2016; Rosenblat et al., 2014). Immune dysregulation in bipolar disorder 
is associated with alterations in monoamine and glutamate signaling, impaired 
neuroplasticity and neurotrophic support, and changes in glial and neuronal 
function, most likely contributing to the symptomatic expression and medical 
comorbidities of this mood disorder (Maletic & Raison, 2014; Muneer, 2016). 
Overall, the data suggest that successful treatment leading to a euthymic state may 
reverse inflammation and normalize peripheral levels of inflammatory mediators 
(Maletic & Raison, 2014), but this has not been seen in all studies (Rosenblat et al., 
2014). Combined with autonomic disturbance, increased platelet/endothelial 
aggregation, and unhealthful lifestyle, elevated inflammation may contribute to a 
substantially increased risk of respiratory and gastrointestinal disorders, 
cerebrovascular and cardiovascular disease, and migraines in the bipolar 
population (Leboyer et al., 2012; Maletic & Raison, 2014; Rosenblat et al., 2014). 
However, not all patients suffering from mood disorders have an inflammatory 
component (Bhattacharya et al., 2016). 
 
 
2.4.3.  Structure and function in brain imaging studies 
 
New findings have emerged with modern methodologies although there is still a 
paucity of longitudinal studies and studies of different mood states. The main 
findings from structural neuroimaging studies have been summarized in recent 
reviews (Abe et al., 2015; Arnone et al., 2009; Emsell & McDonald, 2009; Hanford 
et al., 2016; Lim et al., 2013; Phillips & Swartz, 2014) supporting the main themes 
from functional neuroimaging studies. The authors have found cortical changes, 
mainly decreased gray matter volume, decreased white matter volume, and 
decreased cortical thickness in prefrontal, anterior temporal, and insula cortices. 
Also, decreased gray matter volume, in particular in the right ventrolateral 
prefrontal cortex and orbitofrontal cortex, has been found. The main subcortical 
findings have been a decreased volume of amygdala and hippocampus, as well as 
altered striatal volumes. The main white matter tract findings from diffusion 
tensor imaging (DTI) studies have been an altered fractional anisotropy (FA) and 
increased radial diffusivity in frontally situated white matter, supporting the main 
themes from functional neuroimaging studies. Some structural imaging 
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differences have been found between patients with BD I and BD II (Abe et al., 
2015). However, according to Hanford et al. (Hanford et al., 2016), there is little 
support for the idea that cortical changes precede the onset of BD.  
The advances in neuroimaging techniques have produced prolific 
neuroimaging research in BD. Although discrepancies exist among neuroimaging 
research reports, a common hypothesis has been found, namely, that bipolar 
disorder arises from abnormalities within brain systems that modulate emotional 
behavior. Strakowski et al. (Strakowski et al., 2012) hypothesized that 
developmental failure to establish healthy ventral prefrontal-amygdala networks 
underlies the onset of mania and ultimately, with progressive changes throughout 
these networks over time, a bipolar course of illness.  
Phillips and Swartz (Phillips & Swartz, 2014) provided a new 
conceptualization of neural circuitry abnormalities in bipolar disorder based on 
the most consistent themes emerging from neuroimaging research. They stated 
that emotional over-reactivity and emotion dysregulation are characteristic 
symptoms of bipolar disorder. According to them, a large number of functional 
neuroimaging studies has examined (and found abnormalities in) the emotion-
regulation neural circuitry function in patients with BD during performance of 
emotion-processing and emotion-regulation tasks.  These studies indicated 
abnormalities in adults with BD in prefrontal cortical-amygdala-centered emotion-
regulating circuitry and prefrontal cortical-striatal reward circuitry. They 
suggested four main themes connected with these abnormalities that emerged 
from neuroimaging studies.  
The first theme is that abnormally decreased ventrolateral prefrontal cortex 
activity and abnormally decreased ventrolateral prefrontal cortex-amygdala 
functional connectivity exist during different positive and negative emotion-
processing tasks, emotion-regulation tasks, and response inhibition. The second 
theme, built on the first, is a pattern of abnormally increased amygdala, striatal, 
and medial prefrontal cortical activity and decreased functional connectivity 
between amygdala and prefrontal cortex to positive emotional stimuli (especially 
happy faces). These findings may reflect an underlying attentional bias to positive 
emotional stimuli in bipolar disorder, predisposing to mania. A third theme is 
abnormally increased activity in emotion-processing circuitry, including amygdala, 
orbitofrontal cortex, and temporal cortex during non-emotional cognitive task 
performance in bipolar disorder. These findings suggest heightened perception of 
emotional salience in non-emotional contexts in bipolar disorder. The last theme 
is related to the fact that another feature of bipolar disorder is heightened reward 
sensitivity, indicated by behavioral and event-related-potential studies. 
Accordingly, the findings from neuroimaging studies have demonstrated 
abnormally increased left ventrolateral prefrontal cortex and orbitofrontal cortex 
and ventral striatum activity during reward processing (Phillips & Swartz, 2014).  
Phillips et al. (Phillips & Swartz, 2014) suggested that BD can be 
conceptualized in neural circuity terms as parallel dysfunction in prefrontal 
cortical (especially ventrolateral prefrontal cortex and orbitofrontal cortex)-
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hippocampal-amygdala emotion-processing and emotion-regulation circuits 
bilaterally, along with an “overactive” left-sided ventral striatal-ventrolateral 
prefrontal cortex reward processing circuitry that may, together, result in 
characteristic behavioral abnormalities associated with the disorder – emotional 
lability, emotional dysregulation, and reward sensitivity.  
 
 
2.4.4.  Sleep and circadian rhythms  
 
Rhythm disruption is a core feature of BD, and it has been hypothesized that 
disturbances in the circadian timing system play a fundamental role in the etiology 
of BD (Gonzalez, 2014), with multiple lines of evidence supporting the 
conceptualization of bipolar disorder as a disorder of circadian rhythms (Soreca, 
2014). Sleep disturbances are central to the symptoms of mood disorders, so much 
that hypersomnia and insomnia are diagnostic criteria for depression and mania 
(Frank et al., 2015).  Altered endocrine and neurotransmitter diurnal rhythms in 
bipolar disorder have also been described. The secretion of several 
neurotransmitters is subject to circadian regulation and appears to be altered in 
bipolar disorders. In contrast to large-scale GWAS which have not established an 
association between CLOCK genes and bipolar disorder, smaller linkage studies, 
while lacking adequate replication, have noted an association between several 
circadian genes, including TIMELESS, ARNTL1, PER3, NR1D1, CLOCK, and GSK-
3 beta, and bipolar illness (Maletic & Raison, 2014). 
Many lines of evidence suggest that circadian disturbances are not likely to 
be a secondary epiphenomenon of bipolar illness given that they are present 
during mania and depression, in euthymic state, and in healthy relatives of bipolar 
patients (Maletic & Raison, 2014). However, the possibility still exists that the 
rhythm disturbances are a secondary epiphenomenon, rather than there being a 
primary dysfunction in the timing system itself (Gonzalez, 2014). It has also been 
suggested that multisystemic involvement in bipolar disorder, with high rates of 
psychiatric and medical comorbidity, may be a consequence of the underlying 
circadian pathology (Soreca, 2014). Even though compelling evidence suggests 
biological rhythm disruption in BD, no consensus has been reached as to the exact 
nature of these disturbances (Gonzalez, 2014). 
  
 
2.4.5.  Psychosocial factors 
 
Although much recent research has focused on biological factors, several 
psychosocial factors have also been identified that may be relevant to 
understanding the development and progression of bipolar disorder or a particular 
individual’s presentation (NCCMH, 2014). Even the most heritable psychiatric 
disorders, including bipolar disorder, are thought to have a multifactorial origin, 
with genetic and non-genetic factors probably interacting. These gene-
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environment interactions assume that environmental factors are major causes of 
the disorder, whereas genes affect the level of susceptibility to these factors (Etain 
et al., 2008). Also, antecedent factors, such as childhood maltreatment, may act as 
predisposing factors for developing the disorder, whereas concurrent factors such 
as social class, social support, and self-esteem, or variation in self-esteem, may act 
as course modifiers or precipitants for episodes (NCCMH, 2014). 
Several environmental factors have been identified as potentially involved in 
this disorder, including early childhood trauma, stressful life events, virus 
infections, cannabis use, obstetric complications, and even very distant 
environmental factors, such as solar cycles (Etain et al., 2008). A potential role for 
psychosocial stressors in both the etiology and exacerbation of acute episodes has 
been identified in bipolar disorder (Hosang et al., 2010), with stressful life events 
being one of the strongest predictors of relapse in BD, and impairment in the 
stress response has been recognized as a core feature of BD clinical expression 
(Brietzke et al., 2012). The relationship between stressful life events and 
development of BD appears to be age/or developmental stage dependent. 
Childhood abuse and neglect have been postulated to affect endocrine systems, 
producing permanent reprogramming of the HPA axis (Lai & Huang, 2011), 
leading to systemic and neurological consequences, including dysfunction in the 
prefrontal cortex, amygdale, hippocampus, gonadal hormones, and immune 
system. The effect of stress in increasing the risk of BD is progressively diminished 
as the person gets older, suggesting the existence of critical windows for this effect 
(Brietzke et al., 2012). Also, several other biological pathways, including 
neuroplasticity, inflammation, and circadian system, are proposed to play a role in 
mediating the impact of childhood trauma on risk of developing BD or a more 
severe form of the disorder (Aas et al., 2016). Preliminary results have 
demonstrated that candidate genes belonging to these pathways help moderate the 
effects of childhood trauma on age at onset and suicidality in BD (Aas et al., 2016).  
Several lines of evidence suggest that childhood trauma not only predisposes 
subjects to bipolar disorder, but also modulates the clinical expression and course 
of the disease (Etain et al., 2008). In a large study, Gilman et al. (Gilman et al., 
2015) investigated the role of childhood adversities and adulthood stressors in 
liability for bipolar disorder using data from NESARC (n=33 375). They analyzed 
risk for initial-onset and recurrent DSM-IV manic episodes. Stressors 
characterized as personal losses, financial and interpersonal problems, and 
economic difficulties were associated with 1.5 to 3-fold increases in the risk of both 
first-onset and recurrent manic episodes during a three-year follow-up period. 
Moreover, a history of childhood abuse and sexual maltreatment was associated 
with the risk of both first-onset and recurrent manic episodes independent of 
adulthood stressors. Adulthood stressors were more likely to precipitate first-onset 
mania among individuals with a history of childhood physical abuse or neglect. 
Sexual maltreatment, in contrast, was such a powerful predictor of bipolar 
disorder that stressful life events in adulthood did not further increase the risk of 
mania among adults who experienced this type of adversity.  
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Childhood physical abuse and sexual abuse seem to be the strongest predictors of 
unfavorable clinical characteristics in bipolar disorders (Etain et al., 2013). In BD, 
there are indications that childhood trauma is associated with a more severe form 
of the disease, including earlier age at onset of illness, a rapid cycling course, 
greater proneness toward depression, more psychotic features, higher number of 
lifetime mood episodes, and suicide ideation and attempts (Aas et al., 2016; Etain 
et al., 2013; Larsson et al., 2013). Etain et al. (Etain et al., 2013) also found a clear 
dose-response effect of abuse on all of these clinical variables, in the direction of 
associating increased trauma with more severe clinical expression. The influence 
of childhood trauma on the clinical expression of bipolar disorder may involve two 
types of link. For suicidal behavior, substance misuse, and psychotic features, 
childhood trauma may have a direct and probably non-specific effect, as this effect 
seems to be independent of the psychiatric disorder. Nevertheless, this direct link 
may be reinforced by an earlier onset of the disease (as childhood trauma is linked 
with earlier onset of BD and earlier onset of BD is linked with suicidal behavior, 
substance misuse, and psychotic features). For other clinical components, the 
effects of childhood trauma may be mediated by an earlier age at onset (e.g., rapid 
cycling or comorbid panic disorder) (Etain et al., 2008). 
However, no study has so far definitely demonstrated causality between 
childhood trauma and bipolar disorder (Larsson et al., 2013). Although there has 
been a long-standing suspicion that social stressors contribute to the risk of 
bipolar disorder, the limited evidence that exists is not strong enough to support 
causation, despite evidence from twin studies indicating that environmental 
factors account for approximately a quarter to a third of the population variance in 
bipolar disorder (Gilman et al., 2015). There is the unresolved chicken and egg 
debate (Etain et al., 2008). The high incidence and severity of childhood trauma in 
bipolar disorder was initially seen as causal. Another interpretation is also 
possible, namely, that being predisposed to bipolar disorder may increase the 
likelihood of experiencing trauma during childhood. According to this hypothesis, 
high trauma scores may be a consequence of childhood behavioral disturbances 
linked to an early onset of BD, to prodromal features of adulthood onset BD, or to 
early comorbid disorders and may lead to dysfunctional attitudes in parents. 
Alternatively, the genetic characteristics and psychopathology of the parents might 
lead both to disease in the offspring and to an increase in the likelihood of 
childhood trauma. In this interpretation, the genetic substrate of the parents leads 
to both the abuse and to the illness in children.  Presently, the most reliable 
predictor for BD remains a positive family history for BD. Apart from a positive 
family history, stressful life events are associated with the onset of first as well as 
subsequent mood episodes in BD (Hosang et al., 2012; Kemner et al., 2015; 
Koenders et al., 2014). 
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2.4.6.  Neuroprogression  
 
The term neuroprogression has been increasingly used to define the pathological 
reorganization of the central nervous system along the course of severe mental 
disorders. This reorganization could arise as a result of several insults, such as 
inflammation and oxidative stress.  In BD, neural substrate reactivity is changed 
by repeated mood episodes, ultimately promoting a brain rewiring that leads to an 
increased vulnerability to life stress (Gama et al., 2013).  
However, illness trajectories in BD are largely variable and it seems that 
illness progression is not a general rule in BD (Passos et al., 2016). Martino et al. 
(Martino et al., 2016) have written a critical review of the clinical evidence 
supporting the concept of neuroprogression in BD. They stated that since the 
emergence of the staging models (Berk et al., 2007; Kapczinski et al., 2009), 
copious amounts of narrative reviews have proposed BD as a neuroprogressive 
illness in which there is a higher risk of recurrence and cognitive impairment as 
well as poorer response to treatment and functional outcome as a function of 
previous episodes, as one of the pillars of the notion. After reviewing the studies 
reported on these topics, they concluded that clinical evidence supporting the 
concept of neuroprogression in BD is scarce and limited. Because in the studies 
only a part of the patients (around 20% to 40%) have been reported to have each 
of these measures of neuroprogression, they speculated that the same subgroup of 
about a third of patients may have most of these features: increased risk of 
recurrence and cognitive deficits, as well as poorer response to treatment and 
psychosocial functioning. So that it would not necessarily be a question of 
neuroprogression, rather that they are different kinds of patients from the start. 
At the moment, multimodal neuroimaging techniques such as DTI, 
functional magnetic resonance imaging (fMRI), and magnetic resonance 
spectroscopy (MRS) do not clearly support a neuroprogression model in BD. 
However, additional studies that take a lifespan and longitudinal perspective are 
needed to address this area of controversy definitively (Sajatovic et al., 2015). 
 
 
 
2.5.  Course and outcome of bipolar disorder 
 
2.5.1.  Age at onset 
 
Patients generally experience their first manic episode in their early twenties, 
although this can occur at any stage of life, from childhood to old age (Treuer & 
Tohen, 2010). Goodwin and Jameson (Goodwin & Jamison, 2007) reviewed 15 
studies published between 1990 and 2003 and derived a weighted mean of 22 
years. Baldessarini et al. (Baldessarini et al., 2010) reported pooled data from 
1,566 patients with BD from six international sites (5 European, 1 US) to compare 
ages in subgroups. They found that median age of onset was 25 years (≤13 years 
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3%, >13-19.9 years 22%, ≥ 20-29.9 years 37%, ≥ 30 years 38%). Juvenile onset 
(age≤ 20) involved 25%, and childhood onset (age ≤ 13) 3%, of cases. Median age 
at onset in BD II was six years later than in BD type I (24 years vs. 30 years).  Post 
et al. (Post et al., 2008) examined the incidence of childhood onset BD in the US 
and Europe in 543 patients with BD (type not reported). In their sample, 61% of 
the US patients had their onset of BD prior to age 19, double the rate for the 
European sites (30%). In the European sites, the mean age at onset was 25.2 years 
vs. 19.4 for the US sites. In a Norwegian sample of 225 patients with BD I or II, the 
onset age was 6% for age ≤12 years, 32% for 13-18 years, 43% for 19-29, and 19% 
for >30 years (Larsson et al., 2010). The mean age was 22.8 years. In the Finnish 
JoBS, the mean age of onset was 21.2 years (Mantere et al., 2004) and 30% of the 
patients had an age of onset <18 years (Suominen et al., 2007).    
Although the rates of recovery from index episodes are high (70%–100%) 
among children and adolescents with BD, of those who recover, up to 80% will 
experience one or more syndromal recurrences over a period of two to five years, 
particularly depressive episodes and multiple subsyndromal recurrences. 
Compared with adult BD studies, youth with BD spend more time symptomatic 
and with mixed/rapid cycling, subsyndromal symptoms, and with more mood 
changes (Birmaher, 2013). Evidence also suggests that experiencing (hypo)manic 
symptoms is a common adolescent phenomenon that infrequently predicts mental 
health use, the probability increasing linearly with the number of manic 
symptoms.  Thus, (hypo)manic symptoms may be conceived as partially pertaining 
to normal adolescent behavior (Tijssen et al., 2010).  
BD considerably affects the normal psychosocial development of a child and 
increases the risk of academic, social, and interpersonal problems (e.g., family, 
peer, work); it is also linked to an increased risk of suicidality, substance use, and 
poor health utilization (Birmaher, 2013). Earlier onset of BD is also an important 
predictor of a more severe clinical course and poorer outcome, as well as a longer 
time to correct diagnosis (Larsson et al., 2010; Suominen et al., 2007). 
At the other end of life, epidemiological studies report that types I and II BD 
affect 0.5% to 1.0% of older adults, and it is estimated that 5% to 10% of 
individuals with BD will be aged ≥50 at the time of the first manic or hypomanic 
episode (Sajatovic et al., 2015). BD becomes less common with age; in the geriatric 
population (>65 years), it is about a third (0.1-0.4%) as common as in younger 
populations (Dols et al., 2014; Sajatovic et al., 2015). Mania or hypomania that 
first appears in later life (after age 40) usually follows many years of repeated 
episodes of unipolar depression or is secondary to other factors such as steroid 
medication, infection, neuroendocrine disturbance, or neurological problems. 
However, only 15% of people with bipolar disorder presenting for the first time to 
mental health services are precipitated by a medical problem (NCCMH, 2014).  
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2.5.2.  Frequency of episodes (cycle length)  
 
Variation in cycle length (the time from the onset of one episode to the onset of the 
next) reflects primarily variation in the length of the symptom-free interval 
because the duration of episodes tends to be relatively constant in a given 
individual (Goodwin & Jamison, 2007).  Studies have found differing results 
concerning the hypothesis of progressive shortening of euthymic phases or cycle 
lengths with more recurrences. About 40% of reports found a decreasing length of 
euthymic phases, but in most reports there was either no significant change or the 
course was random (Baldessarini et al., 2012). Some studies have found a 
decreasing length of euthymic phases mainly in the first three episodes, with 
unchanging euthymic phases of about one per year for further episodes (Goodwin 
& Jamison, 2007). According to long-term follow-up studies, there seems to be no 
‘burnout’, declining of the frequency of cycles with age (Angst et al., 2003; 
Goodwin & Jamison, 2007). 
 
 
2.5.3. Onset, duration, and polarity of episodes 
 
Often, the onset of manic episodes is abrupt, developing over a few days. 
Depressive episodes develop more gradually, over weeks, although bipolar 
depressive episodes are more abrupt in onset than unipolar depressive episodes 
(Goodwin & Jamison, 2007). In the Finnish JoBS study, only half of the patients 
with BD reported having had discrete prodromal symptoms. The first prodromal 
symptom was mostly congruent with mood (e.g., decreased need to sleep before 
manic and hypomanic episodes and fatigue, loss of interest before depressed 
mood). For most patients (80%), the prodromal symptoms lasted more than a 
week, thus potentially allowing time for intervention (Mantere et al., 2008b).  
Before introduction of effective treatments, the reported duration of manic 
episodes was between 4 and 13 months and a mean length of depressive episodes 
between 4 and 8 months (Angst & Sellaro, 2000; Fagiolini et al., 2013). The 
studies conducted after effective medication has been available have shown 
decreased duration of episodes, with a mean time to recovery from 6 to 17 weeks, 
with depression lasting longer than manias in some studies (Goodwin & Jamison, 
2007). However, the recovery of treated mania, even very early in the course of 
BD, can still require three to six months before the patient no longer meets 
standard diagnostic criteria for an acute episode (syndromal remission); it can 
take even longer to reach symptomatic remission, defined as the presence of 
minimal symptoms, and still longer to attain the beginning of recovery, defined as 
remission sustained for at least two months. Time to remission is even longer 
following repeated recurrences.  
The polarity of the index episode can predict the polarity of subsequent 
episodes. Different definitions have been proposed for predominant polarity 
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across studies, from the simple definition of having more lifetime episodes of a 
given polarity to the later concept of having at least two-thirds of lifetime episodes 
in a given polarity (Carvalho et al., 2014). Patients with a depressive predominant 
polarity are most likely to attempt suicide, have depressive onset, and be 
diagnosed with BD II that follows a seasonal pattern. Conversely, with manic-
predominant polarity, drug misuse is common and patients usually present at a 
young age with a manic episode and have BD I (Grande et al., 2015). Predominant 
polarity may influence response to acute treatment for bipolar depression and 
should be considered when selecting maintenance treatment for BD (Carvalho et 
al., 2014). 
 
2.5.4.  Long-term outcome 
 
2.5.4.1.  Course and outcome 
 
Traditionally, BD has been thought of as an episodic condition characterized by 
periods of hypomania/mania and depression (Vazquez et al., 2015). However, 
studies have shown that for most patients BD is a recurrent, lifelong illness with 
high risk of disability and excess mortality, and evidence is accumulating to 
suggest that this condition is associated with significant chronicity (Judd et al., 
2002; Judd et al., 2003; Mantere et al., 2008a; Pallaskorpi et al., 2015; Perlis et 
al., 2006; Post et al., 2003; Tohen et al., 2003). For a large proportion of patients 
with BD, residual subsyndromal symptoms persist between major syndromal 
episodes, and studies have shown that many patients with BD are symptomatic for 
approximately 50% of the time over follow-up periods greater than 10 years. 
Unfortunately, despite many treatment options with demonstrated short-term 
efficacy, evidence concerning long-term treatment effectiveness in BD remains 
limited (Vazquez et al., 2015).  
 
2.5.4.2.  Rates of remission and relapse 
 
One way to study the burden of BD is through the timing and rates of 
remission/recovery and relapse/recurrence. The risk of recurrence in the 12 
months after a mood episode is especially high (50% in one year, 75% at four years 
and, afterwards, 10% per year) compared with other psychiatric disorders. So, the 
rate of relapse in those who make a full recovery from the index episode and have 
not relapsed in four years is about 10% per year; unfortunately, very few with 
residual symptoms from the index episode reach four years without having at least 
one further episode (NCCMH, 2014). 
 
2.5.4.2.1.  First manic episode follow-up studies   
 
In the McLean-Harvard First-Episode Mania Study, Tohen et al. (Tohen et al., 
2003) followed 166 patients with BD for two to four years after their first 
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hospitalization for a manic or mixed episode. Most patients (n=125, 75%) were in 
their first lifetime affective episode, but 41 (25%) had experienced prior episodes 
of depression that did not require hospitalization. By two years, most subjects 
achieved syndromal recovery (98%, with 50% achieving recovery by 5.4 weeks), 
and 72% achieved symptomatic recovery, but only 43% achieved functional 
recovery (returned to their occupational and residential status in the year before 
intake). Within two years of syndromal recovery, 40% experienced a new episode 
of mania (20%) or depression (20%), and 19% switched phases without recovery.  
In the Systematic Treatment Optimizing Program for Early Mania (STOP-
EM), Gignac et al. (Gignac et al., 2015a) followed a cohort of 81 patients with a 
first episode of mixed or manic episode for four years. They reported high 
remission and recovery rates: At 6 months, remission and recovery rates were 99% 
and 91%, respectively, and all patients remitted by 12 months and all recovered by 
18 months. Within a year of remission, 58% of patients had a recurrence of their 
mood disorder, and by four years a recurrence rate of 74% was observed. First 
recurrences were predominantly depressive, and patients who had a recurrence of 
their mood disorder within the first year had significantly higher rate of 
recurrences over the follow-up period.  
Gignac et al. (Gignac et al., 2015b) also performed a systematic review and 
meta-analysis of the former prospectively characterized cohorts of 734 patients 
with a first episode of mania. They reported a syndromal recovery rate of 84% at 
six months and 88% at one year. While most patients achieved syndromal 
recovery, only 62% had achieved a period of symptomatic recovery within one 
year. Recurrence rates were 26% within six months, 41% by one year, and 60% by 
four years (so 40% did not have a recurrence in four years).   
 
2.5.4.2.2.  Follow-up studies of unselected populations  
 
Perlis et al. (Perlis et al., 2006) reported the primary outcomes from STEP-BD. 
From 1,469 participants symptomatic at study entry, 858 (58%) subsequently 
achieved recovery. During up to two years of follow-up, 49% of these individuals 
experienced recurrences, with more than twice as many developing depressive 
episodes (35%) as those who developed manic, hypomanic, or mixed episodes 
(14%). Residual depressive or manic symptoms at recovery and the proportion of 
days depressed or anxious in the preceding year were significantly associated with 
shorter time to depressive recurrence. Residual manic symptoms at recovery and 
proportions of days of elevated mood in the preceding year were significantly 
associated with shorter time to manic, hypomanic, or mixed recurrence.   
Simhandl et al. (Simhandl et al., 2014) reported the results of a prospective 
four-year naturalistic follow-up of 300 consecutively admitted hospitalized 
patients with BD I and BD II and found that 68% of the patients relapsed within 
four years. Pallaskorpi et al. (Pallaskorpi et al., 2015) reported the five-year 
outcome of the JoBS cohort. Nearly all subjects had recovered from the index 
episode (96% had reached full remission of at least two months), but almost all 
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(90%) had a recurrence and almost half (48%) experienced three or more 
recurrences. 
Vazquez et al. (Vazquez et al., 2015) made a systematic comparison of long-
term prospective, naturalistic studies (10 studies, with 3,904 patients with BD, 
86% BD I, followed up to 2.1 years) versus randomized controlled trials (RCTs). 
Among the 10 naturalistic studies analyzed, the overall recurrence risk averaged 
55% (from 40% to 66%), and the annualized recurrence rates averaged 26%/year 
(from 20%/years to 31%/year) with clinically determined treatments. Most 
subjects in these clinical trials (70%) presented with depressive index episodes, 
and a majority (56%) of their first recurrent episodes during two-year follow-up 
was also depressive. 
 
2.5.4.3.  Time with symptoms 
 
Another way to examine the burden of BD is to analyze the proportion of time ill. 
The evidence shows the disabling nature of BD, with patients having symptoms 
about half of the time followed. According to the results, BD II is not a milder form 
of BD; in some ways, it is even worse than BD I. 
Judd et al. (Judd et al., 2002; Judd et al., 2003) reported the results of the 
National Institute of Mental Health Collaborative Depression Study (CDS), a 
prospective long-term follow-up of 146 patients with BD I and 86 patients with BD 
II. Patients with BD I were symptomatically ill 47% of weeks throughout a mean of 
12.8 years of follow-up. Depressive symptoms predominated over 
manic/hypomanic symptoms; patients experienced three times more depressive 
than manic symptoms (32% vs. 9% of total follow-up weeks). Subsyndromal and 
minor depressive/dysthymic symptoms were much more prevalent than major 
depressive-level symptoms (23% vs. 9% of weeks). Overall, most symptomatic 
weeks involved subsyndromal, minor depressive, and hypomanic symptoms 
(74%). Only 12% of all follow-up weeks were spent with symptoms at the threshold 
for major depression or mania.  Patients with BD II were symptomatically ill for 
more than half of the follow-up weeks (54%). They experienced 39 times more 
depressive symptoms (50% of all follow-up weeks) than hypomanic symptoms (1% 
of all follow-up weeks). Subsyndromal, minor depressive/dysthymic, and 
hypomanic symptoms combined were three times more prevalent than full major 
depressive-level symptoms (41% vs. 13% of all follow-up weeks).  
Post et al. (Post et al., 2003) reported morbidity in 258 bipolar outpatients 
followed for one year in the SFBN. Patients were treated naturalistically with a 
mean of four psychotropic medications during the year.  Despite comprehensive 
pharmacological treatment, two-thirds of the patients were substantially affected 
by their illness; 26% was ill for more than three fourths of the year, and 41% was 
intermittently ill with major affective episodes. Patients experienced symptoms 
almost half (47%) of the year, with manic symptoms 11% of the time and 
depressive symptoms 33% of the time. Only 9% of the patients had no episodes, 
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28% had one to three episodes, 32% had four to eight episodes, and 31% of the 
population had more than eight episodes in the year. 
In another SFBN study (Kupka et al., 2007), clinician-adjusted self-ratings of 
mood were completed daily for one year for naturalistic treated outpatients with 
BD I (n=405) or BD II (n=102). The percentages of time spent ill for BD I vs. BD II 
were; euthymia 48% vs. 50%, depression 36% vs. 37%, hypomania 12% vs. 10%, 
mania 1% vs. 0%, and rapid cycling 4% vs. 3%. The study confirmed that 
depression is the most common illness state in BD outpatients receiving 
naturalistic treatment, but the more depressive course of BD II than BD I seen in 
Judd et al.’s long-term follow-up was not seen in this study. Based on the Finnish 
JoBS study, Mantere et al. (Mantere et al., 2008a) reported the outcome results of 
18 months’ follow-up. Patients with BD II spent a higher proportion of time ill 
(48% vs. 38%) and 40% more time in depressive states (58% vs. 42%) than BD I 
patients. Pallaskorpi et al. (Pallaskorpi et al., 2015) studied the five-year outcome 
of the same cohort and reported that, contrary to the 18-month follow-up and 
similar to the findings of Kupka et al., there were no differences in the time spent 
in depressive states between patients with BD I and BD II. They found that the 
patients spent almost a third of the time in illness episodes and about a sixth of the 
time with subthreshold symptoms. Half the time, they were euthymic.   
 
 
2.6.  Disability in BD 
 
Functioning is a complex concept that involves many different domains, including 
the capacity work, study, live independently, and engage in recreational activities 
and interpersonal relationships (Zarate et al., 2000). Functional recovery is 
defined as the return to premorbid levels of psychosocial activity (Strakowski et 
al., 1998). In most studies, functional recovery has been described as the ability to 
achieve the level of functioning prior to the most recent episode (Martinez-Aran et 
al., 2007).  
 
 
2.6.1.  Burden of bipolar disorder  
 
In the era prior to modern pharmacotherapy, Kreapelin (1921) described a 
relatively good long-term outcome of manic-depressive illness, with periodic 
manic or depressive episodes typically followed by a return to what was considered 
normal functioning (Rosa, Sanchez-Moreno et al., 2007). However, modern 
outcome studies have found that most bipolar patients evidence high rates of 
functional impairment (Zarate et al., 2000). Psychosocial functioning in BD runs 
the full gamut of human potential. Whereas some people with BD accomplish 
historical landmarks in human achievement, others experience significant 
difficulties in managing the tasks of daily living (Levy & Manove, 2012).  
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Poor premorbid functioning tends to present early in the course of BD. Although 
many patients with BD regain psychosocial functioning upon symptomatic 
remission, the majority of patients suffer significant and persistent interpersonal, 
social, and vocational impairment, often despite adequate control of affective 
symptoms (Andreou & Bozikas, 2013). Disappointingly, despite several new 
treatment options, the proportion of patients with BD who are able to retain their 
premorbid levels of social and vocational functioning has not increased since the 
1970s (Dickerson et al., 2010).   
Bipolar disorder is among the 20 leading causes of disability worldwide, just 
below schizophrenia (Vos et al., 2012), and imposes a tremendous burden on 
patients and the health care system (Dean et al., 2004). At the individual level, 
disability and costs of BD are greater than in major depressive disorder, although 
MDD has a larger impact on the general population due to its higher prevalence 
(Goldberg & Harrow, 2011; Kessler et al., 2006; McIntyre, Wilkins et al., 2008). 
Long-term follow-up studies of patients with BD have indicated strikingly high 
levels of sustained morbidity, on the order of 30% to 50% of time observed, mostly 
accounted for by depressive-dysthymic-dysphoric morbidity that persists or recurs 
despite treatment (Huxley & Baldessarini, 2007). Several studies have also 
confirmed that 30% to 60% of bipolar patients, even if in syndromic remission, fail 
to regain full functioning in occupational and social domains (MacQueen et al., 
2001). Even patients who achieve full clinical remission show difficulties in 
reaching a complete functional recovery, that is, returning to their premorbid level 
of functioning (Sanchez-Moreno et al., 2009). In the McLean-Harvard First-
Episode Mania Study, Tohen et al. (Tohen et al., 2003) followed 166 patients with 
BD for two to four years after their first hospitalization for a manic or mixed 
episode. Within two to four years of first lifetime hospitalization for mania, all but 
2% of patients’ experienced syndromal recovery, but 28% remained symptomatic, 
with only 43% achieving functional recovery. 
 
 
2.6.2.  BD and vocational ability 
 
Work is an important part of functioning and vocational disability affects the 
patient, his or her nearest, and society as a whole in many ways. Work is highly 
valued by people with mental illness and return to work is seen as integral to their 
notion of recovery (Gilbert & Marwaha, 2013). High rates of unemployment, 
absenteeism, failure to return to work following acute episodes, and work 
impairment are frequent (Dean et al., 2004). According to a recent review 
(Marwaha et al., 2013), most studies (follow-up from 6 months to 15 years) with 
samples of people with established BD have suggested that approximately 40% to 
60% is employed, while the employment rate in the general population in Europe 
ranges from 62% to 66% and in the US from 66% to 74%.  About 30% to 40% of 
patients with BD have significant difficulties in work performance, and 40% to 
50% may suffer a slide in their occupational status over time.  Also, Morselli et al. 
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(Morselli et al., 2004) found that for each of the European nations studied, the 
percentage of unemployed people in the BD group was significantly above the 
mean level of unemployment in each country. Reed et al. (Reed et al., 2010) 
reported the results of a prospective study of 1,795 patients with a manic or mixed 
episode followed up for two years (European mania in bipolar longitudinal 
evaluation of medication study [EMBLEM]). Most (69%) of the patients had high 
work impairment in the year prior to the acute episode. Impairment in work 
ability at two years was found in 42% of the patients, and 15% was unable to work 
due to mental illness.   
The reasons for the poor vocational outcome of patients with BD are not well 
understood. Studies have focused on work impairment in terms of long-term 
employment, occupational functioning, absenteeism due to emotional problems 
and somatic complaints, and poor work performance (Dean et al., 2004). Studies 
have searched explanations from demographic, clinical, and neurocognitive risk 
factors, and many of these have been associated with disability (Huxley & 
Baldessarini, 2007; Sanchez-Moreno et al., 2009; Tse et al., 2014).  
Many factors have also been associated with vocational outcome, but they 
vary between studies and have been difficult to replicate, in part due to 
methodological differences in assessing functional outcome and the populations 
studied (Martinez-Aran et al., 2007).  Symptoms of illness phases, also 
subsyndromal symptoms, affect functioning, even if hypomanic symptoms 
sometimes temporarily involve a higher level of functioning (Altshuler et al., 2006; 
Judd et al., 2005; Rosa et al., 2010; Simon et al., 2007). Also, the number of 
hospitalizations, as a proxy for overall severity of the illness, has been found to 
predict work disability (Tse et al., 2014). However, as even patients who achieve 
clinical remission show difficulties in returning to their premorbid level of 
functioning (Sanchez-Moreno et al., 2009), other reasons must also exist. The 
factors  most consistently associated with functional impairment in patients with 
BD after episode remission include residual depressive symptoms (Altshuler et al., 
2006; Bonnin et al., 2010; Bonnin et al., 2012; Gitlin et al., 2011; Judd et al., 2005; 
Rosa et al., 2009) and specific deficits in cognitive functioning (Andreou & 
Bozikas, 2013; Martinez-Aran et al., 2007; Mur et al., 2009; Wingo et al., 2009), 
but additional explanations for the disability in patients with BD in remission have 
also been sought. In recent studies, Yan-Meier et al. (Yan-Meier et al., 2011) found 
stressful life events in the prior three months, Strejilevich et al. (Strejilevich et al., 
2013) found mood instability, Jimenez et al. (Jimenez et al., 2012) found 
impulsivity, and Gershon et al. (Gershon & Eidelman, 2015) found inter-episode 
intensity and instability to be associated with functional impairment. So, in 
addition to cross-sectional severity, longitudinal course of illness, and cognitive 
functioning, other clinical factors may influence the ability to work. 
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2.6.3.  Long-term vocational disability and disability pension  
 
Patients with BD who are on disability pension or long sick leave likely suffer from 
the most severe forms of work disability due to their illness. Nevertheless, despite 
their marked public health and economic relevance, only a few cross-sectional 
studies (Grande et al., 2013; Gutierrez-Rojas et al., 2011; Schoeyen et al., 2013) 
have specifically investigated risk factors for disability pensions and/or long sick 
leaves among patients with BD. The predictors of receiving a disability pension in 
these studies were Axis II comorbidity, number of manic episodes, being without a 
stable partner, and older age (Grande et al., 2013), previous repeated manic 
episodes, three or more hospitalizations, and current depressive symptoms, lower 
educational attainment (Gutierrez-Rojas et al., 2011), the preceding number of 
hospitalizations for depressive episodes and illness duration (Schoeyen et al., 
2013). The factors that are correlated to current work status and true predictors of 
future disability pension may differ because in cross-sectional studies causes and 
consequences are difficult to differentiate. A cross-sectional design also precludes 
specifying the timing and conditions under which the pension was granted. 
 
 
2.7.  Mortality 
 
An increasing body of research has shown that BD is associated with premature 
mortality. Where previously it was believed this was mostly attributable to 
unnatural causes such as suicide, homicide, or accident, patients with BD are also 
at risk of premature death from a range of medical illnesses (Hayes et al., 2015).  
In a large national cohort study (Crump et al., 2013), women and men with 
BD had, respectively, 2.3-fold and 2.0-fold increased mortality and died 9.0 (mean 
age, 73.4 vs. 82.4 years) and 8.5 (mean age 68.9 vs. 77.4 years) years earlier on 
average than the rest of the population. This life expectancy difference was not 
fully explained by unnatural deaths. Patients with BD had an increased risk of 
death from ischaemic heart disease, diabetes, COPD, influenza or pneumonia, 
unintentional injury, and suicide for both women and men and cancer for women 
only. After adjusting for age and other sociodemographic factors, the risk of death 
from suicide was 10-fold among women and 8-fold among men with BD compared 
with other women or men. Although the highest hazard ratios were for suicide, the 
leading causes of death were cardiovascular disease and cancer, as in the general 
population.  Substance use disorders explained only a modest part of these 
findings. The authors also found that these associations between BD and mortality 
from chronic diseases (ischaemic heart disease, diabetes, COPD, or cancer) were 
much weaker among persons with an earlier diagnosis of these conditions, 
suggesting that timely medical diagnosis and treatment may effectively reduce 
mortality among patients with BD to approach that of the general population. 
Another nationwide register study from Denmark (Kessing et al., 2015) found that 
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for a typical male or female patient with BD aged 25 to 45 years, the remaining life 
expectancy was decreased by 12.0-8.7 years and 10.6-8.3 years, respectively.  
A recent systematic review and meta-analysis by Hayes et al. (Hayes et al., 
2015) showed that all-cause mortality in BD is double that expected in the general 
population. Natural deaths are more than 1.5 times greater in BD than in the 
general population; these natural deaths include an almost double the risk of 
death from circulatory illnesses (e.g., heart attacks, strokes) and three times the 
risk of death from respiratory illness (e.g., COPD, asthma). Unnatural deaths are 
around seven times more common, with an increased risk of suicide of around 14 
times and other violent deaths (e.g., accidents, homicides) almost four times as 
likely.  There is no evidence that all-cause mortality for patients with BD has 
improved over time (from the 1950s) relative to the general population, despite the 
modern treatments since then.  
A review by the International Society for Bipolar Disorders (ISBD) Task 
Force on Suicide in BD (Schaffer et al., 2015) found that the pooled suicide rate in 
bipolar disorder is 164 per 100,000 person-years. Sex-specific data on suicide 
rates identified a 1.7:1 ratio in men compared to women. People with bipolar 
disorder accounted for 3.4% to 14% of all suicide deaths, with self-poisoning and 
hanging being the most common methods. According to the reviewed 
epidemiological studies, 23% to 26% of people with bipolar disorder attempt 
suicide, with higher rates in clinical samples. In the Finnish JoBS study, 80% of 
patients had suicidal behavior and 51% had attempted suicide during their lifetime 
(Valtonen et al., 2005). 
 
 
2.8.  Treatment of bipolar disorder 
 
2.8.1.  Pharmacotherapy 
 
The treatment of BD can be divided into acute phase treatment, in which the aim 
is symptomatic recovery with stable eythymic mood, and maintenance phase 
treatment, in which the aims are relapse prevention, reduction of subtreshold 
symptoms, and enhanced social and occupational functioning (Geddes & 
Miklowitz, 2013). The basic treatments for BD have been mood stabilizers 
(lithium, valproate, carbamazepine, lamotrigine) and antipsychotics (traditional 
and atypical antipsychotics) accompanied by appropriate psychosocial treatment. 
Over the last 10 to 15 years, there has been a substantive increase in the number of 
treatments for each phase of BD that have been well established in large, 
methodologically sound trials (Ostacher et al., 2015).  However, overall, advances 
in drug treatment remain quite modest. On the other hand, substantial progress 
has been made in the development and assessment of adjunctive psychosocial 
interventions (Geddes & Miklowitz, 2013). 
Because of the difficulty in choosing the right treatment, guidelines have 
been developed; these are “systematically developed statements that assist 
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clinicians and service users in making decisions about appropriate treatment for 
specific conditions” (NCCMH, 2014). They are derived from the best available 
research evidence, using predetermined and systematic methods to identify and 
evaluate the evidence relating to the specific condition in question. The following 
recommendations are mainly based on recent practice guidelines: Canadian 
Network for Mood and Anxiety Treatments (CANMAT) guidelines for the 
management of patients with BD 2005 (Yatham et al., 2005) and updates 2009 
(Yatham et al., 2009) and 2013 (Yatham et al., 2013); World Federation of 
Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment 
of BD, update 2009 on the treatment of acute mania (Grunze et al., 2009), update 
2010 on the treatment of acute bipolar depression (Grunze et al., 2010), and 
update 2012 on the long-term treatment of BD (Grunze et al., 2013); British 
Association for Psychopharmacology (BAP), Evidence-based Guidelines for 
Treating BD, revised second edition 2009 (Goodwin & Consensus Group of the 
British Association for Psychopharmacology, 2009); Finnish Current Care 
Guideline for BD (FCCG), update 2013 (Workgroup for Finnish Current Care 
Guideline, Bipolar Disorder, 2013); National Institute for Health and Care 
Excellence (NICE) clinical guideline for BD 2014 (NICE, 2014), update 2016; 
Florida Best Practice Psychotherapeutic Medication Guidelines (FBPG) for Adults 
with BD, 2015 (Ostacher et al., 2015); and in some parts also the American 
Psychiatric Association (APA) practice guideline for the treatment of patients with 
BD, 2002 (APA, 2002). 
 
2.8.1.1.  Pharmacologic treatment of manic episodes 
 
For patients experiencing a manic or mixed episode, the primary goal of treatment 
is the control of symptoms to allow a return to normal levels of psychosocial 
functioning. The rapid control of agitation, aggression, and impulsivity is 
particularly important to ensure the safety of patients and those around them 
(APA, 2002). The acutely manic bipolar patient may present in an agitated state 
that acts as a barrier to therapy, interrupts the physician-patient alliance, and 
creates a disruptive, even hazardous, environment. Oral therapy should be offered 
first whenever possible as it can be as effective as intramuscular agents. 
Intramuscular injections may be used for patients who refuse oral therapy. 
According to the CANMAT update 2013, intramuscular olanzapine, ziprasidone, 
and aripiprazole or a combination of intramuscular haloperidol and a 
benzodiazepin should be considered. Benzodiazepines may be used as adjuncts to 
sedate acutely agitated patients. 
Acute mania is the phase best studied. A significant number of treatment 
options are available with solid evidence to support them (Fountoulakis et al., 
2012). Lithium, carbamazepine, valproate, haloperidole, and atypical 
antipsychotics (quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, 
asenapine, and paliperidone) have been shown to be efficacious against mania 
(Smith et al., 2007). The practice guideline recommendations for the first and 
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second line of monotherapy are represented in table 1. When choosing medication, 
one should consider the types of symptoms of mania the patient has (e.g., 
euphoric, mixed, psychotic) and their severity, previous experiences and patient 
preference, long-term treatment, modifying medical factors, and safety profile 
(WFSBP, 2009). 
Lithium is recommended as a first-line treatment for acute mania in most 
guidelines (APA 2002, WFSBP 2009, BAP 2009, CANMAT 2013, FBPG 2015), but 
NICE 2016 recommends it only if the patient is already taking it or as an add-on to 
the first-line antipsychotic. The usefulness of lithium in acute mania may be 
limited by the need for regular plasma level checks to avoid toxicity, as well as by 
its side-effect profile and contraindications. Its potentially slower onset of action 
together with the low levels of sedative properties often makes it necessary to 
combine it with a tranquilizing agent at treatment initiation (WFSBP 2009).  
Valproate is also recommended as a first-line treatment for acute mania in 
most guidelines (APA 2002, WFSBP 2009, BAP 2009, CANMAT 2013, FBPG 
2015), but, as with lithium, NICE 2016 recommends valproate only if the patient is 
already taking it or as an add-on to the first-line antipsyhotic.  The safety margin 
of valproate is relatively large, allowing rapid titration (“dose loading”) and a 
subsequent earlier onset of action (WFSBP 2009). The use of valproate is limited 
by the risk of teratogenicity, including developmental delay in children exposed to 
it in utero, and a high risk of unplanned pregnancy in women with BD (Geddes & 
Miklowitz, 2013). Therefore, it is important that the potential harm to developing 
fetuses be discussed with women and their families (CANMAT 2013, FBPG 2015), 
in addition to discussion of the use of effective contraception (APA 2002, WFSBP 
2009, BAP 2009, FCCG 2013, CANMAT 2013, FBPG 2015). The NICE 2016 
guideline recommends against offering valproate to women of childbearing 
potential for acute or maintenance treatment. 
A substantial amount of data demonstrates that carbamazepine has efficacy 
similar to lithium and valproate (WFSBP 2009, CANMAT 2005), but because of 
safety, tolerability, and interactions with other medications, it is rarely advocated 
for first-line treatment (usually recommended as a second-line treatment) (APA 
2002, WFSBP 2009, BAP 2009, CANMAT 2013, FBPG 2015). In the FCCG for 
Bipolar Disorder 2013, which only lists medications by efficiency, it is listed among 
the ones that are efficient for mania. The NICE 2016 guideline does not list 
carbamazepine among the medications recommended for mania.  
Several second-generation or atypical antipsychotics, including olanzapine, 
quetiapine, risperidone, aripiprazole, asenapine, and zipraridone (FCCG 2013) and 
paliperidone (CANMAT 2013, FBPG 2015) have been found to be effective against 
mania. Few trials directly assessing the comparative efficacy of different second-
generation or atypical antipsychotics exist, but a mixed treatment meta-analysis 
compared 13 agents studied in 68 randomized controlled trials (16,073 
participants) (Cipriani et al., 2011). This review found substantial and clinically 
important differences in terms of both efficacy and tolerability between agents.  
According to this review, antipsychotic drugs seem to be better than 
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anticonvulsants and lithium in the treatment of manic episodes, and olanzapine, 
risperidone, and the first-generation antipsychotic haloperidol had the best profile 
of agents included (Geddes & Miklowitz, 2013). Most guidelines recommend 
atypical antipsychotics as a first-line treatment. Of the (atypical) antipsychotics, 
the NICE 2016 guideline recommends only olanzapine, risperidone, and 
quetiapine and the first-generation antipsychotic haloperidol against mania. 
Paliperidone, a metabolite of risperidone, is recommended as first-line treatment 
in CANMAT 2013 and as second-line treatment in FBPG 2015. The major concern 
with especially olanzapine, but to a lesser extent also quetiapine and risperidone, 
is weight gain and metabolic problems.  Because of these safety concerns, the 
FBPG 2015 guideline sets olanzapine to a lower level (1B) and the BAP 2009 
guideline sets both olanzapine and quetiapine to level 2.    
 
 
Table 1.  First- and second-line treatment recommendations for acute manic 
phase according to practice guidelines. 
 
Practice  
guideline 
Manic phase 
Li Val Car Lam SGA OFC FGA AD 
BAP 2009 + ++ +  ++1  + D/C 
WFSBP 2009 +/++ ++ +  ++2  +8  
CANMAT 2013 ++ ++ +  ++3  +8 D/C 
FCCG 2013 ++ ++ ++  ++4  ++8  
NICE 2016 +5 +5   ++6  ++8  
FBPG 2015 ++ ++ +  ++7  +8  
1aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, 2aripiprazole, risperidone, 
ziprasidone; olanzapine as second line because of safety concerns, quetiapine and asenapine also 
as second line. 3aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, asenapine, 
paliperidone, 4aripiprazole, asenapine, quetiapine, olanzapine, risperidone, ziprasidone, 5add-on 
antipsychotic, 6olanzapine, quetiapine, risperidone, 7aripiprazole, asenapine, quetiapine, 
risperidone, ziprasidone; olanzapine 1B because of safety concerns, 8haloperidol. SGA=Second 
generation antipsychotic, FGA=First generation anti-psychotic, OFC=Olanzapine+fluoxetine, 
D/C=discontinue. 
 
 
 
Of the first-generation antipsychotics, haloperidol has been shown to be effective 
against mania (WFSBP 2009) and is recommended as a first-line treatment in 
NICE 2016 and a 1B level treatment in FBPG 2015, and it is listed among the 
agents effective against mania in FCCG 2013. Because of the neurological side-
effects (extrapyramidal motor symptoms and tardive dyskinesia), it is rated second 
line in the other guidelines (WFSBP 2009, BAP 2009, CANMAT 2013). 
 
 
50 
 
2.8.1.2.  Pharmacologic treatment of mixed episodes 
 
The simultaneous presentation of manic and depressive symptoms poses 
significant treatment challenges. Data suggest that patients who are in a mixed 
state are less likely to achieve remission and take longer to do so (CANMAT 2005). 
Suicide risk also appears to be high (Valtonen et al., 2008). Mixed episodes are not 
included in the DSM-5; instead, it has a mixed features specifier which can apply 
to the current manic, hypomanic, or depressive episode in BD I or II or MDD. For 
mixed episodes, APA 2002, BAP 2009, and NICE 2016 guidelines recommend the 
same medications as for a manic phase. According to CANMAT 2005, lithium may 
not be as effective in mixed states as it is in classic mania, while valproate and 
atypical antipsychotics appear to be equally effective in both. The FCCG 2013 
recommends aripiprazole, carbamazepine, olanzapine, risperidone, tsiprasidone, 
and valproate for mixed episodes. The more recent guideline, FBPG 2015, which 
was written during a period of transition from DSM-IV to DSM-5, gives no 
recommendations for the treatment of manic or hypomanic episodes with a mixed 
specifier as there is no evidence for treatments in these phases. 
 
2.8.1.3.  Pharmacologic treatment of hypomanic episodes 
 
Untreated hypomania may be associated with major financial, legal, and 
psychosocial problems, without ever commanding medical attention, but virtually 
no studies have been carried out to assess effective treatments. Treatment 
approaches for acute hypomania have typically mimicked those for manic episodes 
(CANMAT 2005). Hypomania may be the prelude to full-blown mania in 
individual patients, in which case treatment should be as for mania. Otherwise, 
hypomania is not a common point for the initiation of new treatment. In case the 
patient is receiving prophylactic treatment with an antimanic agent, the best 
recommendation is to check the plasma level of the medication and, depending on 
the result, increase the dosage. If no further prophylaxis is planned, short-term 
treatment with either valproate or an atypical antipsychotic may be the best 
choice, as both are well tolerated and have a good safety profile and relatively 
rapid onset of action, minimizing the danger that hypomania develops into mania 
within the next days. In this respect, it is also important to intervene early against 
sleep loss as this may be an important factor for developing full-blown mania 
(WFSBP 2009). The FCCG 2013 recommends increasing the dosage of the 
maintenance treatment against mania, discontinuing antidepressant medication 
that predisposes to hypomania, and using atypical antipsychotics for a short 
period. 
 
2.8.1.4.  Pharmacologic treatment of depressive episodes 
 
Patients with BD, especially patients with BD II, spend much more time in 
depressive phases than in any other acute phase and so treatment of depression is 
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of major importance. The depressive phase of bipolar disorder is chronic in 20% of 
patients and causes more disability and decreased quality of life than any other 
phase of the illness. Even subsyndromal depressive symptoms are associated with 
functional impairment. In rapid cycling bipolar patients, depressive episodes are 
more refractory to treatment than hypomanic or manic episodes. Suicidal acts are 
a major concern in patients with bipolar disorder and are associated with severe 
depressive and mixed phases of illness, higher depression scores, and a greater 
number of severe depressive episodes (CANMAT 2005). However, unfortunately, 
the treatment of bipolar depression is a major challenge, with few treatments of 
proven efficacy and, in particular, substantial controversy about the role of 
antidepressant drugs (Geddes & Miklowitz, 2013). 
 
 
Table 2.  First- and second-line treatment recommendations for acute bipolar 
depression according to practice guidelines. 
  
Practice  
guideline 
Depressive phase 
Li Val Car Lam SGA OFC FGA AD 
BAP 2009 (+) (+)  ++ ++2   +3 
WFSBP 2010     ++2 +   
CANMAT 2013 ++ + (+) ++ ++1 ++  +4 
FCCG 2013 + (+)  + ++2 +  +4 
NICE 2016    + ++1 ++   
FBPG 2015 +   + ++1 +   
1quetiapine; lurasidone (Canmat as second line, FBPG), olanzapine monotherapy as second line 
(NICE) or third line (CANMAT), 2quetiapine, 3together with an antimanic agent in BD I and with 
caution in BD II if without antimanic agent, 4combined with mood stabilizer, SGA=Second 
generation antipsychotic, FGA=First generation antipsychotic, OFC=Olanzapine+fluoxetine. 
 
 
 
For the management of bipolar depression, WFSBP 2010 concludes that no choice 
of first step in treating BD shows unequivocal benefits. They give no overwhelming 
preference for any single treatment, but quetiapine is the only one recommended 
on grade 1. They see previous response as one of the strongest predictors of 
treatment success.  Lithium may be used if it has been ongoing, after checking the 
serum levels. Lamotrigin may be started if lithium optimization is unsuccessful. 
The CANMAT 2013 guideline recommends lithium, lamotrigine, and quetiapine 
monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor 
(SSRI), and lithium or valproate plus SSRI/bupropion as first-line options. The 
2016 NICE guideline recommends olanzapine plus fluoxetine combination (OFC) 
or quetiapine monotherapy or, if the person prefers, either olanzapine or 
lamotrigin monotherapy. The second level, if there is no response to OFC or 
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quetiapine, is lamotrigine monotherapy. If the patient is already on lithium or 
valproate, the recommendation is to check the plasma levels, increasing the dose if 
necessary and adding one of the first-line treatments. In the FBPG 2015 guideline, 
quatiapine (BD I or II) or lurasidone (BD I) monotherapy or as adjunctive to 
lithium or valproate (BD I) have the highest level (1A) recommendation for BD I 
(with quetiapine the only specific treatment recommended for any phase of BD II). 
OFC is recommended at level 1B because of the safety concerns associated with 
olanzapine’s metabolic effects. Lithium, lamotrigine, and a combination of lithium 
plus lamotrigine are level 2 recommendations because the evidence for them is not 
as strong as for the ones listed for level 1.  
 
2.8.1.5.  Pharmacologic maintenance treatment 
 
There is no doubt that all patients need aftercare for some months with 
continuation treatment after acute symptoms have resolved. This period can last 
from a few months to a year. However, no controlled prospective studies indicate 
when long-term prophylaxis (beyond aftercare) becomes compulsory (WFSBP 
2012). Most recent guidelines (BAP 2009, CANMAT 2013, NICE 2016, FBPG 
2015) do not specify when long-term prophylactic treatment becomes necessary. 
The WFSBP 2012 does not make an explicit recommendation, as there is a lack of 
studies to rely on, but it refers to the Dutch guideline (Nolen et al., 2008), which 
considers the number of episodes and variables such as positive family history of 
BD suggestive of an increased genetic risk. For patients with a first episode of not-
severe mania, without a first-degree family history of BD, the guideline does not 
recommend maintenance treatment. However, they recommend considering 
maintenance treatment for patients with a first episode (mania) and positive first-
degree family history of BD or if the episode of mania has been severe; they also 
recommend maintenance treatment for patients with a second episode (at least 
one manic episode) without a positive first-degree family history. They 
recommend maintenance treatment for patients with a third (or more) episode of 
which at least one is (hypo)mania and for patients with a second episode (at least 
one manic episode) and a positive first-degree family history and/or severe 
episode. The FCCG 2013 recommends starting maintenance treatment always 
when the diagnosis of BD is made. For patients with BD I, it recommends 
permanent maintenance treatment; the same recommendation is also made for 
patients with BD II if there has been marked suicidality, psychotic depressive 
episodes, or significant functional disability or if there have been many episodes. 
In other cases with BD II, and if the patient has been in remission for many years, 
slowly discontinuing the maintenance treatment can be considered. However, 
whatever the advice from doctors, the limiting consideration at this stage is often 
the attitude of the patient and the family, underlining the necessity of 
psychoeducation (WFSBP 2013). 
CANMAT 2013 recommends lithium, valproate, olanzapine, and quetiapine, as 
well as lamotrigine (primarily for prevention of depression), aripiprazole, and 
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long-acting risperidone as first-line monotherapy treatments for maintenance 
treatment of BD. Quetiapine, long-acting risperidone, aripiprazole, and 
ziprasidone are also recommended as adjunctive to lithium or valproate as first-
line treatments.  WFSBP 2012 recommends lithium, quetiapine, aripiprazole, and 
lamotrigine as first-line treatments. Olanzapine and risperidone have been 
downgraded to second-level treatments because of safety issues (weight gain with 
both, and also metabolic issues with olanzapine and hyperprolactinemia with 
risperidone). NICE 2016 recommends’ taking into account drugs that have been 
effective during episodes of mania or depression and discussing with the patient 
whether he or she wants to continue this treatment or switch to lithium. Lithium is 
recommended as the first-line maintenance treatment and, if ineffective, adding 
valproate is recommended. If lithium is poorly tolerated or not suitable, NICE 
2016 recommends’ valproate or olanzapine monotherapy, or quetiapine if it has 
been effective during the acute phase. FBPG 2015 recommends lithium, 
quetiapine, aripiprazole, and lamotrigine (evidence strongest for prevention of 
depression, usually as adjunct) and long-acting risperidone as first-line 
monotherapy treatments (Level 1A). Olanzapine monotherapy is only 
recommended for 1B level because of concerns about weight gain and metabolic 
syndrome. 
 
 
 
Table 3.  First- and second-line treatment recommendations for maintenance 
phase according to practice guidelines. 
 
Practice 
guideline 
Maintenance phase 
Li Val Car Lam SGA OFC FGA AD 
APA 2002 ++ ++ + +     
BAP 2009 ++ + + + +1   (+) 
WFSBP 2010 ++   ++ ++2/+3    
CANMAT 2013 ++ ++ + ++ ++4    
FCCG 2013 ++ ++   ++6    
NICE 2016 ++ +   +5    
FBPG 2015 ++   ++ ++6    
1aripiprazole, quetiapine, olanzapine, risperidone, ziprasidone, 2aripiprazole, quetiapine, 
3olanzapine, risperidone, 4olanzapine, quetiapine, risperidone LAI, aripiprazole; paliperidone 
second line; asenapine third line, 5olanzapine, quetiapine, 6quetipine, aripiprazole, risperidone LAI; 
olanzapine level 1B because of safety concerns, SGA=Second generation antipsychotic, 
FGA=First generation antipsychotic, OFC=Olanzapine+fluoxetine. 
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2.8.1.6.  Pharmacologic treatment of BD II 
 
The only recommendation for the pharmacological treatment of BD II in the FBPG 
2015 is quetiapine monotherapy for BD II depression. It states that they did not 
want to extend the recommendations for BD I to the treatment of BD II as the 
evidence does not support doing so. BAP 2009 follows the same line. The other 
recent guideline (NICE 2016) does not separate BD into type I and II so the same 
recommendations apply for both types. The CANMAT 2013 guideline has 
recommendations also for BD II depression. It recommends quetiapine 
monotherapy as the only first-line treatment, whereas lithium, lamotrigine, and 
valproate monotherapy as well as lithium or valproate in combination with an 
antidepressant, lithium combined with valproate, and atypical antipsychotics 
combined with antidepressants are recommended as second-line treatments. The 
CANMAT recommendations for BD II maintenance treatment are lithium, 
lamotrigine, and quetiapine as first line-treatments and valproate monotherapy, 
lithium, valproate or atypical antipsyhotic combined with antidepressant, 
adjunctive quetiapine, adjunctive lamotrigine, combination of two of lithium, 
valproate, or atypical antipsychotic as second-line treatments.  According to FCCG 
2013, quetiapine is efficient in acute bipolar II depression, but it is uncertain if 
lamotrigin is efficient. Adding antidepressants to mood stabilizers may be of use if 
there are no concurrent hypomanic symptoms. The guideline recommends 
quetiapine as a first-line treatment for maintenance treatment in BD II and 
lithium, lamotrigin, valproate, and carbamazepine as second-line treatments. 
 
2.8.1.7.  Electro-convulsive therapy  
 
Electro-convulsive therapy (ECT) is highly effective for treatment-resistant acute 
mood episodes, particularly in patients with psychotic or catatonic features 
(Grande et al., 2015; Schoeyen et al., 2015). The BAP 2009 guideline recommends 
considering ECT for depressive BD patients with high suicidal risk, psychosis, 
severe depression during pregnancy, or life threatening inanition and for manic 
patients who are severely ill and/or whose mania is treatment resistant, patients 
who express a preference for ECT, and patients with severe mania during 
pregnancy. The CANMAT 2013 guideline recommends ECT as a third-line 
treatment for BD depression, but for earlier consideration in patients who have 
psychotic bipolar depression, in those at high risk for suicide, and in those with 
significant medical complications due to not drinking and eating. For manic 
patients, the CANMAT 2013 guideline recommends ECT as a second-line 
treatment.  
 
2.8.2.  Psychosocial interventions 
 
The development of effective psychological interventions for bipolar disorder is 
relatively recent. Historically, individuals with this diagnosis were seen as poor 
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candidates for psychotherapy because of potentially challenging interactions with 
therapists. However, there has been a growing awareness that psychological 
factors play an important role in bipolar disorder and that treatment approaches 
addressing these factors can improve clinical outcomes (NCCMH, 2014). 
Although pharmacotherapy is the mainstay of treatment for bipolar disorder, 
medication offers only partial relief for patients. Treatment with pharmacological 
interventions alone is associated with disappointingly low rates of remission, high 
rates of recurrence, residual symptoms, and psychosocial impairment (Swartz & 
Swanson, 2014). Substantial progress has been made in the development and 
assessment of adjunctive psychosocial interventions (Geddes & Miklowitz, 2013) 
and bipolar-specific therapy is increasingly recommended as an essential 
component of illness management (Swartz & Swanson, 2014). 
A number of psychological interventions is available for which there is a 
current evidence base (NCCMH, 2014). Evidence-based models of psychotherapy 
include cognitive-behavioral therapy, family-focused therapy, interpersonal and 
social rhythm therapy, group psychoeducation, and systematic care management 
(Geddes & Miklowitz, 2013). A common aim of these approaches is to provide the 
service user with a set of mood regulation and self-management skills to address 
the challenges of living with bipolar disorder more effectively after the 
psychological intervention. The main approaches currently employed for bipolar 
disorder are family interventions, cognitive behavioral therapy, interpersonal and 
social rhythm therapy, and psychoeducation.  Oud et al. (Oud et al., 2016) in a very 
recent systematic review and meta-analysis of psychological interventions for 
adults with BD recommended the use of psychological interventions in the 
treatment of people with BD to reduce relapse rates and to reduce depressive 
symptoms. They reported that, although there is insufficient evidence to 
recommend one specific treatment over the others, the best evidence is for 
individual, structured psychological interventions, with weaker evidence for group 
and family interventions and collaborative care. 
 
2.8.2.1.  Family-focused therapy and other family interventions 
 
A reciprocal relationship exists between BD and the family and BD affects not only 
the patients but also their relatives. Specific family attitudes/interactions affect the 
course of BD and, equally, the illness itself has a strong impact on family 
functioning, caregivers’ burden, and caregivers’ health. Several studies have 
suggested that the emotional atmosphere of the family during the post-discharge 
period may be an important predictor of the illness outcome in BD. A variety of 
family psychoeducation programs has been developed for BD. Although they differ 
in many respects (e.g., multifamily, single-family, relatives only, 
inclusion/exclusion of patient, duration and intensity of treatment, clinical state of 
the patient), most of the approaches involve giving support to the relatives 
encouraging self-care, psychoeducation about the illness and its management, and 
training in communication and problem solving (Reinares et al., 2016).  
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Despite differences in format, target population, duration, setting, and period of 
implementation, most studies support the benefits of adjunctive family 
intervention (single-family and multifamily approaches) on both the patient 
outcomes and caregiver well-being. While positive findings have been reported 
when treatment starts after discharge or the patient is in remission, discrepant 
findings have been reported when adjunctive family intervention was introduced 
in the acute phase, although the treatment seems to be useful to improve 
depression for at least a subgroup of patients (Reinares et al., 2014). For patients 
with family members who are willing and able to participate in treatment, family 
therapy is an excellent option. Families with greater levels of impairment may 
derive additional benefit from family therapy when it is delivered either as 
individual or multifamily group therapy (Swartz & Swanson, 2014).   
Family-focused therapy (FFT) is based on the frequently replicated 
association between criticism and hostility in caregivers (so-called expressed 
emotion) and an increased likelihood of relapse in mood disorders and 
schizophrenia. FFT involves the patient and caregivers (parents or spouse) in up to 
21 sessions of psychoeducation, communication skills training, and problem-
solving skills training. Studies have shown that adjunctive family interventions 
have the potential to lengthen periods of stability and alleviate residual symptoms 
in maintenance care (Geddes & Miklowitz, 2013). Compared with psychoeducation 
only, FFT hastens recovery and confers additional protection against recurrence 
(Swartz & Swanson, 2014). The benefits of FFT have been shown to extend to at 
least the two-years follow-up, being particularly useful for depressive symptoms 
and improving adherence, and compared to individual treatment, people having 
had FFT have a lower number of relapses and lower risk of hospitalization in the 
two-year post-treatment follow-up (Reinares et al., 2016). 
 
2.8.2.2.  Cognitive behavioral therapy 
 
Cognitive-behavioral therapy (CBT) presumes that recurrences of mood disorder 
are determined by pessimistic thinking in response to life events and core 
dysfunctional beliefs about the self, the world, and the future. CBT to treat 
depression has been adapted for patients with bipolar disorder with recognition 
that manic episodes are often associated with excessively optimistic thinking 
(Geddes & Miklowitz, 2013). CBT for BD adds additional modules of 
psychoeducation, strategies for coping with prodromes, activities for regulating 
sleep and routines, and approaches to managing long-term sequelae of the illness 
(Swartz & Swanson, 2014).  
The evidence for adjunctive CBT for relapse prevention is inconclusive 
(Geddes & Miklowitz, 2013). Several trials have analyzed the impact of adjunctive 
CBT but mixed findings have been reported, highlighting the need to study under 
what conditions CBT works in BD (Reinares et al., 2014). Miziou et al. (Miziou et 
al., 2015) concluded that the available data so far give limited support for the 
usefulness of CBT during the acute phase of bipolar depression as adjunctive 
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treatment in patients with BD, but definitely not for the maintenance phase. 
During the maintenance phase, booster sessions might be necessary, but the data 
are generally negative. Probably, patients at earlier stages of the illness might 
benefit more from CBT. Reinares et al. (Reinares et al., 2014) took a somewhat 
more optimistic view of the outcome of CBT in BD. They stated that, on the whole, 
the impact of adjunctive CBT seems to be particularly useful in prevention of 
depression, especially in recovered and less recurrent patients, although booster 
sessions might be needed to maintain the benefits of the intervention (Reinares et 
al., 2014).  
 
2.8.2.3.   Interpersonal and social rhythm therapy 
 
Substantial evidence exists that mood instability in bipolar disorder is related to 
changes in circadian rhythms. The relation between sleep and mood disturbances 
seems to be bidirectional (Geddes & Miklowitz, 2013). Interpersonal and social 
rhythm therapy (IPSRT), an adaptation of interpersonal psychotherapy for 
depression, uses a problem-solving approach to interpersonal problems by 
encouraging patients to maintain and regulate daily routines and sleep and wake 
rhythms (Geddes & Miklowitz, 2013).  
Overall, there are no convincing data on the usefulness of IPSRT during the 
maintenance phase of BD. However, some data suggest that if applied early and 
particularly during the acute phase, IPSRT might prolong the time to relapse 
(Miziou et al., 2015; Reinares et al., 2014). Interestingly, it appears that 
administering it in the acute phase of treatment confers the greatest advantage to 
patients. IPSRT also shows promise as monotherapy (i.e., without medication) for 
BD II depression (Swartz & Swanson, 2014). In their systematic review and meta-
analysis, Oud et al. (Oud et al., 2016) found no evidence of benefit from IPSRT. 
 
2.8.2.4.  Psychoeducation 
 
In view of the many patients who could benefit from psychoeducation (PE), group 
approaches following a predesigned curriculum have been proposed. The 
Barcelona approach emphasizes awareness of illness, treatment adherence, early 
detection of recurrences, and sleep and wake regularity (Geddes & Miklowitz, 
2013).   
Recent reviews have drawn somewhat differing conclusions of the outcome of 
PE. Reinares et al. (Reinares et al., 2014) concluded that the six-month group PE 
seems to have long-lasting prophylactic effects over all sorts of episodes, time 
spent ill, and hospitalization per patient in individuals with BD who were euthymic 
at recruitment. Also, Swartz et al. (Swartz & Swanson, 2014) reported that 
treatment with a PE group (both 21- and 6-session formats) conferred benefits for 
those with bipolar disorder including longer time to recurrence, decreased rates of 
hospitalization, and improved symptoms over time.  Miziou et al. (Miziou et al., 
2015) more critically stated that even though interventions of the six-month group 
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PE seem to exert a long-lasting prophylactic effect, this was restricted to manic 
episodes and to patients in the earlier stages of the disease who had achieved 
remission before the intervention started. Similarly, Bond and Anderson (Bond & 
Anderson, 2015) concluded that PE appears to be effective in preventing relapse in 
BD, with the strongest evidence for reducing overall and manic relapse. The 
greatest effect was found in the group format, which also had a longer follow-up 
and more hours of therapy. However, no consistent effect on mood symptoms, 
quality of life, or functioning were found, although PE improved medication 
adherence and short-term knowledge about medication. Both Miziou et al. (Miziou 
et al., 2015) and Reinares et al. (Reinares et al., 2014) stated that the data suggest 
group PE to be less efficacious in patients with a higher number of previous 
episodes. According to Swartz and Swanson (Swartz & Swanson, 2014) the 
advantages of PE are less apparent when a PE group is compared with a more 
active comparator than treatment as usual. For instance, outcomes with 6-session 
PE did not differ from 20-session individual CBT. Similarly, both 21-session PE 
and functional remediation (FR) groups were associated with improvement in 
global functioning, although those assigned to FR fared even better than those 
assigned to PE. The authors stated that these studies raise the possibility that a 
stepped-care approach to bipolar disorder may be indicated, that is, treating 
patients with the less costly/burdensome group PE prior to adding CBT or 
functional remediation for those who do not achieve an adequate benefit with PE 
alone.  
 
 
2.9.  Adequacy of treatment received 
 
2.9.1.  Adequacy of acute phase treatment 
 
Treatment of BD focuses on acute stabilization, in which the goal is to bring 
patients with mania or depression to a symptomatic recovery with euthymic mood 
(Geddes & Miklowitz, 2013). Because of the difficulty of choosing the right 
treatment, there are clinical guidelines, “systematically developed statements that 
assist clinicians and service users in making decisions about appropriate treatment 
for specific conditions,” (NCCMH, 2014). However, for many reasons, the 
recommendations for how to treat patients with BD are not always followed and a 
gap exists between optimal and actual pharmacotherapy treatments.  Reports of 
several clinical studies (Blanco et al., 2002; Frye et al., 2005; Lim et al., 2001; 
Simon et al., 2004) have indicated that the treatment recommendations of 
practice guidelines and treatments prescribed to patient in practice differ, often 
markedly. The treatment of patients with BD in accordance with guidelines varies 
widely throughout studies, ranging from 50% to 80% (Paterniti & Bisserbe, 2013). 
Perlis et al. (Perlis, 2007) found that 34% of psychiatrists reported not having 
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recourse to guidelines on a regular basis to treat BD, whereas only a very small 
percentage identified guidelines as their primary source of information.  
For example, Simon et al. (Simon et al., 2004) reported that of the first 1,000 
participants in the STEP-BD study, only for 59% did the pharmacotherapy meet 
the criteria for “minimally adequate” mood stabilizer use. In another study, Lim et 
al. (Lim et al., 2001) examined medications at discharge of 1,471 patients admitted 
to a hospital with BD I mania or depression and found that only 1 in 3 patients 
with psychotic features, and 1 in 6 without psychotic features, received medication 
consistent with the 2000 Expert Consensus Guidelines for bipolar disorder. A 
third study by Blanco et al. (Blanco et al., 2002) analyzed 865 visits to a 
psychiatrist by patients with bipolar disorder which were recorded in the National 
Ambulatory Medical Care Survey database between 1992 and 1999. They found 
that more than a third of the visits did not include a prescription for any mood 
stabilizer, but antidepressants had been prescribed during almost half the visits 
and in about half of these visits without a prescription for a mood stabilizer. 
Actually, treatment practices that are not recommended and even rejected by 
virtually all guidelines, such as antidepressant monotherapy without a mood 
stabilizer (Blanco et al., 2002; Frye et al., 2005; Ghaemi et al., 1999; Lim et al., 
2001) seem surprisingly common.  
However, some studies have reported somewhat better adherence to 
practice guideline recommendations. For example, in a survey of French 
psychiatrists, Verdoux et al. (Verdoux et al., 1996) reported that 82% of bipolar 
outpatients had at least one mood stabilizer, and 68% had at least one 
antipsychotic. In another study, Ahmed et al. (Ahmed & Anderson, 2001) reviewed 
case notes of outpatients with a clinical diagnosis of bipolar affective disorder and 
found that 75% had a mood stabilizer and 20% had antipsychotics alone or, in 43% 
of patients, combined with a mood stabilizer. However, the dosage of mood 
stabilizers was often inadequate. Lloyd et al. (Lloyd et al., 2003) investigated the 
charts of patients under the care of four hospitals in northeast England and found 
that 85% had a mood stabilizer. Antidepressants were prescribed for 23% of 
patients, combined with a mood stabilizer in all but three cases. Farrelly et al. 
(Farrelly et al., 2006) reviewed the case notes of 84 consecutive patients attending 
the Cambridge Mental Health Service outpatient clinics and reported that the 
treatment was consistent with the BAP 2003 guidelines in 72% of episodes. In all, 
the treatment was not optimal in any of these reports and actually in many cases 
the treatments seem to have been clearly inadequate for the majority of bipolar 
patients. More recently, Paterniti et al. (Paterniti & Bisserbe, 2013) reported 
pharmacotherapy and concordance with treatment guidelines in a survey of 113 
BD patients who had been referred to tertiary care services in Canada in 2006-
2009. They found that all patients with BD I and 90% of the BD II group were 
given at least one psychotropic treatment. Antidepressants were the most 
frequently (for more than 60% of patients) prescribed class of psychotropics. At 
least one CANMAT 2009 guideline-concordant treatment was received by 74% of 
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patients when considering only the type of treatment and by 68% if also the dosage 
is considered. 
  
   
2.9.2.  Adequacy of maintenance phase treatment 
 
BD is an inherently recurrent disorder, requiring maintenance preventive 
treatments in the vast majority of patients. For virtually all patients with BD, the 
question of maintenance treatment is when, not if (Gitlin & Frye, 2012). Nearly 
every patient with BD will experience recurrent episodes during their lifetime; 
patients having only one episode are rare at best (Gitlin & Frye, 2012; Goodwin & 
Jamison, 2007; Perlis et al., 2006). Recurrent episodes carry with them an 
increased risk of suicide, accumulating social problems, possible cognitive decline, 
and high costs (Goodwin & Jamison, 2007). Controlled clinical studies have shown 
significantly better outcomes in patients with BD on maintenance treatment 
with mood stabilizers (Gitlin & Frye, 2012; Goodwin & Jamison, 2007; Maj et al., 
1998). In addition to the syndromal states, adequate maintenance treatment also 
prevents development of subsyndromal states (Frye et al., 2006; Keller et al., 
1992; Marangell, 2004), which are often prodromes of escalating recurrent 
episodes (Perlis et al., 2006) and involve other problems, including functional 
disability (Altshuler et al., 2002; MacQueen et al., 2003; Marangell et al., 2009). 
The core goal in the treatment of BD should be prevention of new illness episodes 
(Belmaker, 2007). Thus, practice guidelines consistently recommend maintenance 
treatment after the acute phase. Unfortunately, the treatments provided for 
patients with BD are often short-term and episode-focused (Bowden & Singh, 
2005). In this context, it is important to understand the factors that affect 
prescribing of maintenance treatment in actual clinical practice. 
An obstacle in this field of study is lack of complete consensus on how the 
longitudinal treatment phases of BD should be defined. The basic controversial 
issue is whether or not a distinct continuation phase should be included, precisely 
when it should end, and, consequently, when the maintenance phase should start. 
Long-term treatment in mood disorders, originally developed for MDD, has 
traditionally been divided into continuation and maintenance treatments (Grunze 
et al., 2013), which are, in turn, associated with the starting points “remission” and 
“recovery,” respectively. Even though these concepts of recurrence and relapse 
(and the corresponding treatment phases) are theoretically meaningful, they can 
only be identified under certain circumstances. Therefore, DSM-IV and ICD-10 
have adopted a wholly pragmatic set of definitions, separating two episodes by an 
interval of at least eight weeks of remission, implying that the continuation phase 
ends after eight weeks of continuous absence of symptoms (Grunze et al., 2013). 
Another difficulty in comparing studies is that, even though major studies have 
investigated long-term treatment received by patients with BD, it often remains 
ambiguous whether the treatment provided is for chronic symptoms or true 
maintenance phase treatment. 
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A study of the German centers of the SFBN (Dittmann et al., 2002) found that of 
the 111 patients in their 2.5-year follow-up, almost all (97.3%) were on at least 
one mood stabilizer during follow-up, and a high proportion of patients received 
long-term treatment (for at least six months) with antidepressants (42.3%) 
or typical antipsychotics (24.5%). The EMBLEM study is a two-year prospective, 
observational study on the treatment and outcome of patients who are treated for 
a manic or mixed episode. That study found that during one-year follow-up, rapid 
cycling patients were more likely to receive antidepressants and lamotrigine (Cruz 
et al., 2008). The exact treatment phase (acute or maintenance) was not reported 
in these studies. However, in the STEP-BD study (Ghaemi et al., 2006), a cross-
sectional intake treatment data during different phases for the first 500 patients 
taken in the study, they reported the treatments received in the maintenance 
phase; the authors stated that most of the agents used in the acute phases of BD 
were similarly used in the maintenance phase of treatment.   
In Britain, Farrelly et al. (Farrelly et al., 2006) reviewed the case notes of 84 
consecutive patients attending the Cambridge Mental Health Service outpatient 
clinics. They reported that during the two-year study period, 82% of patients were 
maintained on long-term preventative treatments with mood stabilizers, and eight 
patients continuously took antidepressants throughout the study period. Also in 
this study, the treatment phase during the follow-up was not specified, so it may 
have included both acute and maintenance phases. In addition, several other 
major studies have investigated the treatments received by patients with BD 
(Ahmed & Anderson, 2001; Anderson et al., 2004; Blanco et al., 2002; Farrelly et 
al., 2006; Frangou et al., 2002; Lloyd et al., 2003; Simon et al., 2004; Verdoux et 
al., 1996). Even though most of them are informative, they suffer from important 
limitations regarding evaluation of maintenance phase treatment.  
Most of these studies have not clearly defined the treatment phase (acute or 
maintenance) investigated (Ahmed & Anderson, 2001; Anderson et al., 2004; Cruz 
et al., 2008; Dittmann et al., 2002; Farrelly et al., 2006; Lloyd et al., 2003; Simon 
et al., 2004; Verdoux et al., 1996); patients have often been sampled exclusively 
from specialty clinics (Al Jurdi et al., 2008; Dittmann et al., 2002; Ghaemi et al., 
2006). In other cases, only patients with BD I are included (Cruz et al., 2008; 
Frangou et al., 2002) or the diagnosis is made based on a patient register or on a 
clinical diagnosis alone (Ahmed & Anderson, 2001; Anderson et al., 2004; Farrelly 
et al., 2006; Frangou et al., 2002; Lloyd et al., 2003; Verdoux et al., 1996), leaving 
the validity of the diagnosis uncertain.  All of the former studies have included 
only clinically diagnosed bipolar patients, which gives an overly optimistic view of 
the true clinical epidemiology of treatment of BD. 
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2.10.  Adherence 
 
Pharmacotherapy is the foundation of treatment for BD, but the recommendations 
of practice guidelines do not always actualize in the clinical reality. Adequate 
treatments may be offered, but only treatments taken have an effect, and 
effectiveness of pharmacological treatment is undermined by poor adherence. 
Rates of long-term nonadherence in BD have ranged from 20% to 66%, with a 
mean of 41% (Lingam & Scott, 2002). These rates seem not to have changed 
significantly since the introduction of new pharmacological agents (Berk et al., 
2010; Lingam & Scott, 2002).  Rates of nonadherence in schizophrenia have been 
in the same range (Sendt et al., 2015) as for other long-term diseases (Osterberg & 
Blaschke, 2005). Adherence rates are typically higher among patients with acute 
conditions, as compared to those with chronic conditions. 
Poor adherence is the single most important factor in poor treatment 
response among patients with BD (Goodwin & Jamison, 2007). Even though 
effective treatments for BD are available, their realization is problematic. The 
difference between efficacy and effectiveness has been largely attributed to 
treatment nonadherence (Guscott & Taylor, 1994). The consequences of 
nonadherence to pharmacotherapy are profound and can be life-threatening, 
equivalent to those of untreated or inadequately treated manic-depressive illness 
(Goodwin & Jamison, 2007). So, the potential benefits of pharmacological 
treatment on recovery, preventing relapse, and reducing mortality are significantly 
undermined by poor adherence (Berk et al., 2010). Studies have reported 
nonadherence to be associated with decreased likelihood of achieving remission 
and recovery, increased rates of relapse and hospital readmissions, increased risk 
of suicidal behavior, and greater healthcare costs (Hong et al., 2011; Velligan et al., 
2009). The potential problems with adherence also make it very difficult, if not 
impossible, for the prescribing clinician to assess whether the lack of response is 
related to the medication regimen itself or poor adherence. Thus, the physician 
may continue to prescribe additional medications for patients who are not 
showing desired improvement, although the real cause for the lack of response 
may be that patients are not taking medications as prescribed (Velligan et al., 
2009). Unfortunately, clinicians are poor judges of adherence and routinely 
underestimate the rates of nonadherence among their patients (Baldessarini et al., 
2008; Stephenson et al., 2012).  
However, unlike non-responsiveness to treatment, nonadherence is 
potentially reversible through experience, education, learning, and psychotherapy 
(Goodwin & Jamison, 2007), as reported in recent reviews (Berk et al., 2010; 
Colom et al., 2005; Crowe et al., 2012). MacDonald et al. (MacDonald et al., 2016) 
reported a systematic review and meta-analysis of randomized controlled trials of 
interventions to support adherence to medication in BD during the last 30 years. 
They found strong evidence that interventions can improve medication adherence 
(the pooled OR was 2.27 [95% CI 1.45-3.56]). The effects appeared to be durable 
and studies with two-year follow-up still reported positive effects on adherence. 
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Brief interventions tending to specifically focus on adherence were more effective 
in improving adherence than longer interventions where medication adherence 
was combined with other aspects of self-management. Most of the interventions 
involved psychoeducational techniques which appeared to be effective.  However, 
in a review of effectiveness of interventions to improve medication adherence in 
BD, Crowe et al. (Crowe et al., 2012) reported that most of the studies included in 
their review found that although their interventions did not improve adherence 
they did improve clinical outcomes.   
The World Health Organization (WHO) defines adherence as “the extent to 
which a person’s behaviour – taking medication, following diet, and/or executing 
lifestyle changes – corresponds with agreed recommendations from a healthcare 
provider” (WHO, 2003).  The term adherence is preferred to compliance because 
adherence emphasizes active patient participation in a treatment formed through 
therapeutic alliance or shared decision making in a patient-centered model of 
healthcare (Busby & Sajatovic, 2010).  
On a purely practical level, adherence involves a number of behaviors 
including assessing treatment, obtaining medications, understanding and 
following instructions about taking and monitoring medications, and 
remembering to take medications. Nondherence may be ‘voluntary’, or intentional, 
when the person decides not to adhere to treatment, or ‘involuntary’, where the 
lack of adherence is unintentional, (e.g., forgetting to take the medication) (Berk et 
al., 2010).  
Nonadherence can occur through four types of errors: (1) omission, not 
starting the drug at all, or once started, failing to take it, (2) dosage, taking too 
much or too little, (3) timing, failure to follow directions about when to take the 
drug, for how long, or when to change levels, and (4) purpose of commission, 
taking the drug for the wrong reasons (Goodwin & Jamison, 2007). It has been 
noted that patients may modify rather than completely accept or abandon 
treatment regimens (Berk et al., 2010) and patterns of nonadherence may vary 
over time and from patient to patient. Non-adherent behavior can take different 
forms: Full nonadherence refers to the patients’ complete failure to adhere to the 
physician’s directions in the self-administration of any medication. Selective 
nonadherence means nonadherence to only some kind of medication. Intermittent 
adherence, probably the most common pattern, includes, for example, abandoning 
treatment for certain periods, such as a weekend, before an important meeting or 
appointment or the patient adhering for a period of time, then stopping, but 
starting again after a recurrence. In late adherence, patients show initial 
resistance to accepting that they have BD and deny their need for treatment, but 
after repeated relapses begin to recognize the relationship between stopping the 
medication and recurrence of their illness. In late nonadherence, after two or 
three years of full adherence, some patients start to discontinue their maintenance 
treatment.  Abuse involves taking more medication than prescribed (Colom et al., 
2005; Goodwin & Jamison, 2007). These factors indicate that adherence is 
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dynamic, varying in a number of ways, and thus requiring repeated discussions 
throughout treatment (Berk et al., 2010).    
Although adherence to pharmacotherapy among patients with BD has been 
explored for decades, the number of studies remains limited, and most of them 
have investigated adherence to lithium; only more recent studies have examined 
other medications. Very few studies have reported adherence to psychosocial 
treatment in patients with BD, mainly examining therapy drop-outs (Busby & 
Sajatovic, 2010) or non-attendance or non-participation (Cakir et al., 2009; Even 
et al., 2007). For example, Cakir et al. (Cakir et al., 2009) investigated patients’ 
motivation to attend a six-week psychoeducational program and found 72% of 
patients to be adherent (i.e., attending at least 75% of scheduled appointments). 
The risk factors for nonadherence to psychosocial treatments in patients with BD 
are poorly known.  
Studies have reported many risk factors to be associated with nonadherence 
in patients with BD, but only a few have been constantly associated with 
pharmacotherapy nonadherence. Like in the recent reviews by Busby and 
Sajatovic (Busby & Sajatovic, 2010) and Leclerc et al. (Leclerc et al., 2013), these 
factors may be divided into those related to patient characteristics (e.g., younger 
age, being single, substance abuse, lower level of education, negative attitude to 
medication), disease (e.g., mixed episode, rapid cycling), treatment (e.g., side-
effects, number of medications), and health care system (e.g., lower access to care, 
fewer resources). The relative importance of each of these domains is not well 
known, but of obvious importance for improving care outcomes. In the STEP-BD 
study (Perlis et al., 2010), which is one of the biggest studies of patients with BD, 
the authors reported that clinical features associated with poor adherence (missing 
at least 25% of total doses) included younger age, single marital status, earlier 
onset, history of suicide attempts, rapid cycling, and current anxiety or alcohol use 
disorder; the study included 3,640 subjects who completed at least one follow-up 
visit. In another study, Sajatovic et al. (Sajatovic et al., 2009) investigated a 
community mental health clinic sample of 140 BD patients and defined 
nonadherence as missing 30% or more of prescribed medication. In that study, the 
only clinical predictor for nonadherence was substance use comorbidity. 
Moreover, nonadherence was associated with negative attitudes toward mood-
stabilizing pharmacotherapy and difficulty in managing to take medication in the 
context of one’s daily schedule. Recent studies on adherence among patients with 
BD have reported an association of residual depressive symptoms (Belzeaux et al., 
2013), non-planning impulsivity (the inability of an individual to weigh the long-
term as opposed to immediate results of his or her action) (Belzeaux et al., 2015), 
illness insight (Novick et al., 2015), and perceived therapeutic alliance and 
treatment environment (Sylvia et al., 2013) with nonadherence among patients 
with BD.  The effect of cognitive functioning on adherence in BD has been rarely 
studied, however, according to the the study by Jonsdottir et al. (Jonsdottir et al., 
2013) neurocognitive impairment is not a risk factor for nonadherence in BD. 
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A major difficulty for progress in this field is that major methodological differences 
exist in definitions of adherence and assessment methods; thus, rates of adherence 
may vary widely merely due to methodological factors. Most studies have used 
subjective or indirect methods to assess adherence (e.g., reports from patients, 
providers, or significant others; chart review), and few have used direct or 
objective methods (e.g., pill count, blood/urine analysis, electronic monitoring, 
refill records) (Velligan et al., 2009).  Adherence to medication recommendations 
can be reported in a continuing (fraction or percentage of medication taken or not 
taken) or categorical fashion (adherent vs. non-adherent) (Busby & Sajatovic, 
2010). It remains to be determined exactly what level of adherence is necessary for 
positive clinical outcomes under different medication regimens and in different 
settings of BD. As there is no objective or generally accepted cutoff (% taken) for 
adherence in BD, studies have used different definitions, and it is difficult, if not 
impossible, to compare studies which may have chosen different levels of 
adherence (Busby & Sajatovic, 2010). Most of the experts in the Expert Consensus 
Guideline on adherence problems in serious mental illnesses (Velligan et al., 
2009) considered that an appropriate cutoff for adherence in BD is 20% or less 
medication not taken.  This 80%/20% cutoff is used in many studies. Some studies 
have divided the non-adherent group into partial, usually ≥50% and <80% 
medication taken, as also recommended by experts (Velligan et al., 2009) and 
total, <50% medication taken, nonadherence. Unfortunately, there is currently no 
ideal operationalization or measure of adherence (Berk et al., 2010), and different 
types of assessment cover different aspects of behavior (Velligan et al., 2009). 
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3. AIM OF THE STUDY 
 
   
The aim of this 18-month follow-up study was to investigate the treatments 
received (during the acute and maintenance phase), adherence to treatments, and 
predictors of long-term disability of BD I and II patients with an acute phase at 
intake in secondary-level psychiatric care. 
 
The specific aims of the study were to: 
 
1. Investigate the adequacy of acute-phase pharmacotherapy received in a 
representative secondary-level sample of psychiatric in- and outpatients 
with a research diagnosis of bipolar I or II disorder. 
2. Investigate the adequacy of maintenance-phase pharmacotherapy received 
in a representative secondary-level sample of psychiatric in- and 
outpatients with a research diagnosis of bipolar I or II disorder. 
3. Investigate the continuity of, attitudes toward, and adherence to various 
types of psychopharmacological and psychosocial treatments among 
psychiatric in- and outpatients with BD I or II. 
4. Investigate the prevalence of disability pensions at baseline and predictors 
for being granted a disability pension during an 18-month follow-up of the 
patients in the labor force at baseline. 
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4.   Materials and methods  
 
 
4.1.  General study design   
 
The JoBS is a collaborative bipolar research project between the Unit of Mental 
Health of the National Institute for Health and Welfare, Helsinki (the former 
Department of Mental Health and Alcohol Research of the National Public Health 
Institute, Helsinki) and the Department of Psychiatry, Jorvi Hospital, Helsinki 
University Central Hospital (HUCH), Espoo, Finland. The Department of 
Psychiatry of Jorvi Hospital provides secondary-care in- and outpatient 
psychiatric services to all citizens of Espoo, Kauniainen, and Kirkkonummi 
(261,116 inhabitants in 2002). The Ethics Committee of HUCH approved the study 
protocol.  
 
 
4.2.  Screening   
 
The first phase of patient sampling for the JoBS cohort involved screening all in- 
and outpatients at the Department of Psychiatry of Jorvi Hospital who currently 
had a possible new phase of DSM-IV BD from January 1, 2002, to February 28, 
2003.  During that period, every patient between the ages 18 and 59 years, who (1) 
was seeking treatment, (2) had been referred, or (3) had already received care and 
was now showing signs of deteriorating clinical state, or a change in mood in case 
of mania or hypomania, was screened with the Mood Disorder Questionnaire 
(MDQ) (Hirschfeld et al., 2000). Patients were also included as positive, despite a 
negative MDQ screen, if suspected to have BD due to a clinical diagnosis of BD or 
pertinent symptoms. A clinical diagnosis of ICD-10 schizophrenia was an 
exclusion criterion for screening. The response to MDQ item 3 ("problems due to 
episodes") was ignored based on the pilot study of the JoBS (Isometsa et al., 
2003). The sampling procedure is presented in Figure 1. After receiving a positive 
MDQ screen, or after suspicion of BD, the patients were fully informed about the 
study project and written informed consent was requested. In all, 1,630 patients 
were screened, 546 of whom proved to be MDQ-positive or suspected bipolar 
(Figure 1). Of 546 eligible patients, 49 declined a face-to-face interview and 7 could 
not be contacted.  
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4.3.  Baseline evaluation   
 
 
4.3.1.  Diagnostic measures   
 
In the second phase of sampling, the 490 participating patients were interviewed 
face-to-face to make a diagnosis.  The diagnosticians were all psychiatrists (Outi 
Mantere, Hanna Valtonen, Petri Arvilommi, Kirsi Suominen, Sami Leppämäki, 
Marita Pippingsköld), and weekly meetings were held to solve diagnostic 
problems. Using the Structured Clinical Interview for DSM-IV Disorders, 
researcher version with psychotic screen (SCID-I/P) (First et al., 2002), 
supplemented with a section for diagnosing mixed episodes, they evaluated 
whether the patient fulfilled the criteria for diagnosis of BD. All psychiatric and 
medical records were available, and if the diagnosis was uncertain, attending 
personnel, family members, or other informants were contacted. The final study 
group included in the analyses comprised 191 DSM-IV bipolar I and II patients 
with a current phase. The index episode was defined according to DSM-IV criteria 
and could be monophasic or polyphasic. We also included as bipolar II those 
bipolar NOS patients with hypomania of two-three days, or depressive mixed 
states (DMX3=three or more simultaneous intra-episode hypomanic symptoms 
present for at least 50% of the time during a major depressive episode) as defined 
by Benazzi and Akiskal (Benazzi & Akiskal, 2001), that clearly belonged to the 
bipolar II group. To test diagnostic reliability, we used videotaped interviews that 
were then blindly assessed by another diagnostician. In the 20 randomly selected, 
videotaped diagnostic interviews, agreement was complete (the kappa coefficient 
for BD overall was 1.0; also specifically, for BD I it was 1.0 and BD II it was 1.0). To 
assess comorbid diagnoses on axis II, we used the Structured Clinical Interview for 
DSM-IV Personality Disorders (SCID-II) (First et al., 1997). 
 
 
4.3.2.  Observer and self-report scales  
 
In the third phase, the current symptomatology of the index episode was 
evaluated. The Young Mania Rating Scale (YMRS) (Young et al., 1978) was used to 
assess the severity of mania, and the 17-item Hamilton Depression Scale (HAM-D) 
(Hamilton, 1960) and the self-reported 21-item Beck Depression Inventory (BDI) 
(Beck et al., 1961) were used to assess the severity of depression. Other self-
reported scales, in addition to BDI, included the Beck Anxiety Inventory (BAI) 
(Beck et al., 1988) to assess the level of anxiety, the Scale for Suicidal Ideation 
(SSI) (Beck et al., 1979) for suicidal behavior, and Beck Hopelessness Scale (BHS) 
(Beck et al., 1974). Moreover, the self-report scales included the Interview for 
Recent Life Events (IRLE) (Paykel, 1997) and the Perceived Social Support Scale 
Revised (PSSS-R) (Blumenthal et al., 1987), the Social Adjustment Scale Self-
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Report (SAS-SR) (Weissman & Bothwell, 1976), and the Eysenck Personality 
Inventory (EPI) (Eysenck HJ, 1964). The Social and Occupational Functioning 
Assessment Scale for DSM-IV (SOFAS) (Goldman et al., 1992) was used to assess 
the functional level. Some delay occurred from screening to estimating symptom 
scores in the first interview, which especially in the case of short hypomanias 
meant that the patient had often passed the index phase. In the analysis of 
symptom severity, these latter patients were omitted. 
 
 
 
Figure 1.  Screening of eligible bipolar patients in the Jorvi Bipolar Study 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Scored as positive or a 
clinical diagnosis of bipolar 
disorder n=546/1630, 33.5% 
Screened negative 
n=1038/1630, 63.7% 
Screening with Mood 
Disorder Questionnaire 
n=1630 
Completed face-to-face 
SCID-I interview 
n=490/546, 89.7% 
Eligible bipolar patients 
n=201/490, 41.0% 
Declined screening 
n=46/1630, 2.8% 
Declined face-to-face SCID-I 
interview n=49/546, 9.0% 
Not bipolar I or II 
n=289/490, 59.0% 
Could not be contacted 
n=7/546, 1.3% 
Included in the JoBS 
n=191/201, 95.0% 
Declined to participate or 
interrupted n=10/201, 5.0% 
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4.3.3.  Other characteristics  
 
We also collected information on demographic characteristics and variables for 
prior illness history and preceding treatment using a graphic retrospective life 
chart. Age at illness onset was defined as the time of onset of the first mood 
episode fulfilling the DSM-IV criteria. A polyphasic episode was defined as an 
episode consisting of more than one distinct phase (depressive, hypomanic, manic, 
mixed, or depressive mixed phase). The index episode and index phase were 
defined as the episode or phase, respectively, when the patients were included in 
the study.  
 
 
4.4.  Follow-up procedure  
 
 
4.4.1.  Study drop-outs 
 
Of the 191 subjects with a current phase initially included in the study, at six 
months, 5 (2.6%) declined to participate, 15 (7.9%) were missing, and 171 (89.5%) 
were interviewed. Of the missing patients, reliable information was available for 
five in patient records. At 18 months, of the original sample of 191 patients, 3 were 
known to have died, 6 more refused to be interviewed, 142/188 (75.5%) were 
interviewed in person, and 5/188 were interviewed by phone. For 13 patients, 
information from patient records was sufficient to construct a life chart, and 
another 3 patients with too short (less than one year) follow-up were excluded. 
Thus, 160/188 patients (85.1%) were included in the 18-month analyses. Of BD II 
patients, seven converted to BD I due to mania, three due to a mixed phase during 
the follow-up (between beginning of index phase and 18-month follow-up). In 
analyses, all patients were categorized according to their baseline diagnosis. In 
addition, based on a similar clinical picture, eight BD NOS patients at intake were 
included in the analysis as BD II patients. Of these BD NOS patients, seven were 
followed up for 18 months, with two (29%) converting to BD II (Mantere et al., 
2004).     
 
 
4.4.2.  Follow-up assessment and life-chart methodology 
 
The patients participating were interviewed again 6- and 18-months after baseline.  
The course of the disease, with timing and durations of different phases, was 
examined by gathering all available data, which were then combined in the form of 
a graphical life chart, analogous to the life chart used in the Vantaa Depression 
Study (VDS) (Melartin et al., 2004) and based on DSM-IV criteria. Repeated 
SCID-I/P interviews and all observer- and self-reported scales were included at 
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both follow-up assessments. All medical and psychiatric records were available. In 
addition to information from symptom ratings and visits to attending personnel, 
change points in the psychopathologic states were also inquired about using 
probes related to important life events to improve the accuracy of the assessment. 
The onset of the index phase and the index episode were evaluated retrospectively. 
We defined an episode according to the DSM-IV criteria and this could be 
monophasic or polyphasic. Accordingly, a phase in this study refers to a 
monophasic episode or a single phase of a polyphasic episode and, similarly, an 
episode refers to a monophasic or polyphasic episode. A depressive, manic, or 
mixed phase was defined as in DSM-IV; a hypomanic phase had a minimum 
duration of two days (Akiskal & Benazzi, 2005; Angst, 1998; Judd et al., 2003). 
Depressive mixed phases (=three or more simultaneous intra-episode hypomanic 
symptoms present for at least 50% of the time during a major depressive episode), 
as defined by Benazzi and Akiskal (Benazzi & Akiskal, 2001), were also evaluated. 
States of subsyndromal symptoms (including prodromal and residual symptoms) 
were rated when the patient was not euthymic and did not fulfill the criteria of a 
phase; durations of more than one week for hypomanic symptoms and more than 
two weeks for depressive symptoms and cyclothymia were required. A state of 
euthymic mood was used when the duration of euthymia was longer than two 
weeks.  
Time after the beginning of the index phase was divided into three periods: 
(1) mood episode, (2) partial remission, or (3) full remission. In partial remission, 
the full criteria of a DSM-IV mood episode were not met, but some symptoms were 
present. In full remission, no DSM symptoms were present. The patient had 
reached remission if during at least two consecutive months the criteria for a mood 
episode were not met (DSM-IV). Relapse was defined as a return of a mood 
episode after a period of less than two months with symptoms below the mood 
episode threshold. Recurrence was defined as the emergence of symptoms 
sufficiently severe to satisfy criteria for a new mood episode after at least two 
consecutive months of partial or full remission.  
 
 
4.4.3.  Definition of maintenance phase 
 
We defined maintenance treatment, and thus the maintenance phase, as 
starting on the day when the time with full criteria of a phase ended and ending on 
the day when the criteria for a relapse or recurrence were met, or at the last follow-
up interview. Thus, the maintenance phase could include states of either full or 
partial remission. We based the discrimination of different phases on the life 
chart. We focused only on the first maintenance phase (lasting ≥ two weeks) after 
the index episode. 
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4.5.  Data collection and definitions concerning 
treatment 
 
We gathered data on all regularly used medicines and psychosocial treatments. 
Treatment was defined as ongoing as long as it was provided or prescribed 
according to psychiatric records, while termination was the date when treatment 
was first documented as not ongoing or reported as terminated by the patient with 
no later contact with a professional. 
 
 
4.5.1.  Adequate acute-phase pharmacotherapy (study I) 
 
We defined adequate acute-phase pharmacotherapy based on published treatment 
guidelines (APA, 2002; Goodwin & Young, 2003; Grunze et al., 2002; Grunze et 
al., 2003; Sachs et al., 2000) and regardless of dosage, serum concentrations, or 
duration of treatments: (1) Adequate treatment for bipolar depression was defined 
as monotherapy with lithium or lamotrigine, or combinations of lithium, 
valproate, carbamazepine, or olanzapine with an antidepressant; a combination of 
lamotrigine with an antidepressant was interpreted as inadequate for patients with 
BD I, (2) adequate treatment for mania was defined as monotherapy and 
combinations of lithium, valproate, carbamazepine, atypical antipsychotics, or 
haloperidol; the treatment was interpreted as inadequate if an antidepressant was 
used, (3) adequate treatment for hypomania was defined the same as for mania, 
(4) adequate treatment for mixed state was defined the same as for mania except 
that treatment was interpreted as inadequate if a conventional antipsychotic was 
used, (5) adequate treatment for depressive mixed state was defined the same as 
for mixed state, and (6) adequate treatment for rapid cycling was defined as 
monotherapy or combinations of lithium, valproate, or carbamazepine. Treatment 
with lamotrigine was interpreted as adequate for BD II patients. Treatment of 
rapid cycling was classified as inadequate if an antidepressant was used. 
 
 
4.5.2.  Adequate maintenance phase pharmacotherapy (study II) 
 
We defined adequate maintenance-phase pharmacotherapy also based on 
published treatment guidelines (APA, 2002; Goodwin, 2003; Grunze et al., 2004; 
Keck et al., 2004; Yatham et al., 2005). To be defined as adequate, the 
maintenance treatment had to include lithium, valproate, carbamazepine, or 
olanzapine. Monotherapy with lamotrigine was defined as adequate in BD II. We 
defined the treatments regardless of dosage or serum concentrations. 
Antidepressants were not included in the definition of adequate maintenance 
treatment, but we reported their use separately. We defined mood stabilizers as 
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follows: lithium, valproate, carbamazepine, oxcarbazepine, and lamotrigine. 
Atypical antipsychotics included olanzapine, risperidone, quetiapine, and 
aripiprazole. 
 
 
4.5.3.  Methods concerning continuity and adherence (study III) 
 
Treatments provided were investigated at baseline and at both follow-up 
interviews. Psychotherapeutic support comprised regular appointments with a 
mental health professional aimed at helping the patient by discussing his or her 
problems (weekly psychotherapy excluded). Psychotherapy was defined as weekly 
therapy sessions for four or more weeks with a qualified, certified therapist. 
Continuity of psychotherapeutic and medical treatment was assessed by 
interviewing patients and investigating all medical and psychiatric records. The 
treatment phase was defined as a continuous time of treatment starting on the day 
the treatment was prescribed and ending on the day it was agreed to end, as 
reflected in psychiatric records. If treatment had been ongoing before baseline, it 
was considered as started at the time of the first baseline evaluation. 
Self-reported treatment adherence was investigated by interviewing patients 
during follow-ups. Using all the information available, the interviewer determined 
whether the patient had come to sessions/been on medication (1) regularly 
(treatment compliance is adequate with respect to treatment goals), (2) somewhat 
irregularly (it is unclear whether this would affect treatment goals), (3) very 
irregularly (the treatment did not proceed according to plan), (4) not at all (the 
provided treatment could not be implemented), and (5) the question is not 
relevant (treatment was not provided). Patients fulfilling the requirements of the 
first response were defined as adherent to treatment. All other patients were 
considered nonadherent to that treatment.  
Attitudes toward psychotherapeutic treatments and medications were 
assessed by interviewing the patients during follow-up and giving the 
following Likert-scale response options: Attitudes toward treatment are (1) very 
positive, (2) positive, (3) neutral, (4) negative, (5) very negative, (6) so negative 
that it prevents using the treatment, or (7) could not answer. The attitudes were 
investigated regardless of having actually received the treatment in question. 
 
 
4.5.4.  Methods concerning disability pension (study IV) 
Information on disability pensions granted to subjects belonging to the JoBS 
cohort was obtained from interviews, patient records, and registers of the Social 
Insurance Institution of Finland and the Finnish Centre for Pensions. In Finland, 
employees aged under 63–65 years become eligible for disability pension after 
receiving a daily allowance from sickness insurance for 300 days during a two-year 
period (counted at six days per week) if they are still considered incapable of 
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working because of an illness. The 300 days usually comprise several consecutive 
shorter sick leave periods. Medical certificates issued by a psychiatrist for work 
disability allowances are referred to and granted by the Social Insurance 
Institution of Finland and by other pension providers; records on all pensions 
granted in Finland are collected by the Finnish Centre for Pensions.  A part-time 
pension may also be granted. In this study, all forms of disability pension, whether 
temporary or permanent, full-time or part-time, were treated as one group. 
Homemakers and individuals working part-time were treated as working. Patients 
who had been granted a disability pension before baseline were excluded from the 
prospective analyses of the cohort followed up because the endpoint had in their 
case already occurred. Information on disability pensions for this study was 
obtained from the registers up to the time of the 18-month follow-up if it had been 
realized or up to 18 months after baseline if the 18-month follow-up data were 
missing.  
 
4.6.  Statistical methods  
   
Studies I and II 
 
In the study I and study II, we first counted the frequencies of different 
pharmacological agents and their combinations during the index acute phase 
(study I) and at the beginning, the end, and during the first maintenance phase 
after the index episode (study II).  
Then we compared the crude frequency differences of a wide range of 
variables, including the following clinical and background variables: gender, 
bipolar subtype, type of index phase, treatment setting, rapid cycling, type of 
episode (mono- or polyphasic), bipolar diagnosis before index phase in study I, 
and gender, bipolar subtype, last phase before remission, rapid cycling, clinical 
bipolar diagnosis before maintenance phase, hospital treatment during index 
phase, and any personality disorder in study II. We used Pearson's chi-squared 
test and Fisher's exact test at the same time points for different pharmacological 
agents and their combinations at study intake in study I and at different time 
points in the maintenance phase in study II; we also used them for proportions of 
patients receiving adequate treatment at study intake in study I and at different 
time points during the maintenance phase in study II. In Study II, using Pearson's 
chi-squared test, we also compared the frequency differences in gender, age, 
bipolar subtype, marital status, education, work status, any lifetime anxiety 
disorder, any lifetime substance use disorder, psychotic symptoms lifetime, 
clinical diagnosis of BD before maintenance phase, rapid cycling, hospital 
treatment during lifetime, for uninterrupted adequate maintenance treatment. 
Finally, we performed logistic regression analyses with adequacy of index 
phase treatment as the independent variable separately for all the patients and for 
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those with a clinical diagnosis of BD at study intake (study I). We used age, gender, 
bipolar subtype, index phase, rapid cycling, treatment setting, type of index 
episode (mono- or polyphasic), any lifetime anxiety disorder, any lifetime 
substance use disorder, any personality disorder, and the number of hospital 
treatments as dependent variables in study I. In study II, we made regression 
analysis for adequate maintenance treatment received throughout the 
maintenance phase as the independent variable, separately for all the patients 
having a maintenance phase during the follow-up and for those with a clinical 
diagnosis of BD before the maintenance phase and age, gender, bipolar subtype, 
the last phase before the maintenance phase, rapid cycling, treatment setting in 
the phase before the maintenance phase, any lifetime or current anxiety or 
substance use disorder, any personality disorder, and clinical diagnosis of BD 
before maintenance phase as dependent variables, to assess the variables 
independently related to adequate treatment while controlling for potential 
confounding factors.  
 
Study III 
 
In the third study, we used the Pearson chi-squared test to evaluate categorical 
and non-parametric data and the Mann–Whitney or Kruskall–Wallis test to 
compare continuous variables not normally distributed. To compare adherence 
(dichomotized as adherent/nonadherent) of the same patient at the 6- and 18-
month interviews, we used the McNemar test, and to compare attitudes of the 
same patient at the 6- and 18-month interviews we used the Marginal 
Homogeneity Test. The one-sample binomial test was used to compare the 
observed and expected proportions of medications autonomously discontinued in 
different phases with the proportion of time spent in each phase. To compare the 
attitudes of the same patients toward different types of treatments (different 
medications, psychosocial treatments, electro-convulsive treatments), we used the 
related samples Cochran Q test. We used Spearman's correlation to analyze the 
correlations of adherence and attitudes between treatment groups. Finally, to 
adjust for confounding factors, three logistic regression models were created with 
nonadherence to mood stabilizers, nonadherence to antipsychotics, and 
nonadherence to psychotherapy/supportive psychotherapy as dependent 
variables, adjusting for age, gender, and bipolar subtype in all models; all the 
significant factors in the univariate analysis and factors that were considered 
clinically or theoretically important as independent variables were used. 
 
Study IV 
 
In the fourth study, we used the Pearson's chi-squared test for nominal variable 
comparisons and analyzed normally distributed continuous variables by two-
sample t-tests and non-normally distributed variables using the Mann-Whitney U- 
and Kruskal-Wallis tests.  
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For univariate and multivariate analyses to predict the time interval to the date 
that the pension was granted, we used Cox proportional hazards models. We 
included all of the hypothesized predictors and other variables significant or 
almost significant (p<0.10) in the univariate analyses, including age, gender, 
duration of disease, perceived working ability, type of index episode, number of 
depressive phases, number of manic/hypomanic phases, comorbidity with anxiety 
or substance use disorders currently or during lifetime, comorbidity with 
personality disorder, and number of hospital treatments in the multivariate 
analyses. Since we were specifically interested in examining the possible effect of 
comorbidities on being granted a disability pension, we included all diagnoses of 
anxiety disorders and personality disorders in the multivariate analysis regardless 
of their significance in the univariate analyses. We also made separate models 
incorporating information from the 18-month follow-up, including time and 
proportion of time in different phases during the follow-up. To assess 
intercorrelations between the predictors, we computed Spearman bivariate 
correlations. Kaplan-Meyer curves and log-rank tests were also used to 
demonstrate subgroup differences.  
We conducted separate analyses by splitting the data for the 151 patients by 
bipolar subtype (BD I vs. BD II), age (<40 vs. ≥40 years at baseline), and gender.  
We made Cox regression models for each of these six subgroups, adjusting for the 
remaining variables (age, gender, and bipolar subtype) and used the same 
predictors that were significant in the first model. 
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5.  RESULTS  
 
5.1.  Adequacy of acute phase pharmacotherapy 
in BD (Study I) 
 
5.1.1.  Mood stabilizers and atypical antipsychotics 
 
Only just over a half (107/191, 56%) of the patients had received one or multiple 
mood stabilizers during the index acute phase. Having received mood stabilizers 
was in univariate analyses associated with several factors. Patients with BD I had 
them more often than those with BD II (63/90 [70%] vs. 44/101 [44%], p<0.001), 
men more often than women (61/90 [68%] vs. 46/101 [46%], p=0.002), and 
inpatients more often than outpatients (48/65 [74%] vs. 59/126 [47%], p<0.001). 
Patients with a clinical diagnosis of BD mostly had a mood stabilizer, whereas 
patients without the diagnosis very rarely (102/117 [87%] vs. 5/74 [7%], p<0.001). 
Somewhat unexpectedly, patients with rapid cycling had mood stabilizers less 
often than non-rapid cycling patients (27/62 [44%] vs. 80/129 [62%], p=0.016). 
Valproate was the most commonly prescribed mood stabilizer, the proportion 
being nearly three times the proportion of lithium treatment (28/117 [66%] vs. 
79/117 [24%]) among clinically diagnosed patients with BD.  
Atypical antipsychotics were prescribed to 16% (31/191) of patients. The 
patients treated with atypical antipsychotics had mainly BD I (28/31, 90%), were 
equally often in depressive (15/31, 48%) or manic (14/31, 45%) phases, and had a 
clinical diagnosis of BD (29/31, 94%). Only three patients had monotherapy with 
atypicals, whereas most of the patients with atypicals had combinations with mood 
stabilizers or antidepressants.  
 
5.1.2.  Antidepressants 
 
Overall, half (94/191, 49%) of the patients had an antidepressant. Patients with BD 
II had them more often than patients with BD I (63/101 [62%] vs. 31/90 [34%], 
p<0.001), patients without a clinical diagnosis of BD more often than patients with 
the diagnosis (51/74 [70%] vs. 43/117 [37%], p<0.001), and patients with a 
polyphasic last episode more often than those with a monophasic last episode 
(57/98 [58%] vs. 37/93 [40%], p=0.032). Most of the depressive (73/106 [69%]) 
and half of the depressive mixed patients (13/26 [50%]) had an antidepressant. 
Even a fourth (5/21 [24%]) of hypomanic patients received antidepressants.  
In all, 26% of all patients, and half (53%) of the patients with an 
antidepressant, received antidepressant monotherapy without a concurrent mood 
stabilizer or an atypical antipsychotic (Table 5). Of the patients receiving 
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antidepressants, 35 (37%) had a concurrent mood stabilizer, two (2%) had an 
atypical antipsychotic, and seven (7%) had a mood stabilizer plus an atypical 
antipsychotic (Table 5). However, most of the 43 clinically diagnosed patients 
(39/43 [91%]) with an antidepressant had also a mood stabilizer, whereas nearly 
all of the 51 patients (48/51 [94%]) without a clinical diagnosis of BD and an 
antidepressant had no mood stabilizer.  
 
 
Table 5.  Proportions of antidepressants, mood stabilizers and atypical 
antipsychotics in use with the 191 patients in Jorvi Bipolar Study 
 
1AD=antidepressant, 2MS=mood stabilizer, 3AAP=atypical antipsychotic,*Significant with 
Bonferroni correction p<0.05/8=0.006 
 
AD1 
only 
MS2 
only 
AAP3 
only 
AD+ 
MS 
AD+ 
AAP 
MS+ 
AAP 
AD+ 
MS+ 
AAP 
No drugs 
of these 
groups 
Variable 
N % N % N % N % N % N % N % N % 
Gender                 
Men (n=90) 17 18.9 30 33.3 3 3.3 17 18.9 1 1.1 10 11.1 4 4.4 8 8.9 
Women (n=101) 33 32.7 16 15.8 0 0.0 18 17.8 1 1.0 9 8.9 3 3.0 21 20.8 
p value 0.029 0.005* 0.033 NS NS NS NS 0.020 
Bipolar subtype                 
I (n=90) 10 11.1 25 27.8 3 3.3 14 15.6 1 1.1 18 20.0 6 6.7 13 14.4 
II (n=101) 40 39.6 21 20.8 0 0.0 21 20.8 1 1.0 1 1.0 1 1.0 16 15.8 
p value <0.001* NS 0.033 NS NS <0.001* 0.030 NS 
Last phase                  
Depression (n=106) 34 32.1 14 13.2 1 0.9 30 28.3 2 1.9 5 4.7 7 6.6 13 12.3 
Hypomania(n=21) 4 19.0 7 33.3 0 0.0 1 4.8 0 0. 2 9.5 0 0.0 7 33.3 
Mania (n=23) 0 0.0 9 39.1 2 8.7 0 0.0 0 0.0 12 52.2 0 0.0 0 0.0 
Mixed (n=15) 2 13.3 8 53.3 0 0.0 1 6.7 0 0.0 0 0.0 0 0.0 4 26.7 
Depressive mixed 
(n=26) 
10 38.5 8 30.8 0 0.0 3 11.5 0 0.0 0 0.0 0 0.0 5 19.2 
p value 0.001* 0.001* NS <0.001* NS <0.001* NS 0.007 
Treatment setting                 
Outpatient (n=126) 40 31.7 32 25.4 0 0.0 18 14.3 2 1.6 6 4.8 3 2.4 25 19.8 
Inpatient (n=65) 10 15.4 14 21.5 3 4.6 17 26.2 0 0.0 13 20.0 4 6.2 4 6.2 
p value 0.012 NS 0.010 0.049 NS 0.001* NS 0.008 
Bipolar diagnosis                 
Yes (n=117) 4 3.4 44 37.6 3 2.6 32 27.4 0 0.0 19 16.2 7 6.0 8 6.8 
No (n=74) 46 62.2 2 2.7 0 0.0 3 4.1 2 2.7 0 0.0 0 0.0 21 28.4 
p value <0.001* <0.001* NS <0.001* 0.050 <0.001* 0.008 <0.001* 
Rapid cycling                 
Yes (n=62) 21 33.9 14 22.6 0 0.0 10 16.1 1 1.6 1 1.6 2 3.2 13 21.0 
No (n=129) 29 22.5 32 24.8 3 2.3 25 19.4 1 0.8 18 14.0 5 3.9 16 12.4 
p value NS NS NS NS NS 0.002* NS NS 
Monophasic (n=93) 16 17.2 26 28.0 3 3.2 18 19.4 1 1.1 11 11.8 2 2.2 16 17.2 
Polyphasic (n=98) 34 34.7 20 20.4 0 0.0 17 17.3 1 1.0 8 8.2 5 5.1 13 13.3 
p value 0.006* NS 0.037 NS NS NS NS NS 
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Table 6.  Proportions of the 191 patients in Jorvi Bipolar Study receiving 
adequate treatment.  
 
 
All patients 
    A clinical diagnosis 
       of BD 
Undiagnosed 
 
 
 
 
Variable 
 
 
Total 
N 
Adequate 
treatment 
 
Tot
al 
N 
Adequate 
treatment 
 
 
Total  
N 
Adequate 
treatment 
n % p* n % p* n % 
Gender            
 Men  90 47 52.2  67 45 67.2  23 2 8.7 
 Women  101 34 33.7 0.009 50 31 62.0 0.563 51 3 5.9 
Bipolar subtype            
 I  90 50 55.6  67 47 70.1  23 3 13.0 
 II 101 31 30.7 0.000 50 29 58.0 0.174 51 2 3.9 
Last phase            
 Depression 106 33 31.1  61 30 49.2  45 3 6.7 
 Hypomania 21 9 42.9  13 9 69.2  8 0 0.0 
 Mania  23 23 100.0  23 23 100.0  0 0 0.0 
 Mixed  15 8 53.3  7 6 85.7  8 2 25.0 
 Depressive mixed 26 8 30.8 0.000 13 8 61.5 0.000 13 0 0.0 
Treatment setting            
 Inpatient  65 36 55.4  51 34 66.7  14 2 14.3 
 Outpatient 126 45 35.7 0.009 66 42 63.6 0.733 60 3 5.0 
Rapid cycling             
 Yes  62 15 24.2  30 13 43.3  32 2 6.3 
 No  129 66 51.2 0.000 87 63 72.4 0.005 42 3 7.1 
Mono/polyphasic            
 Monophasic  93 52 55.9  64 51 79.7  29 1 3.4 
 Polyphasic  98 29 29.6 0.000 53 25 47.2 0.000 45 4 9.9 
Bipolar diagnosis            
 Yes  117 76 65.0         
 No  74 5 6.8 0.000        
*p-values indicate statistical differences between subgroups in different variables (gender, bipolar 
subtype etc.). 
 
5.1.3.  Overall adequacy of acute-phase treatment 
 
Less than half (81/191, 42.4%) of the patients received adequate acute-phase 
treatment (Table 6); men more often than women, bipolar I patients more often 
than bipolar II patients, inpatients more often than outpatients. All manic 
patients received adequate treatment, whereas less than one-third of depressive 
or depressive mixed patients. Only one-fourth of patients with rapid cycling and 
less than one-third of patients with a polyphasic index episode received adequate 
treatment. Among the patients with rapid cycling or a polyphasic index episode, 
inadequacy in treatment was mainly due to not having a mood stabilizer or 
atypical antipsychotic and/or having an antidepressant. The main reasons for 
inadequate treatment among the patients with a depressive index phase, included 
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not having a mood stabilizer or an atypical antipsychotic, having an 
antidepressant during rapid cycling, and/or having valproate monotherapy 
without an antidepressant.  
 
5.1.4.  Impact of diagnosis on adequacy of treatment 
 
Lack of a bipolar diagnosis was by far the most important predictor of inadequate 
treatment (Table 6). These patients rarely had a mood stabilizer and often had an 
antidepressant without a mood stabilizer (Table 5). But, even among the patients 
with a clinical diagnosis of BD, pharmacotherapy was often (in 35% of cases) 
classified as inadequate.  The main reasons for this were lack of a mood stabilizer, 
having an antidepressant in rapid cycling, and/or treatment of depression with 
valproate without an antidepressant.   
 
5.1.5.  Predictors of adequate acute phase treatment in 
multivariate models 
In the logistic regression model, not having a clinical diagnosis of BD (OR=25.3, 
p<0.001), rapid cycling (OR=2.5, p=0.041), polyphasic index episode (OR=2.4, 
p=0.026), and depressive index phase (OR=3.4, p=0.003) predicted not having 
adequate acute phase treatment.  
 
5.2. Adequacy of maintenance phase 
pharmacotherapy in BD (Study II) 
 
5.2.1.  Pharmacotherapy during the maintenance phase 
 
There were 154 patients with a maintenance phase during the follow-up. The 
mean duration of the first maintenance phase was 220 days (minimum 14 days, 
maximum 1180 days).  Three-quarters of all the 154 patients, and most of the 
patients with either BD I or a clinical BD diagnosis (I or II), with a maintenance 
phase during the follow-up, received mood stabilizers or atypical antipsychotics 
at some point during the maintenance phase (Table 7). Valproate was prescribed 
over two times more often than lithium. Of the atypicals olanzapin was the one 
most often prescribed. Most of the patients who had atypical antipsychotics 
received also mood stabilizers. Lamotrigine was only prescribed for patients with 
BD II.  
Over a half (55%) of all the patients (Table 7), and most (21/25 [78%]) of the 
patients without a clinical diagnosis of BD, received antidepressants for some 
time during the maintenance phase, and most of them had depression preceding 
that phase. Surprisingly, even a fifth (9/24 [21%]) of the patients with hypomania 
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preceding the maintenance phase received antidepressants at the beginning of 
the maintenance phase. There was no difference between the patients having 
some anxiety disorder during lifetime at 18-month follow-up and those who had 
not had any anxiety disorders during that time in regard to being prescribed 
antidepressants some time during the maintenance phase (53% vs. 47%, 
p=0.957). There was no statistical difference between the proportion of rapid 
cycling and non-rapid cycling patients being prescribed antidepressants (22/39 
[56%] vs. 62/115 [54%], p=0.786), and actually there was a trend towards rapid 
cycling patients receiving antidepressants more often. Approximately one-third 
(27-37%) of the patients received the antidepressant without mood stabilizers or 
atypical antipsychotics. There were some changes in pharmacotherapy among 
individual patients during the maintenance phase. Nevertheless, most of the  
changes in pharmacotherapy occured in the acute phase, fewer during the 
maintenance phase. 
Table 7.  Proportions of different medications received at different stages of 
maintenance phase during follow-up by the 154 patients in the JoBS. 
 
 
Type of medication 
Medication received at some time during the first maintenance phase 
(≥2 weeks after index episode) 
All patients C             Clinical bipolar diagnosis 
BD I  
N=71 
BD II    
N=83 
Total  
N=154 
                BD I 
               N=66 
                 BD II    
N=63 
Total  
N=129 
 n % n % n % n % n % n % 
Mood stabilizer 62 87.3 52 62.7 114 74.0 60 90.9 49 77.8 109 84.5 
  Lithium 24 33.8 10 12.0 34 22.1 24 36.4 10 15.9 34 26.4 
  Valproate 44 62.0 40 48.2 84 54.5 42 63.6 39 61.9 81 62.8 
  Oxcarbazepine 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
  Carbamazepine 4 5.6 3 3.6 7 4.5 4 6.1 2 3.2 6 4.7 
  Lamotrigine, 0 0.0 11 13.3 11 7.1 0 0.0 10 15.9 10 7.8 
Atypical antipsychotic 24 33.8 8 9.6 32 20.8 24 36.4 7 11.1 31 24.0 
  Olanzapine 18 25.4 3 3.6 21 13.6 18 27.3 3 4.8 21 16.3 
  Risperidone 14 19.7 3 3.6 17 11.0 14 21.2 2 3.2 16 12.4 
  Quetiapine 2 2.8 3 3.6 5 3.2 2 3.0 3 4.8 5 3.9 
  Aripiprazole 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Conventional 
antipsychotic 
11 15.5 6 7.2 17 11.0 11 16.7 6 9.5 17 13.2 
  Haloperidol 1 1.4 1 1.2 2 1.3 1 1.5 1 1.6 2 1.6 
  Other neuroleptics 10 14.1 5 6.0 15 9.7 10 15.2 5 7.9 15 11.6 
Mood stabilizer or 
atypical antipsychotic 
63 88.7 55 66.3 118 76.6 61 92.4 51 81.0 112 86.8 
Mood stabilizer or any 
antipsychotic 
64 90.1 57 68.7 122 79.2 62 93.9 53 84.1 115 89.1 
Antidepressant 29 40.8 55 66.3 84 54.5 15 22.7 32 50.8 47 36.4 
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5.2.2.  Adequacy and continuity of maintenance treatment 
 
We found that the proportion of adequate maintenance treatment received of the 
time needed was 69.3% (783/1129 patient months) for all the 154 patients and 
77.9% (766/984 patient months) for patients with a clinical bipolar diagnosis. 
Less than two-thirds (61%) of the 154 patients received adequate treatment 
throughout the maintenance phase; 72% of patients with a clinical bipolar 
diagnosis, but less than half of them with bipolar II or treated as outpatients 
during the index episode (Table 8). Majority of the patients (94/116, 81.0%) with 
adequate maintenance treatment at some time during the maintenance phase 
received it throughout that phase. Only ten patients received new starts of 
adequate treatment after the beginning of maintenance phase, seven of them 
within two weeks and the rest within three months. The duration of the 
maintenance phase did not have an effect on receiving adequate maintenance 
treatment.  
 
 
5.2.3.  Predictors of adequate maintenance treatment in 
multivariate models 
 
We made logistic regression models to adjust for confounding factors predicting 
adequate maintenance treatment received throughout the maintenance phase. 
The predictors were: having a clinical diagnosis of BD (OR=106.5, p<0.001), 
having been treated in hospital during the episode before maintenance phase 
(OR=11.09, p<0.001), rapid cycling (OR=3.4, p=0.030), and comorbid 
personality disorder (OR=0.373, p=0.038). We also made logistic regression 
models for the patients with a clinical diagnosis of BD before the maintenance 
phase. The factors that independently best predicted adequate maintenance 
treatment received throughout the maintenance phase were the same as in the 
regression models with all patients, except that clinical diagnosis was not 
included and having no comorbid personality disorder did not quite reach 
statistical significance in the model. 
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Table 8. Proportions of the 154 Jorvi Bipolar Study patients receiving adequate 
treatment at maintenance phase. 
 
 
 
5.3.  Adherence (Study III) 
 
5.3.1.  Treatment setting, contents and continuity 
 
Majority of the patients (140/160, 88%) were still in treatment at the 18-month 
follow-up, most of them being treated in psychiatric settings (135, 84%). Most of 
the 20 patients who were not in treatment had BD II (16/20, 80%), and majority 
of them (17/20, 85%) were in remission. Psychiatric hospital treatment during 
the follow-up had received a third (59/170, 35%) of the patients. 
 
Adequate maintenance 
treatment any time 
during maintenance, 
n=154 
Adequate 
maintenance 
treatment 
throughout 
maintenance 
phase, n=154 
Adequate maintenance 
treatment throughout 
maintenance phase, 
patients with a clinical 
bipolar diagnosis, 
n=129 
 
n % p n % p n % p 
Total   116 75.3  94 61.0  93 72.1  
 Female  55 70.5  44 56.4  43 69.4  
 Male   61 80.3 0.159 50 65.8 0.233 50 74.6 0.505 
Bipolar subtype          
 BDI   63 88.7  55 77.5  55 83.3  
 BDII   53 63.9 <0.001 39 47.0 <0.001 38 60.3 0.004 
Last phase before 
remission 
         
 Depression  69 71.1  54 55.7  53 67.1  
 Hypomania   16 66.7  14 58.3  14 66.7  
 Mania    17 100.0  15 88.2  15 88.2  
 Mixed   6 100.0  5 83.3  5 100.0  
 Depressive-mixed  8 80.0 0.005 6 60.0 0.099 6 85.7 0.194 
Rapid cycling           
 Yes  29 74.4  24 61.5  24 80.0  
 No  87 75.7 0.872 70 60.9 0.941 69 69.7 0.270 
Hospital treatment  
during index episode 
         
 Yes 55 93.2  50 84.7  49 92.5  
 No  61 64.2 <0.001 44 46.3 <0.001 44 57.9 <0.001 
Clinical BD diagnosis 
before maintenance 
phase 
         
 Yes  111 86.0  93 72.1     
 No   5 20.0 <0.001 1 4.0 <0.001    
Any personality disorder          
 Yes 46 71.9  36 56.3  36 64.3  
 No 70 77.8 0.402 58 64.4 0.304 57 78.1 0.083 
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Majority of the patients (87%) were prescribed mood stabilizers or atypical 
antipsychotics at some point during the follow-up. Nearly all of the patients (91%) 
also received some kind of psychosocial treatment, mainly 
supportive psychotherapy (69%) or individual psychotherapy (19%). The mean 
duration of psychosocial treatment was 17.5 (range 1-120) months. 
Although most of the patients received psychopharmacological treatment, 
the continuity of treatment was often compromised, as nearly half of the mood 
stabilizer (96/238, 40.3%) and nearly two-thirds of the atypical antipsychotic 
(80/127, 63.0%) treatment phases (one patient could have more than one 
treatment phase of the same category of medication) were discontinued during 
the 18-month follow-up. Even though most of the discontinuations occurred in 
accordance with the treatment plan, nearly half (41/96, 42.7%) of the mood 
stabilizer and one-third (24/80, 30.0%) of the atypical antipsychotic 
discontinuations were autonomous (Table 9). 
The rates of individual patients who discontinued medications were 
expectedly somewhat lower. Of the individual patients, one-quarter using mood 
stabilizers (36/153, 24%) or atypical antipsychotics (19/74, 26%) discontinued at 
least one treatment phase autonomously. Autonomous discontinuations of these 
treatments took place mainly in depression (42%) or euthymia (35%), seldom 
during the other phases. When examined in relation to the follow-up time spent 
in each phase, and adding the discontinuation of antidepressants, 
pharmacotherapy was autonomously discontinued more often in depressive (48% 
observed vs. 36% ecpected, p=0.011) and less often in euthymic (28% observed 
vs. 37% expected, p=0.040) phases. 
 
5.3.2.  Self-reported treatment adherence at 18-month  
follow-up 
 
At the 18-month follow-up most of the patients were adherent to the treatments 
they received between the 6- and 18-month follow-ups (Table 10). Nevertheless, 
some differences emerged in the rates of adherence (from 61% to 85%) between 
categories and types of treatment (p<0.001), adherence to mood stabilizers being 
the worst. Specifically, adherence to anxiolytics was better than to 
psychotherapy/supportive therapy (85% vs. 75%, p=0.004), to mood stabilizers 
(85%, vs. 61%, p<0.001) or to antidepressants (85% vs. 67%, p=0.007), and 
adherence to psychotherapy/supportive therapy was better than to mood 
stabilizers (75% vs. 61%, p=0.019).  
The main self-reported reasons for medication nonadherence were side-
effects, lack of motivation and/or a negative attitude towards the particular 
treatment (Table 11). Of the patients who attributed side-effects as a reason for 
mood stabilizer nonadherence, 65% (11/17) also gave some other reason (negative 
attitude towards medication 7, not effective 2, not motivated 1, wanted to try 
without 1), suggesting that side-effects as such may not always be a sufficient 
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explanation for poor adherence. Respectively, the most often attributed reasons 
for not coming to psychotherapy sessions regularly were practical barriers to 
coming to sessions (15/26, 57.7%) and lack of motivation (9/26, 34.6%).  
 
 
 
Table 9.  History of medication treatment phases and reasons for terminating 
treatment during 18 months’ follow-up in the JoBS 
 
 
 
 
 
History of treatment 
phases 
Lithium Valproate 
Carba-
mazepined 
Lamotri-
gine 
SGA 
Antidepres-
sant 
FGA 
n % n % n % n % n % n % n % 
Number of treatment 
phases 
52 100 139 100 14 100 33 100 127 100 214 100 31 100 
Discontinued treatment 
phases 
14 26.9 62 44.6 8 57.1 12 36.4 80 63.0 177 82.7 29 93.5 
Reasons for discontinuing 
treatment phasesa 
n %b n %b n %b n %b n %b n %b n %b 
Poor/no response 1 6.7 13 16.7 2 25.0 3 21.4 7 7.2 51 26.0 6 23.1 
Side-effects 11 73.3 28 35.9 6 75.0 7 50.0 43 44.3 60 30.6 10 38.5 
Too expensive medication 0 0.0 1 1.3 0 0.0 1 7.1 7 7.2 0 0.0 0 0.0 
No need for treatment   
because 
of recovery 
0 0.0 2 2.6 0 0.0 0 0.0 16 16.5 33 16.8 7 26.9 
Seemed to provoke a new 
phasec  
          10 5.1   
Patient’s autonomous 
decision 
3 20.0 34 43.6 0 0.0 3 21.4 24 24.7 42 21.4 3 11.5 
n=number of treatment phases. One patient could have more than one treatment phase of the same medication. SGA=Second  
generation antipsychotic, FGA=First generation antipsychotic. a One treatment phase could include more than one reason for  
discontinuing; b % of the reasons for discontinuing the medication; c only 6-18 months’  follow-up. 
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Table 10.  Self-reported treatment adherence at the 18-month follow-up in the 
JoBS. 
 
5.3.3.  Stability and predictors of treatment adherence 
 
When examining whether adherence to the same category of treatment changes 
from the 6-month to the 18-month follow-up, we found a change towards lower 
adherence to mood stabilizers (73% vs. 63%, p=0.015) and antidepressants (83% 
vs. 72%, p=0.023), but no changes in other groups of medications 
(antipsychotics, antidepressants) or psychosocial treatment. 
There were 134 patients with mood stabilizers at the 6- and 18-month 
follow-up points and 18 (13%) of them reported nonadherence at both follow-ups.  
We made logistic regression models to predict the factors associated with 
continued nonadherence: we added all the factors significant in the univariate 
analysis in the model, and adjusted for age, gender and bipolar subtype. Only the 
level of education, both low basic (not more than elementary school vs. student 
[p=0.01, OR=5.8 {1.5–22.4}]) and poor professional education (no professional 
education vs. having professional education [p=0.011, OR=4.2, {1.4–12.8}]) 
remained a significant predictor of continued nonadherence to mood stabilizers. 
 
5.3.4.  Differences in adherence and attitudes between 
treatments 
 
We found that adherences to different treatments correlated with each other, 
except between psychosocial treatment and anxiolytic medication (Table 12). 
There was a strong correlation between different types of pharmacotherapies for 
mood disorder. Attitudes towards different forms of treatments were mainly 
positive and correlated with each other, the only exception being between 
attitudes towards psychotherapy and somatic medications. In contrast to 
adherence, these correlations were weak (r=0.10–0.29) or moderate (r=0.30–
0.49). 
 
The patient has come to 
sessions/been on 
medication during the 
last follow-up period 
Mood 
stabilizer 
Anti-
psychotic 
Antidepres-
sant 
Psychosoci
al treatment 
n % n % n % n % 
Regularly 77 61.1 100 74.6 66 67.3 100 74.6 
Somewhat irregularly 15 11.9 20 14.9 12 12.2 20 14.9 
Very irregularly 22 17.5 7 5.2 11 11.2 7 5.2 
Not at all 12 9.5 7 5.2 9 9.2 7 5.2 
         
 
 
 
87 
 
Table 11.  Self-reported reasons for medication nonadherence at the18-month 
follow-up among patients in the JoBS. 
aEach patient could have more than one reason for not using the medication classes as 
prescribed. 
 
Table 12.  Spearman’s correlations between adherences to treatments at the18-
month interview. 
 
5.3.5.  Predictors of treatment nonadherence in multivariate    
models 
 
The logistic regression models to predict nonadherence with different forms of 
treatments included all the variables significant in the univariate analyses as 
explaining variables, adjusted for age, gender and bipolar subtype. In the model 
for nonadherence to mood stabilizers at the 18-month follow-up significant 
predictors were negative attitudes towards mood stabilizers (negative vs. positive 
OR=4.3, p=0.023, [1.2–14.8]) and having some current anxiety disorder at the 6-
month interview (OR=2.6, p=0.029, [1.1–6.0]). Predictors of nonadherence 
to antipsychotics at the 18-month follow-up were borderline personality 
disorder (OR=7.4, p=0.027, [1.2–43.7]), having current substance dependence at 
 
 
 
 
 
Reason(s) for not using  
medication as prescribeda 
Mood 
stabilizer 
Anti-
psychotic 
Anti-
depressant 
 
n 
% of 
non-
adhe-
rents 
N=43 
 
n 
% of 
non-
adhe-
rents 
N=16 
 
n 
% of 
non-
adhe-
rents 
N=30 
Generally a negative attitude 
towards offered treatment 
9 20.9 4 25.0 5 16.7 
Lack of motivation 16 37.2 4 25.0 13 43.3 
Side-effects  17 39.5 6 37.5 7 23.3 
Other reasons 14 32.5 4 25.1 11 36.6 
Treatment adherence at  
18 months 1. 2. 3. 4. 5. 
1.  Mood stabilizers 1,000 ,624** ,291* ,516** ,412** 
2.  Antipsychotics  1,000 ,406* ,654** ,392** 
3.  Anxiolytics   1,000 ,391** ,068 
4.  Antidepressants    1,000 ,290** 
5.  Psychotherapy     1,000 
** Correlation is significant at the 0.01 level (2-tailed). Strong = 0.50-1.00, medium = 0.30-0.49, 
small = 0.10-0.29. 
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the 6-month follow-up (OR=12.1, p=0.45, [1.1–139.4]) and having 
negative attitudes towards antipsychotics (negative vs. positive OR=7.6, p=0.041, 
[1.1–53.3]). Predictors of nonadherence to psychotherapy/supportive 
psychotherapy at the 18-month follow-up were having a current anxiety 
disorder at the 6-month follow-up (OR=3.53, p=0.011, [1.3–9.3]) or during 
lifetime (OR=2.9, p=0.043, [1.0–8.1]) and having negative attitudes towards 
psychotherapy (negative vs. positive OR=23.3, p<0.001, [4.1–133.5]). 
 
 
5.4.  Disability in BD (Study IV) 
 
5.4.1.  Patients on disability pension at baseline 
 
Altogether, a fifth (40, 21%) of the 191 patients were already on disability pension 
before enrollment in the study. These patients were expectedly older, but did not 
differ with regard to gender, bipolar subtype, marital status, or education. 
Patients who had been granted a disability pension before baseline were excluded 
from the prospective analysis. 
 
5.4.2.  Patients granted a pension during the 18-month follow-
up 
 
Of the 151 remaining patients 38 (25%) were granted a disability pension during 
the 18-month follow-up.  Most of the patients had BD (32/38, 84%) as the 
primary clinical diagnosis (ICD-10) for being granted a disability pension; 
however, in four cases the clinical diagnosis was unipolar depression, in one case 
schizoaffective disorder and in one case unknown.   
 
5.4.3.  Sociodemographic and clinical differences  
 
5.4.3.1.  Baseline   
 
There were many differences already at baseline between the patients who were 
granted a disability pension during the follow-up and the non-pensioned patients 
(see study IV, table 1). The patients who had been granted a disability pension 
during follow-up were significantly older, more often male, had more often BD 
type I, had longer duration of BD and had been more often treated in psychiatric 
hospitals than those not pensioned, but they did not differ with regard to marital 
status, living arrangement or education. They also had lower levels of overall 
social and occupational functioning (SOFAS), were more depressed (BDI, HAM-
D), perceived less social support (PSSS-R), were on sick leave and perceived 
themselves unable to work markedly more often than their non-pensioned 
counterparts, and had more often alcohol and other substance use disorders. 
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There were no differences in the proportion of pensioned and non-pensioned 
patients with anxiety disorders overall. However, of specific anxiety disorders, 
pensioned patients had more often GAD (generalized anxiety disorder) (11/38 
[29%] vs. 13/113 [12%], p=0.011). Proportions of patients with any personality 
disorder did not differ between these two groups, neither proportions of manic or 
depressive predominant polarity.  
 
5.4.3.2.  During the 18-month follow-up 
 
The course of the disease differed somewhat between the patients pensioned/not 
pensioned during the 18-month follow-up. The patients who were granted a 
disability pension reached full remission less often (43% vs. 73%, p=0.001) than 
non-pensioned patients, but the proportion of partial remission was similar in the 
two groups (51% vs. 60%, p=0.383).  The patients who were granted a disability 
pension spent less time in in euthymia (mean 28% vs. 45%, p=0.005) and more 
time in major depressive phases (mean 54% vs. 29%, p<0.001) than non-
pensioned patients, but there were no differences in the proportion of time spent 
in manic, hypomanic, mixed or depressive mixed phases, or with hypomanic or 
depressive symptoms. 
As the pensioned patients had overall a more severe and chronic course of 
illness than non-pensioned patients, they expectedly received somewhat more 
treatments and clinical appointments. The median number of visits to doctors 
was equal (3.0) during the first 6 months, but higher between the 6- and 18-
month follow-up (p=0.001) among the pensioned (4.0) than non-pensioned (2.0) 
patients. The median number of visits to any personnel was 10.0 vs. 8.0 
respectively during the first 6 months (p=0.599) and 12.0 vs. 7.0 between the 6- 
and 18-month interviews (p=0.012). The adequacy of pharmacological acute 
phase treatment did not differ significantly (47% pensioned vs. 37% non-
pensioned, p=0.266), but the pensioned patients had more adequate treatment 
during the first maintenance phase (89% vs. 70%, respectively, p=0.048). 
Adherences to medications, or attitudes towards mood stabilizers, antipsychotics 
or psychotherapy did not differ significantly during follow-up, the pensioned ones 
being at least as adherent as the non-pensioned ones.   
The patients with permanent disability pension at 18-month follow-up were 
older (mean 47.2 vs. 33.1 years, p<0.001), more often BD type I (60.3% vs. 
40.8%, p=0.013), had more often had alcohol dependence (53.4%, vs. 33.1%, 
p=0.008) and post-traumatic stress disorder (25.9% vs. 11.5%, p=0.013) during 
their lifetime, had better basic education (p=0.005) but less vocational education 
(p=0.034). They were also more depressed (according to HAM scores p=0.018, 
but there was no difference in BDI scores), anxious (BAI scores, p= 0.039), had 
less social support (PSSR scores p=0.022) and they were more disabeled (SOFAS 
scores, p<0.001).  
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5.4.4.  Predictors for time to disability pension during the 18-
month follow-up  
 
5.4.4.1. Univariate analyses 
 
We made univariate analyses with Cox model to investigate the effect of each 
predictor on the interval time from intake to the date the pension was granted 
(Table 13). In these analyses, the significant predictors of granted disability 
pension were older age, male gender, bipolar type I, depressive index phase, 
number of manic phases, longer duration of BD, comorbid substance abuse, GAD 
and avoidant personality disorder, greater number of psychiatric hospital 
treatments, and perceived poor economic situation. Granted disability pension 
was associated also with more time spent in major depressive episodes, greater 
proportion of time spent in depressive states overall, and smaller proportion of 
time spent in euthymia during the follow-up. Moreover, granted disability 
 
Figure 2.  Kaplan–Meier survival curves for subgroups divided by age (< or ≥40 
years), gender, bipolar subtype, and perceived ability to work, predicting time to 
being granted a disability pension during the 18-month follow-up in the Jorvi 
Bipolar Study. 
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pension was associated with lower perceived working ability, higher BDI (Beck 
Depression Inventory), HAM-D (Hamilton Rating Scale for Depression) and BAI 
(Beck Anxiety Inventory) scores, and lower SOFAS (Social and Occupational 
Functioning Assessment Scale) and PSSS-R (Perceived Social Support Scale-
Revised) scores (Table 13, Figure 2). 
 
5.4.4.2.  Multivariate analyses 
 
To adjust for confounding factors, we created Cox regression models predicting 
the time to being granted a disability pension during the 18-month follow-up 
(Table 14).  
In the first phase, we created models for all 151 patients who were not on 
pension at baseline, controlling for age, gender, and bipolar subtype in all models. 
We added other factors one by one if they were either significant or almost 
significant (p<0.10) in univariate analysis or considered clinically or theoretically 
important. As we were specifically interested in determining the possible effect of 
comorbidities on being granted a disability pension we included all anxiety 
disorders and personality disorders in the multivariate analysis irrespective of 
their significance in the univariate analyses. We found that the time to being 
granted a disability pension was independently predicted by higher age, male sex, 
depressive index episode, GAD, avoidant personality disorder and higher number 
of psychiatric hospital treatments (Table 14). Age was not significant if perceived 
working ability was added in the model, as age and perceived working ability are 
correlated (Spearman’s rho 0.306, p<0.001), but perceived working ability was 
highly significant (HR=9.09, 95%CI=3.85-21.49, p<0.001). When we included 
times and proportions of time spent in different phases during the 18-month 
follow-up, we found that the proportion of time that was spent in depression 
predicted being granted a pension during the follow-up (after removing the highly 
intercorrelated depressive index episode variable), but having avoidant 
personality disorder was no longer significant.  
In the second phase, to evaluate whether the results were dependent on 
specific subgroups, we made stratified analyses by splitting the data with 151 
patients by bipolar subtype (BD I vs. BD II), age (<40 vs. ≥ 40 years at baseline), 
and gender (Table 14). We created Cox regression models for each of these six 
groups using the same predictors as in the first analysis, and found differences in 
predictors between the subgroups.   
We also made logistic regression models predicting being on permanent 
disability pension at the 18-month follow-up, controlling for age, bipolar subtype 
and sex in all models. The significant predictors for being on permanent disability 
pension at 18-month follow-up were higher age, BD type I, borderline personality 
disorder, PTSD and level of basic education (elementary school at highest vs. 
student). 
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Table 13.  Cox model univariate analyses of predictors for time to being granted 
a disability pension for employed patients with BD in the Jorvi Bipolar Study 
during an 18-month follow-up.  
 
Predictor at entry 
Being granted a disability pension 
during the follow-up 
 HR 95% CI p 
Age        1.047 1.02-1.08 0.001 
Gender, male 2.036 1.05-3.99 0.035 
BD I 2.354 1.22-4.55 0.011 
Married or cohabiting 1.368 0.70-2.67 0.369 
Basic education  0.751 0.54-1.06 0.106 
Vocational education            0.976 0.74-1.29 0.862 
Duration of disease 1.042 1.02-1.07 0.002 
Index episode depression 2.239 1.11-4.52 0.024 
Number of episodes before 
baseline 
   
   Depressive  1.004 0.98-1.03 0.711 
   Manic 1.141 1.07-1.22 <0.001 
Psychotic symptoms lifetime 1.242 0.90-1.72 0.187 
Rapid cycling  0.937 0.67-1.32 0.708 
Alcohol dependence, lifetime    2.274 1.20-4.13 0.012 
Some anxiety disorder, 
lifetime 
1.103 0.58-2.09 0.764 
Some personality disorder 1.340 0.71-2.53 0.368 
Borderline personality 
disorder 
1.458 0.74-2.89 0.280 
Avoidant personality disorder 2.582 1.14-5.87 0.024 
PTSD, lifetime 1.748 0.80-3.82 0.160 
GAD,  lifetime 2.824 1.40-5.70 0.004 
Number of psychiatric 
hospital treatments  
1.301 1.18-1.43 <0.001 
Economic situation  10.588  1.42-79.14 0.012 
Perceived work ability 10.463 4.78-22.90 <0.001 
SOFAS score 0.948 0.92-0.98 0.001 
BDI score 1.046 1.02-1.08 0.004 
HAM-D score 1.073 1.03-1.12 0.003 
YMRS score 0.964 0.92-1.01 0.157 
BAI score 1.027 1.00-1.05 0.046 
PSSS-R score 0.959 0.94-0.99 0.002 
Extroversion 0.963 0.89-1.04 0.323 
Neuroticism 1.042 0.97-1.13 0.288 
Life-chart-based predictors    
Duration of depression 
during  follow-up  
1.002 1.00-1.00 0.018 
Proportion of time spent in 
depression during follow-up 
1.020 1.01-1.03 <0.001 
Proportion of time spent in 
euthymia during follow-up 
0.986 0.98-1.00 0.014 
Abbreviations: PTSD=Post Traumatic Stress Disorder, GAD=Generalized 
Anxiety Disorder, SOFAS=Social and Occupational Functioning Assessment 
Scale, BDI=Beck Depression Inventory, HAMD=Hamilton Depression Rating 
Scale, YMRS=Young Mania Rating Scale, BAI=Beck Anxiety Inventory, 
PSSS-R=Perceived Social Support Scale-Revised, EXT= Extroversion, 
NEU=Neuroticism 
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Table 14.  Multivariate analyses using Cox regression model of predictors for time to work disability pension during an 18-month 
follow-up for all 151 patients with bipolar disorder belonging to the labor force in the Jorvi Bipolar Study and for these same 
patients stratified by age, bipolar subtype, and gender.              
                      
 GAD=Generalized Anxiety Disorder; HR= hazard ratio. 
 
 
 
 
 
Predictor 
 
 
All 151 patients belonging to 
labor force 
Patients stratified by age, bipolar subtype, and sex 
Age Gender Bipolar subtype 
<40 years, n=99 ≥40 years, n=52 Male, n=72 Female, n=79 Type I, n=67 Type II, n=84 
p HR 95% CI p HR p HR p HR p HR p HR p HR 
Age 0.005 1,04 1.01-1.08     0.041 1.05 0.053 1.04 0.001 1.10 0.963 1.00 
Gender, 
male 
0.025 2.35 1.11-4.95 0.033 3.55 0.061 2.96     0.215 1.94 0.070 3.12 
BD I 0.095 1.86 0.90-3.39 0.431 0.62 0.004 6.95 0.081 2.44 0.468 1.55     
Index 
episode 
depression 
0.036 2.15 1.05-4.41 0.863 1.10 0.096 2.46 0.041 2.62 0.860 1.13 0.123 2.12 0.325 1.80 
GAD <0.001 4.86 2.21-10.67 0.010 5.59 <0.001 11.22 0.192 2.40 0.001 7.75 0.005 6.88 0.005 5.26 
Avoidant 
personality 
disorder 
0.005 3.70 1.48-9.25 0.153 3.09 0.070 3.41 0.004 8.65 0.182 2.53 0.014 6.41 0.505 1.57 
Borderline 
personality 
disorder 
0.091 1.93 0.90-4.14 0.011 4.88 0.458 1.64 0.683 1.29 0.095 2.75 0.260 2.07 0.162 2.35 
No. of 
psychiatric 
hospitalizat. 
<0.001 1.33 1.18-1.50 <0.001 1.48 0.145 1.16 0.011 1.25 <0.001 1.41 <0.001 1.47 0.500 0.77 
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6.   DISCUSSION 
 
6.1.  Main findings 
 
The most important finding in the first study was that less than half (42%) of the 
patients with an acute phase of BD received adequate treatment. Clinical diagnosis 
was by far the most important predictor of adequate treatment, and our study 
strengthens the value of correctly diagnosing bipolar disorder. However, having a 
diagnosis does not guarantee proper treatment, as only two-thirds (65%) of the 
patients with a clinical diagnosis of BD were given adequate treatment. Lack of 
attention to the longitudinal course is another major problem area, as only a 
minority of patients with rapid cycling or a polyphasic episode received 
appropriate treatment.  Undertreatment is also related to the depressive phases as 
less than a third of depressed patients received adequate treatment.  
Maintenance phase treatment was not more appropriate, as less than two-
thirds (61%) of BD patients received adequate maintenance treatment. As in the 
acute phase, having a clinical diagnosis was by far the most important predictor of 
receiving adequate maintenance treatment. However, maintenance treatment was 
compromised in more than a quarter (27%) of the patients even with a clinical 
diagnosis of BD. In addition to being undiagnosed, patients most at risk for 
receiving inadequate or intermittent maintenance treatment are those treated in 
outpatient settings and those with vaguer or less prominent forms of symptoms 
such as BD II or comorbid personality disorders. Maintenance treatment seems 
mainly to follow the treatment given in the acute phase, and the problems in the 
adequacy of maintenance treatment follow the shortcomings in the acute phase.  
Even though treatments were offered, they were often not used as prescribed. 
A quarter of the patients discontinued pharmacological treatments by their own 
decision, and of the medications continued, a third was not used regularly enough 
to be effective. The highest risk for autonomous discontinuation was when patients 
were depressed. The main reasons for medication nonadherence were side-effects, 
lack of motivation, and negative attitudes toward offered treatment. For individual 
or supportive psychotherapy, the reasons were practical barriers to coming to 
sessions and lack of motivation. Although rates of nonadherence do not 
necessarily differ between mood-stabilizing medications, the predictors for 
nonadherence do. Furthermore, adherence to one medication does not guarantee 
adherence to another, nor does a patient's adherence at one timepoint ensure 
adherence at another, as the patient′s adherence may change over time. Patients’ 
attitudes toward treatments affect adherence to medications as well as to 
psychosocial treatments and should be monitored repeatedly. Nonadherence to 
psychotherapy is as common as medication nonadherence and should be given 
more attention. 
The main finding of the last study is that BD I and II are associated with a 
major risk of long-term work disability, as 25% of the patients belonging to the 
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labor force were granted a disability pension after an acute episode during 
medium-term follow-up. The main predictors of being granted a disability pension 
are a more severe course of the disease, higher age, male gender, depression-
related cumulative burden, and comorbidities. However, the predictors may vary 
depending on bipolar subtype, age, and gender. We also found that patients’ 
subjective estimations of their vocational ability were surprisingly correct in 
predicting the need for future disability pension.  
 
 
6.2.  Methods 
  
6.2.1.  Representativeness of the cohort sample  
 
The JoBS is the first clinical cohort study based on systematic screening for BD 
among psychiatric in- and outpatients within a geographically defined catchment 
area. Due to the screening, the cohort includes both clinically diagnosed and 
undiagnosed patients with BD, which is thus uniquely representative. Screening 
also enabled us to make comparisons of BD I and BD II unbiased by sampling. The 
sampling of patients at the beginning of an acute new phase enabled investigation 
of the patients from the time they usually come to psychiatric care.  
The present naturalistic study was based on a relatively large (N=191) cohort 
of both in- and outpatients of BD, including both BD I and BD II, independent of 
clinical diagnosis, and representing secondary care psychiatric BD patients with an 
acute phase. Finland has no private psychiatric hospitals, and public psychiatric 
care is free of charge. Most BD I patients are likely to seek treatment or contact a 
psychiatrist in an acute phase. By using the MDQ screen, most BD patients in 
psychiatric care in the area with an incident illness episode were likely found.  
 
 6.2.2. Screening 
 
We screened a large number of psychiatric patients (N=1630) with the MDQ, the 
cutoff modified by including as positive patients without problems due to episodes 
to increase sensitivity for BD II. This modification of the cutoff in the screen was 
based on the pilot study of the JoBS (Isometsä et al., 2003). The higher sensitivity 
but lower specificity of the modified MDQ resulted in a higher number of false 
positives to be excluded in the SCID interview.  
 
 6.2.3.  Diagnostic measures and life chart methodology 
 
The diagnoses of BD and comorbid disorders were carefully assigned by 
psychiatrists with a minimum of five years of clinical experience using SCID-I 
interview (First et al., 2002), having information from all patient records available 
and completed with several informants in any case of uncertainty. The interrater 
reliability was excellent (kappa 1.0 for both BD I and II). The SCID is the most 
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commonly used and best validated diagnostic instrument in psychiatric research, 
and it was used here in the way shown to be the most valid. However, the 
reliability of comorbid diagnoses were not evaluated. Axis II diagnoses were 
assessed using the semi-structured SCID-II interview for DSM-IV. Because we 
included the patients in an acute phase, this may have had some impact on the 
results. However, patients were met three times and comorbid disorders were 
assessed in a later subacute phase; the diagnoses of personality disorder were 
based on multiple sources of information and a longitudinal view of patients’ 
functioning during euthymic phases, not on current behavior. Still, despite our 
best efforts, we cannot fully exclude the possibility that the current state might 
have biased the assessment of personality. The design of our study was 
constructed to be as close as possible to the situation in which a clinician meets 
mood disorder patients during the acute phase.  
One of the most influential methods in this study was the use of a life chart. 
The life chart methodology is generally accepted as part of follow-up studies of BD. 
The graphic life chart we used in this study is similar but not identical to the 
Longitudinal Interval Follow-Up Evaluation (LIFE) or NIMH life chart 
methodology used in other prospective studies reporting separately on both BD I 
and II (Dittmann et al., 2002; Joffe et al., 2004; Judd et al., 2002; Judd et al., 
2003; Post et al., 2003; Tondo et al., 1998). As we aimed to assess the life chart 
phases compatible with DSM-IV criteria, which are part of everyday clinical 
practice and known to all clinicians, we used the graphic life chart that was 
planned and used in the Vantaa Depression Study (Melartin et al., 2004). As with 
LIFE, probes related to important events were used to investigate change points in 
the psychopathologic state. However, unlike with LIFE, the life chart was made 
directly comparable with DSM-IV criteria, and the patients’ follow-up time was 
classified into periods of four DSM-IV phases of BD (major depression, mania, 
hypomania, mixed episode), including also depressive mixed states, full remission 
phases with no symptoms, and partial remission when criteria for neither mood 
episode nor full symptomatic remission were fulfilled. Even though the life chart 
was constructed in the two follow-up interviews based on patient reports, all 
available patient records, and other informants when needed, the underreporting 
of some milder illness phases, such as short hypomanic or depressive mixed 
episodes, cannot be excluded. However, bias in the comparison of BD I and II is 
unlikely in this respect.   
In addition, we used many structured and semi-structured measures, both 
objective and subjective, to investigate a broad range of factors from several 
domains: socio-demographic factors, work disability factors, clinical variables, and 
temperamental and psychosocial factors (perceived social support, size of social 
network, and negative life events).  
We also used register-based data on the granted disability pensions, when 
and on the basis of which diagnoses they were granted, and on hospital 
treatments, their dates and diagnoses, enabling us to get precise information for 
the whole cohort.  To our knowledge, no previous prospective studies have been 
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conducted on the predictors of long-term working disability or being granted a 
disability pension among patients with BD I or BD II. 
 
6.2.4.  Study limitations 
 
Although we took patients into the cohort during the early acute phase, thus 
minimizing treatment effect at baseline of the study (Mantere et al., 2004), we 
cannot exclude the possibility that in some cases the study itself may have affected 
somewhat the number of patients receiving a clinical bipolar diagnosis, as well as 
the treatment they received in the acute phase (study I) or during the follow-up 
(study II).  As the study was naturalistic, serum levels of lithium or valproate could 
be related to the self-reported adherence only when measured based on clinical 
indication. Also, to avoid undue complexity in the data, dosages of the numerous 
pharmacological agents were not evaluated. Thus, our results represent the upper 
limit of the proportion of patients classified as having received adequate treatment 
in the acute (study I) or maintenance phase (study II). Also the rates of adherence 
relied on the patients’ self-report, which is likely to underestimate nonadherence 
(study III).   
Since we included depressive mixed states as a distinct phase, which would 
be diagnosed as major depressive episodes in the DSM-IV, we had 26 fewer cases 
of depression in the index phase, and 9 more cases with rapid cycling and 4 more 
cases with polyphasic episodes during the follow-up, as compared with the use of 
strict DSM-IV diagnoses. However, classifying the depressive mixed states as 
depressions would have had no impact on the rate of adequate treatment of 
depression (31.1% vs. 31.1%).  
The timing of study between 2002 and 2004 may have influenced the 
medications chosen, specifically affecting lamotrigine treatment since lamotrigine 
became reimbursed for bipolar disorder in Finland during the study (studies I and 
II). There are no studies of the Finnish prescribing patterns of medications from 
2002 to date, but register studies have been conducted in other Nordic and 
European countries (Bjorklund et al., 2015; Carlborg et al., 2015; Haeberle et al., 
2012; Hayes et al., 2011; Kessing et al., 2016), likely representing the same kind of 
trends as in Finland during the last 15-20 years.  According to these studies, there 
has been a general increase in the proportion of patients with BD who have been 
prescribed psychotropic medication. The proportion of patients treated with 
antidepressants has been steady or increased, but the proportion of patients with 
antidepressant monotherapy has decreased. The proportion of patients treated 
with atypical antipsychotics and anticonvulsants (valproate, lamotrigine) has 
significantly increased.  Simultaneously there has been a significant decrease in 
the proportion of patients treated with typical antipsychotics. The proportion of 
patients treated with lithium has remained constant or decreased. According to 
these rates, the adequacy of treatment today may be somewhat better than during 
our study, but the use of antidepressants that has risen in most of the studies 
deserves attention and might affect the adequacy of treatment in a negative way.  
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However, even though a change has occurred in the proportions of different 
medications prescribed after 2004, according to the aforementioned studies, the 
main change took place before 2002-2004. 
Some changes in the definitions of adequate pharmacotherapy have been 
made since 2002-2004, but as no universally accepted definition of adequate 
treatment for all types and phases of BD exists, any definition of adequate 
pharmacological treatment is somewhat arbitrary. Hence, estimates of the 
frequency of adequate treatment depends on such definition (studies I and II).   
In the second study, we focused on the first maintenance phase after the 
index episode, and the picture might have been somewhat different had we also 
studied maintenance phases over a longer period. A methodological limitation is 
also the timing of the maintenance phase, as no consensus has been reached on 
how the longitudinal treatment phases should be defined. In particular, whether a 
distinct continuation phase should be included and when precisely it should end 
and, consequently, the maintenance phase begin. In this study, we did not 
separate a continuation phase, and the maintenance phase was defined to start on 
the day when full criteria for an acute phase ended. However, we did not find that 
the duration of the maintenance phase had any effect on the adequacy of 
treatment. 
When measuring adherence, we used a self-developed interview 
questionnaire, the same as used in the Vantaa Depression Study, making it 
possible to compare these two studies but likely affecting the comparison of our 
results with other studies.  Also, as in other studies of adherence, attrition is a 
critical question, and we do not know whether the patients who came to follow-up 
visits were more adherent than the dropped-out patients. 
In the fourth study, although we were able to investigate a wide range of 
predictors for disability, an important limitation was that we did not measure 
cognitive functioning, which has been shown to influence functional ability, even 
in euthymic patients with BD (Andreou & Bozikas, 2013; Wingo et al., 2009).  
Even though the study data were collected over 10 years ago, the conditions 
for which a disability pension can be granted have not changed significantly in 
Finland over this period. Likely the only significant epidemiological change has 
been an increase in the number of bipolar diagnoses, probably due to improved 
recognition, so the limitation of the timing of data collection is theoretical and 
unlikely to markedly influence the predictors for a disability pension. 
 
 
6.3.  Adequacy of acute phase pharmacotherapy 
in BD (study I) 
 
Pharmacotherapy is the foundation of treatment for BD, so the finding that even in 
the acute phase less than half (42%) of the patients with BD received adequate 
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treatment is alarming. This result was mostly due to lack of a clinical diagnosis of 
BD, as only a small minority (7%) of the undiagnosed patients received adequate 
treatment. That only a minority of misdiagnosed patients receive guideline-
concordant treatment was reported also in a recent Chinese study (Xiang et al., 
2012). Thus, the value of correctly diagnosing BD cannot be overemphasized, but a 
clinical diagnosis of BD does not guarantee proper treatment, as only two thirds 
(65%) of patients received adequate treatment.  In addition to diagnosis, we found 
that rapid cycling and a polyphasic episode were associated with inadequate 
treatment. Also, the rate of adequate treatment varied markedly by illness phase; 
treatment received was adequate for mania (100%), but far from adequate for 
bipolar depression (31% among all patients, 49% among patients with a clinical 
diagnosis).   
This study was the first to evaluate the difference in quality of treatment 
provided to in- and outpatients. Outpatients received clearly (36% vs. 55%) less 
adequate treatment, reflecting mainly the significantly greater proportion of 
patients with a diagnosis of BD in hospital settings, as well as differences in the 
proportion of BD I and BD II patients and differences in the types of mood phases 
in different settings.  Most BD depressions are treated in outpatient settings, and 
we found that only a fraction of these cases received adequate treatment.  
Treatment of depressive phases may be problematic even among inpatients, as 
Lim et al. (Lim et al., 2001) reported in their study of 1,471 hospitalized BD I 
patients; they found that 31% of depressive patients with psychotic features and 
17% of those without these features were discharged without the recommended 
pharmacotherapy. These findings are of major importance because the course of 
bipolar disorder is dominated by depressive phases (Judd et al., 2002; Judd et al., 
2003; Post et al., 2003), and these phases carry a high risk for suicide (Tondo et 
al., 2003) and functional disability (Judd et al., 2005). 
Undertreatment also appears to be related to the longitudinal course of the 
disorder, as only a minority of patients with rapid cycling or a polyphasic episode 
received appropriate treatment. The main reasons for inadequate treatment in 
rapid cycling were absence of a mood stabilizer and having a concurrent 
antidepressant.  Even though avoiding antidepressants in rapid cycling is 
recommended in most practice guidelines, we found that the proportion of 
patients receiving antidepressants was not lower for rapid cyclers than for non–
rapid cyclers and, in fact, the trend was the opposite; this was also evident among 
the clinically diagnosed patients with rapid cycling. Also previous studies (Lloyd et 
al., 2003; Simon et al., 2004) have found that a rapid cycling course of illness may 
not reduce the proportion of patients receiving antidepressants. So, it seems that 
having a rapid cycling course of disease does not influence whether 
antidepressants are prescribed. Reasons for this prescribing of antidepressants for 
patients with rapid cycling may be that the attending psychiatrists do not pay 
sufficient attention to the longitudinal course of the illness or the 
pharmacotherapy of the former phase or episode remains poorly monitored, with 
the result that the treatment does not follow transitions of rapid cycling and 
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polyphasic episodes. More systematic use of life charts and regular mood ratings 
would likely be beneficial in helping clinicians grasp the longitudinal course of 
their patients’ illness and thus improve the quality of care. 
 
 
6.4.  Adequacy of maintenance phase 
pharmacotherapy in BD (study II) 
 
As BD is a long-term disease with nearly all patients having one or more 
recurrences, practice guidelines recommend maintenance treatment after an acute 
episode.  We found that three-quarters (75%) of patients received adequate 
maintenance treatment at some point during the maintenance phase but only two-
thirds (68%) of the time they should have received it. However, less than two-
thirds (61%) of patients received adequate maintenance treatment throughout the 
maintenance phase and, thus, the benefit of pharmacological protection against 
relapses. Even among the clinically diagnosed patients, less than three-fourths 
(73%) received adequate maintenance treatment continuously. As BD is a life-
threatening (Tondo et al., 2003) and often chronic mental disorder with marked 
psychosocial impairment (Goldberg & Harrow, 2004; Judd et al., 2002; Judd et 
al., 2003; Judd et al., 2005; MacQueen et al., 2001; Post et al., 2003; Strakowski 
et al., 1998) and considerable health costs (Hirschfeld & Vornik, 2005; Kleinman 
et al., 2003), providing adequate maintenance treatment is an important aim. 
Clinical bipolar diagnosis was by far the most important predictor of 
adequate treatment, but it did not guarantee proper treatment. Another important 
predictor of adequate treatment was having been treated as an inpatient during 
the last episode, highlighting the problems present in outpatient contexts.  Also, 
the presence of a comorbid personality disorder predicted a lower likelihood of 
receiving uninterrupted adequate maintenance treatment. This may be one reason 
for the finding in several studies that an additional diagnosis of a personality 
disorder in patients with BD leads to poorer outcomes (Bieling et al., 2003), 
including poorer medication compliance, more days in the hospital, lower rates of 
recovery, more severe mood symptoms, lower levels of functioning, and increased 
incidence of substance use disorders (Magill, 2004). Furthermore, patients with 
comorbid personality disorder may have an increased risk of suicide attempts 
(Garno et al., 2005; H. Valtonen et al., 2005). Another course-related independent 
predictor was rapid cycling, which seemed to have resulted in more 
pharmacotherapy efforts to control repeated illness cycles. 
The efficacy of antidepressants in the maintenance treatment of bipolar 
disorder is not supported by controlled evidence, and most of the treatment 
guidelines recommend discontinuing them after a few months of remission. There 
is striking incongruity between the wide use of and the weak evidence base for the 
efficacy and safety of antidepressant drugs in bipolar disorder. Few well-designed, 
long-term trials of prophylactic benefits have been conducted, and there is 
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insufficient evidence for treatment benefits with antidepressants combined with 
mood stabilizers. A major concern is the risk for mood switch to hypomania, 
mania, and mixed states (Pacchiarotti et al., 2013). Still, in this study, we found 
that more than half of the patients prescribed antidepressants at the beginning of a 
maintenance phase lasting longer than six months still had them after six months 
in remission. Half of these patients had residual or prodromal depressive 
symptoms at the maintenance phase, so in these cases antidepressants may have 
been prescribed for these symptoms. Contrary to the disagreement over the role of 
antidepressants in treating BD in general (Pacchiarotti et al., 2013), 
antidepressants are usually not recommended for patients with rapid cycling. Still, 
we found no significant difference between the proportions of rapid cycling and 
non-rapid cycling patients receiving antidepressants, as in our previous study of 
the treatment in the acute phase (Arvilommi et al., 2007); in fact, we observed a 
trend in patients with rapid cycling being prescribed antidepressants more often. 
Our results are in line with the findings from SFBN (Dittmann et al., 2002), STEP-
BD (Simon et al., 2004), and EMBLEM (Cruz et al., 2008) studies, although in 
these the separation between treatment phases (acute or maintenance) remained 
unclear. Thus, although the patients with rapid cycling more often received 
adequate maintenance treatment, they also often were prescribed antidepressants. 
This may in part be because rapid cycling patients more often experienced 
depression preceding the first maintenance phase and more depressive phases in 
all before the first maintenance phase than non-rapid cycling patients. However, 
even when we included only the patients who had depression preceding the 
maintenance phase in the analyses, we found no significant difference between the 
rapid and non-rapid cycling patients receiving antidepressants either in the 
beginning or any time during the first maintenance phase. That antidepressants 
may be a risk for patients with rapid cycling (even in depression) was supported by 
the STEP-BD study by Schneck et al. (Schneck et al., 2008), in which episodes of 
mood disorder in 1,742 patients with BD I and II were evaluated for up to one year 
of treatment and antidepressant exposure was associated with worse cycling. In an 
a priori analysis in the STEP-BD study, despite preselection for good 
antidepressant response and concurrent mood stabilizer treatment, antidepressant 
continuation in rapid cycling was associated with worsened maintenance 
outcomes, especially for depressive morbidity opposite to antidepressant 
discontinuation (El-Mallakh et al., 2015). 
This study is one of the first to investigate maintenance treatment received 
using the life chart methodology, with the possibility of reporting longitudinal 
patterns of maintenance treatment. In a previous cross-sectional study, Ghaemi et 
al. (Ghaemi et al., 2006) found that most agents used in the acute phases of BD 
were used in similar proportions in the maintenance phase. Our longitudinal 
follow-up confirmed their cross-sectional observation, as treatments were seldom 
changed during the maintenance phase, independent of its duration. Thus, it 
seems that in usual clinical practice, treatment prescribed in the maintenance 
phase typically follows the treatment prescribed in the acute phase. This practice 
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of continuing the agents used in the acute phase was criticized by Goodwin and 
Jamison (Goodwin & Jamison, 2007), who stated that while this is appropriate for 
managing the period immediately after resolution of the acute episode (the 
continuation phase of treatment), it certainly is not the best approach to true 
prophylaxis. Simply because a drug has antimanic properties, one cannot assume 
that it will be effective in the prevention of new episodes in the future, particularly 
depressive episodes (Goodwin & Jamison, 2007). Further longitudinal 
effectiveness studies are needed to assess strategies to enhance the adequacy of 
interventions during the continuation and treatment phases in patients with 
bipolar disorders. 
 
6.5.  Adherence to treatments in BD (study III) 
 
Treatment of BD depends on the illness phase and is complex, usually involving 
numerous medications to be started and discontinued. However, poor adherence 
in BD is a major obstacle to effective treatment. The aim was to investigate 
adherence to pharmacological and psychosocial treatments during an 18-month 
follow-up among patients with BD I and BD II. Even though nearly all patients had 
received mood stabilizers or atypical antipsychotics and psychosocial treatment, 
the effect of pharmacological treatment was often compromised by nonadherence. 
The pharmacological treatments were autonomously discontinued by a quarter of 
the patients, and of the medication continued, a third was not used regularly 
enough to provide a benefit. The main reasons the patients gave for nonadherence 
were side-effects, lack of motivation, and a negative attitude toward the offered 
treatment; for individual/supportive psychotherapy, reasons included practical 
barriers to coming to sessions and lack of motivation. The highest risk for 
discontinuing pharmacotherapy autonomously was present when patients were 
depressed. Negative attitude was the only predictor common to all; otherwise, the 
predictors of nonadherence differed among mood stabilizers, antipsychotics, and 
individual/supportive psychotherapy. Patients’ adherence also often changed 
during the follow-up. 
Lack of treatment provision does not seem to be a central problem among 
patients with BD, as most patients with BD continued to receive psychiatric care 
18 months after entering the study in an acute phase. Also, nearly all patients had 
received mood stabilizers or atypical antipsychotics and psychosocial treatment. 
However, even though some pharmacotherapies were appropriately discontinued 
by the physician, every fourth patient discontinued at least one medication 
treatment phase autonomously.  There were some differences between 
medications in the reasons for discontinuing them. Lithium was discontinued 
nearly always in agreement with the treating physician because of its side-effects, 
whereas valproate was most often discontinued autonomously. The autonomous 
discontinuation occurred most often during depression, even after accounting for 
the high proportion of time spent in depressive phases.  The reason for 
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autonomous discontinuation in depression may be that patients consider their 
depression to be due to their medication or deem the medication to be ineffective, 
although Jamison et al. (Jamison et al., 1979) found no significant relationship 
between perceived effectiveness and reported compliance. 
However, continuing medications does not mean using the medications 
appropriately, as about a third of patients admitted not having taken them 
regularly. Even though it is somewhat difficult to compare studies because of 
methodological differences, our results are broadly in line with other studies 
(Colom et al., 2000; Copeland et al., 2008; Gonzalez-Pinto et al., 2010; Keck Jr et 
al., 1997; Manwani et al., 2007; Perlis et al., 2010; Sajatovic, Bauer et al., 2006; 
Sajatovic et al., 2008; Sajatovic et al., 2009), confirming nonadherence to be a 
major problem in the treatment of BD. The adherence of individual patients often 
changed in the follow-up, so adherence at one timepoint does not guarantee 
adherence at another.  The adherence rates between different mood stabilizers 
were very similar, consistent with many previous studies (Baldessarini et al., 
2008; Colom et al., 2000; Gianfrancesco et al., 2006; Sajatovic, Valenstein et al., 
2006; Sajatovic et al., 2007), suggesting that nonadherence is more a question of 
patient factors. Even though we found that the correlations between categories of 
drugs are strong, adherence to one drug does not guarantee adherence to another. 
In our study, the main reasons patients gave for nonadherence were side-
effects, lack of motivation, and negative attitudes.  There were no major 
differences between mood stabilizers, antipsychotics, and antidepressants in the 
reasons patients gave for discontinuance, despite marked pharmacological 
differences between the medications. There are different views of the importance 
of side-effects as a reason for nonadherence in BD. Experts perceive side-effects to 
be a prominent reason for adherence problems (Velligan et al., 2009), but data 
suggest that clinicians are less likely than patients to attribute nonadherence to 
side-effects (Vieta et al., 2012). Even though several studies have linked side-
effects to nonadherence (Baldessarini et al., 2008; Gitlin et al., 1989; Keck Jr et al., 
1997; Manwani et al., 2007), others have not (Kleindienst & Greil, 2004; Sajatovic 
et al., 2006; Scott & Pope, 2002). In the STEP-BD study, (Perlis et al., 2010) found 
only a weak association. Some have argued that it is the fear of side-effects rather 
than actual side-effects that predicts nonadherence (Scott & Pope, 2002). It may 
also be that, although side-effects influence nonadherence, their role is most 
important when other negative factors are also present. Schumann et al. 
(Schumann et al., 1999) noted that while side-effects were often reported as a 
reason for discontinuing medications, no differences were seen between adherent 
and nonadherent patients with respect to frequency and type of side-effects. Also, 
Rosa et al. (Rosa, Marco et al., 2007) reported that every patient, adherent or not, 
had side-effects from lithium. In this study, we found that most (65%) of the 
patients who attributed side-effects to explain mood stabilizer nonadherence also 
gave some other reason for it.  
Even though only a few differences existed between mood stabilizers and 
antipsychotics in the reasons the patients gave for nonadherence, their predictors 
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differed. Anxiety disorders predicted nonadherence to mood stabilizers but not to 
antipsychotics, whereas borderline personality disorder and current substance 
dependence predicted nonadherence to antipsychotics, but not to mood 
stabilizers. Negative attitudes predicted nonadherence to both mood stabilizers 
and antipsychotics. One possible explanation for these differences is differences in 
the patients for whom the medications were prescribed. However, there were no 
differences in the proportions of patients with substance use problems, anxiety 
disorders, personality disorders, including borderline personality disorder, or a 
low level of education. The reason for the differing adherence rates between 
medications may be related to the more sedative, anxiety-relieving, and weight-
gaining properties of atypical antipsychotics. 
In this study, the effect of comorbidity on adherence varied between 
medications. The findings regarding the role of comorbidity on adherence in 
previous studies are partly conflicting (Busby & Sajatovic, 2010). Comorbid 
substance abuse has been significantly correlated with poor treatment adherence 
in many (Baldessarini et al., 2008; Gonzalez-Pinto et al., 2006; Keck Jr et al., 
1997; Manwani et al., 2007; Perlis et al., 2010; Sajatovic et al., 2006; Sajatovic et 
al., 2007; Sajatovic et al., 2009; Teter et al., 2011) but not all studies (Colom et al., 
2000; Sajatovic et al., 2008). Anxiety disorder has seldom been reported as an 
important predictor of nonadherence. However, Perlis et al. (Perlis et al., 2010) 
found that current anxiety disorder at study entry was associated with poor 
adherence. Feske et al. (Feske et al., 2000) reported that a history of panic attacks, 
but not current or past anxiety, predicted poor adherence. There was no difference 
in the presence of anxiety between adherent and non-adherent patients in the 
studies by Sajatovic et al. (Sajatovic et al., 2006; Sajatovic et al., 2008). 
Comorbidity with personality disorder was the strongest factor in predicting poor 
compliance in the study of euthymic bipolar patients by Colom et al. (Colom et al., 
2000), but not by Schumann et al. (Schumann et al., 1999). 
In our study, negative attitude was an important predictor of nonadherence, 
the only predictor common to all treatments. Also, in previous studies, attitudes 
and beliefs have been related to medication adherence (Jamison et al., 1979; Pope 
& Scott, 2003; Sajatovic et al., 2009; Schumann et al., 1999; Scott & Pope, 2002). 
Schumann et al. (Schumann et al., 1999) even observed that a negative attitude 
toward prophylaxis was the only factor that correlated significantly with 
nonadherence. Scott and Pope (Scott & Pope, 2002) reported that attitudes and 
behavior were better predictors of nonadherence in BD than medication side-
effects. Also, Adams and Scott (Adams & Scott, 2000) found that highly adherent 
patients showed a greater perception of illness severity and had stronger beliefs 
about the benefits of treatment and that these variables were better predictors of 
adherence than side-effects. In addition, Dharmendra and Eagles (Dharmendra & 
Eagles, 2003) noted that adherence was associated with more positive attitudes 
toward lithium, but not with better lithium knowledge. However, knowledge and 
attitude were positively correlated. On the other hand, Rosa et al. (Rosa et al., 
2007) reported that knowledge level was directly related to treatment adherence. 
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Although we found that attitudes are quite stable, it may be possible to modify 
them (Strauss & Johnson, 2006). Attitudes can be modified with, for example, 
psychoeducation and cognitive therapy (Berk et al., 2010). Levin et al. (Levin et al., 
2015) reported the results of a secondary analysis of pooled data from two 
uncontrolled prospective trials of customized adherence enhancement (CAE), a 
psychosocial intervention delivered over four to six weeks. CAE is a module-based 
intervention flexibly administered to address the specific reasons a person with BD 
might be non-adherent with prescribed medications. Over two-thirds of the 86 
poorly adherent patients with BD who received CAE converted to good adherence. 
Converters had better medication attitudes than non-converters following 
treatment, even after controlling for baseline adherence. The authors concluded 
that their results support the notion that improved attitudes are a driver of 
behavioral change that translates into better adherence.   
 Although psychosocial treatments are effective components of managing BD 
(Miklowitz, 2008; Miklowitz & Scott, 2009), adherence to psychosocial treatments 
among patients with BD has rarely been studied. The only reported results are 
drop-out rates from psychotherapy studies, which have been similar to rates for 
pharmacotherapy nonadherence in BD (Busby & Sajatovic, 2010), consistent with 
our rates of psychosocial nonadherence. In our study, the main reasons patients 
with BD gave for poor psychosocial adherence were practical barriers to coming to 
sessions and lack of motivation. The independent predictors for nonadherence 
were negative attitudes toward psychotherapy and, somewhat unexpectedly, 
having an anxiety disorder. In previous studies, comorbid anxiety disorder has 
been associated with a more complicated course of BD (Lee & Dunner, 2008). 
Accordingly, non-adherent patients with anxiety disorder may form a subgroup 
with a more difficult course of BD.  
 
6.6.  Predictors of long-term disability in BD 
(study IV) 
Work is an important part of functioning and long-term working disability has 
many negative consequences. However, long-term work disability and disability 
pension among patients with BD has been very little studied. Only a few previous 
cross-sectional studies have reported on long-term working disability and 
disability pensions for patients with BD (Grande et al., 2013; Gutierrez-Rojas et 
al., 2011; Schoeyen et al., 2013). Consequently, the factors predicting long-term 
working disability and disability pensions among patients with BD are not well 
known. This study is the first prospective study of predictors for being granted a 
disability pension among patients with BD I and BD II. 
This study confirms the view of patients with BD having a poor prognosis, as 
after an acute episode, a quarter of the patients belonging to the labor force were 
granted a disability pension. Being granted a disability pension was predicted by 
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higher age, male gender, depressive index episode, comorbidity with GAD or 
avoidant personality disorder, and a higher number of psychiatric hospital 
treatments. In addition, patients’ subjective estimations of their vocational ability 
were surprisingly accurate in predicting the granting of a future disability pension. 
Moreover, the depression-related cumulative burden and proportion of time spent 
in depression during the follow-up were important predictors. On the other hand, 
the predictors seemed to be, in part, dependent on bipolar subtype, age, and 
gender. 
Twenty-one percent of the 191 patients were already on a pension before 
entering the study. During the 18-month follow-up, an additional quarter (25%) of 
the remaining 151 patients were granted a disability pension, which is more than 
twice the proportion of patients with unipolar MDD (11.3%) being granted a 
disability pension during a similar 18-month follow-up in the neighboring city of 
Vantaa, Finland (Rytsala et al., 2007). By the end of the 18-month follow-up, 
nearly half (41%) of the JoBS cohort patients had been granted a disability 
pension. The proportion of patients in the few previous studies that reported the 
proportions of patients unable to work has ranged from 15% to 22% (Kogan et al., 
2004; Reed et al., 2010; Suppes et al., 2001). Also, very few previous studies have 
reported the proportions of patients with BD receiving a disability pension 
(Grande et al., 2013; Gutierrez-Rojas et al., 2011; Schoeyen et al., 2011a; Schoeyen 
et al., 2011b; Schoeyen et al., 2013), the proportion  ranging from 17% among 
euthymic patients with BD (Grande et al., 2013) to 52.5% (also including patients 
who were in the process of receiving a disability pension) among patients selected 
from district computerized records as suffering from BD (Gutierrez-Rojas et al., 
2011). The proportions of bipolar patients with a long-term disability found in the 
present study are broadly similar to those in previous cross-sectional studies. 
However, regardless of the apparent similarity in percentages, they are only 
partially comparable, owing to differences in measures.  
Older age was strongly associated with being granted a disability pension, 
with an unadjusted risk among patients over 40 years of age more than double 
that of younger patients. Of the other sociodemographic factors, only male gender 
was also associated with risk. Grande et al. (Grande et al., 2013) and Schoeyen et 
al. (Schoeyen et al., 2013) also found higher age to be associated with receiving a 
disability pension. 
Of the illness-related factors, we found that the total number of psychiatric 
hospitalizations predicted being granted a disability pension during the follow-up. 
The number of hospitalizations has also been found to predict work functioning in 
many (Burdick et al., 2010; Dickerson et al., 2004; Elinson et al., 2007; Rosa et al., 
2009), but not all (Hammen et al., 2000) previous studies (Tse et al., 2014). 
However, the studies using the granting of a disability pension as an outcome 
measure differ somewhat regarding the significance of the number of 
hospitalizations. For example, Schoeyen et al. (Schoeyen et al., 2013) reported that 
the number of hospitalizations for depressive episodes predicted the granting of 
disability pension, Gutierrez-Rojas et al. (Gutierrez-Rojas et al., 2011) found that 
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repeated hospitalizations (three or more) were associated with being 
occupationally disabled, but Grande et al. (Grande et al., 2013) reported no 
association between the number of admissions and receiving a disability pension.  
In all, the number of previous hospitalizations likely represents a proxy for the 
long-term course of the illness, thus serving as a crude indicator of a recurrent and 
chronic course.  
Another important factor that predicted being granted a disability pension 
was depression. A depressive index episode and the proportion of time in 
depression during the follow-up predicted being granted a disability pension. 
Current depression, either syndromal or subsyndromal, is also one of the most 
consistent predictors of work functioning in previous studies (Huxley & 
Baldessarini, 2007; Sanchez-Moreno et al., 2009). It appears that even modest 
changes in the severity of depression are associated with changes in functional 
impairment and disability, whereas changes in mania or hypomania are not as 
consistently associated with differences in functioning (Altshuler et al., 2006; 
Judd et al., 2005; Simon et al., 2007). Even though the number of previous 
episodes has been reported to predict functional disability there has been no 
agreement about whether it is the previous manic or the previous depressive 
phases that have a more deleterious effect (Grande et al., 2013). In a long-term 
follow-up, Goldberg and Harrow (Goldberg & Harrow, 2011) found that depressive 
syndromes, but not manic syndromes, in the year preceding follow-up were 
significantly associated with poorer global, work, and social functioning.  Also, the 
studies using the granting of a disability pension as an outcome measure have 
reported somewhat discrepant findings on the impact of current and previous 
episodes on disability. For example, Gutierrez-Rojas et al. (Gutierrez-Rojas et al., 
2011) found current depressive symptoms and a higher number of previous manic 
episodes to be associated with being granted a disability pension. Also, Grande et 
al. (Grande et al., 2013) found an association between the number of manic 
episodes and being granted a disability pension in their euthymic patients but no 
association between the number of other phases and being granted a disability 
pension. In contrast, Schoeyen et al. (Schoeyen et al., 2013) found no difference in 
pensioned and non-pensioned patients with more than four episodes of depression 
or mania/hypomania.  In our study, the number of previous manic episodes, but 
not previous depressive phases, predicted being granted a disability pension, but 
the effect of manic phases disappeared when controlled for age and bipolar 
subtype. On the other hand, the granting of a disability pension was associated 
with more time spent in major depressive episodes and a greater proportion of 
time spent in depressive states overall during the follow-up.  In general, it seems 
that depression has a more current effect on vocational disability, whereas the 
effect of mania accumulates with a progressing number of episodes.  
Although, consistent with Grande et al. (Grande et al., 2013), we did not find 
anxiety disorders overall to be predictive of receiving a disability pension in our 
subjects, we found that one of the specific lifetime comorbid anxiety disorders, 
GAD, predicted being granted a disability pension. Comorbidity with anxiety 
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disorders has been associated in previous studies with a younger age at onset, 
greater overall morbidity reflected in more hospitalizations and worse overall 
prognosis, slower or inferior treatment responses, more substance abuse, and 
greater economic costs (Vazquez et al., 2014). Some anxiety disorders may be 
characterized as persistent rather than episodic and have trait-like aspects. In a 
study by Boylan et al. (Boylan et al., 2004) they found that of the anxiety 
disorders, GAD and social anxiety disorder had the most negative impact on 
outcome. They speculated that the adverse impact of GAD and social anxiety 
disorders may be explained by the clinical course of these anxiety disorders 
because for patients with either of these disorders, symptoms of negative 
emotionality, worry, and tension are likely to persist in euthymic periods. 
Although in our study social anxiety disorder did not predict the granting of a 
disability pension, avoidant personality disorder and, possibly, borderline 
personality disorder among the younger patients were predictors. Personality 
disorder comorbidity also predicted the granting of a disability pension in the 
study by Grande et al. (Grande et al., 2013), but the authors did not report the 
significance of specific personality disorders. Previous studies have revealed that 
co-occurring personality disorder features in patients with BD predict a worse 
outcome (Fan & Hassell, 2008). On the other hand, although Wenze et al. (Wenze 
et al., 2014) found that the degree of personality disorder pathology predicted 
depressive symptoms, they did not find an association with functional impairment.  
Loftus et al. (Loftus & Jaeger, 2006) also observed that comorbid personality 
disorder was associated with impaired functioning but this relationship was not 
independent of mood symptoms in multivariate analysis. The adverse effects of 
personality disorder comorbidity are likely to persist also during the euthymic 
period. Some patients may have coping capabilities that permit them to work 
effectively despite episodes or subsyndromal symptoms, whereas patients with 
comorbid personality disorder or GAD may function poorly even when their 
symptoms of BD do not attain the level of diagnosis.  
Many factors affect working ability, some of which may be conceived as 
subjective. Accordingly, one of our most striking findings was that patients’ 
subjectively perceived ability to work at the time of the baseline interview was the 
most powerful predictor of being granted a disability pension during the follow-up, 
if included as a predictor. This finding was in line with the results of the five-year 
follow-up of the analogous study among patients with MDD in Vantaa, Finland 
(the Vantaa Depression Study) (Holma et al., 2012). We found that a poor or 
lacking perceived ability to work was related to a more difficult course of BD and 
correlated with age, duration of disease, number of hospital treatments, and 
SOFAS score. Thus, the subjective perception appears firmly rooted in individual 
patients’ true illness experience, as well as the clinician-assessed current level of 
functioning. Still, perceived ability likely also captures other subjective aspects of 
vocational ability, such as feelings regarding ability to work and motivation to 
work. 
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7.  CONCLUSIONS AND FUTURE 
IMPLICATIONS 
 
7.1   Conclusions 
 
Treatment of BD depends on the illness phase and is complex, usually involving 
numerous medications to be started and discontinued. To receive adequate 
treatment for this disorder, a clinical diagnosis is by far the most important 
prerequisite. In addition, besides the correct diagnosis being crucial, rapid cycling 
and polyphasic episodes make receiving adequate treatment in secondary care less 
probable. Thus, a lack of attention to the longitudinal course of bipolar disorder 
appears to pose an obstacle to providing adequate treatment. Problems in 
treatment are associated mostly with outpatient settings, where adequacy of 
treatment of bipolar depression is a major concern. Thus, improving the quality of 
treatment of bipolar depression in psychiatric outpatient settings is a central 
public health issue.   
Provision of continuity in maintenance treatment is compromised in more 
than a third of patients with BD. As expected, clinical diagnosis plays a decisive 
role in determining adequacy of maintenance treatment. It seems that 
maintenance treatment mainly follows the treatment given in the acute phase, and 
the problems in the adequacy of maintenance treatment follow the shortcomings 
in the acute phase. In addition to the central role of clinical diagnosis, patients 
most at risk for receiving inadequate or intermittent maintenance treatment are 
those treated in outpatient settings and those with more vague or less prominent 
forms of symptoms such as BD II or comorbid personality disorders. 
However, even if patients receive adequate treatment, they often are 
nonadherent to the medications received. During a period of 18 months, more 
than half of the patients had either autonomously discontinued a medication or 
admitted to using it too irregularly to derive a benefit. The highest risk for 
discontinuing pharmacotherapy autonomously is present when patients are 
depressed. Even though rates of nonadherence appear not to differ between 
treatments, their predictors do. Moreover, adherence to one medication does not 
guarantee adherence to another, nor does a patient's adherence at one timepoint 
ensure adherence at another. Nonadherence to psychosocial treatment is an 
important problem and should be given more attention. Patients’ attitudes toward 
treatments influence adherence to all treatments and should therefore be given 
more attention and monitored. Because attitudes can be modified with 
psychosocial interventions (e.g., with psychoeducation), such interventions should 
be offered to all patients with BD. 
Our study contributes to the findings that BD places a major burden on 
patients and society. BD I and BD II are associated with a major risk of long-term 
work disability, with the proportion of patients with a disability pension rising to 
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41% in the 18-month follow-up. Severe clinical course, depressive burden, 
comorbid disorders, higher age, and male gender are likely to be the main 
predictors of being granted a disability pension for BD. In addition, patients’ 
subjective perceptions of their ability to work are a surprisingly correct in 
predicting their future work status. However, the predictors may vary depending 
on the subtype of illness, gender, and age group of the patient.    
 
 
7.2.  Clinical and research implications 
 
BD is a complex disease, with many different phases appearing in different 
sequences in time and requiring different treatments, so the clinician is faced with 
many more options than in the treatment of MDD.  The first, and often difficult, 
task is to recognize and diagnose BD. As the disease often begins with, and often 
involves years of, depression, it is not possible to make a diagnosis before the first 
manic, mixed or hypomanic phase. Also, even when the patient has experienced 
manic, mixed or hypomanic phases, the patient most often comes into contact 
with health services in a depressive phase and in that mood often does not 
remember or express having also had other kinds of phases. However, fortunately, 
the proportion of bipolar patients receiving a clinical diagnosis of BD has markedly 
increased in the last 10 to 20 years.  Even so, the importance of making the right 
diagnosis cannot be overemphasized.  
Unfortunately, once the right diagnosis is finally made the difficulty does not 
end. To make the right treatment decision, it is not enough to recognize the nature 
of the acute phase; the clinician also has to work out how the disease developed 
earlier, the longitudinal course of BD.  So, even if the clinician makes the right 
treatment choice considering the phase the patient is suffering at that moment, the 
decision may be inadequate when considering the phases before the current one. 
Also, even if the decision is right at that moment, the phase and the longitudinal 
course may change, demanding new decisions and changes to the treatment. In 
particular, this is the case with rapid cycling or polyphasic episodes.  
Our studies show that the adequacy of treatment of BD is compromised in 
both the acute and the maintenance phases of the disorder. Besides clinical 
diagnosis, one of the most difficult aspects in considering the adequacy of 
treatment, in both the acute and maintenance phases, is taking the longitudinal 
course into account. Thus, antidepressants are often used in patients with a rapid 
cycling course even if practice guidelines and evidence show that antidepressants 
should not be used if there is a rapid cycling course, not even when the present 
phase is depression. Also, treatments are not easily discontinued or changed, even 
if the phase changes. This is also reflected in the maintenance phase where 
problems seem to follow the shortcomings of the treatment in the acute phase. The 
problems are especially seen in the outpatient context where most bipolar 
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depressions are treated. Because of these difficulties, a life chart should always be 
created for patients with BD and available when treatments are considered.  
A lot has happened since our study was conducted; people with BD are being 
diagnosed much more often, sometimes even too often, and the prescription of 
mood stabilizing agents has increased. However, the use of antidepressants 
deserves attention because the rate has been stable or possibly increased since the 
time of study, although evidence for the efficacy of antidepressants in BD is poor; 
antidepressants are only recommended in acute depression in addition to mood 
stabilizing agents in some guidelines, but are not recommended as maintenance 
treatment. However, despite the stable or increased use of antidepressants, the 
proportion of patients receiving antidepressant monotherapy has fortunately 
decreased. The high use of antidepressants may partly reflect that treatment of 
bipolar depression is still problematic as only a few effective choices exist, and 
they help only a proportion of patients. So, the prescription of antidepressants 
may be an effort to help people with bipolar depression in some way, as learned 
from the treatment of MDD. However, when prescribed, the antidepressants are 
often not discontinued after the depression has remitted and are continued in the 
maintenance phase. There is a need for studies investigating the factors affecting 
the prescribing patterns in BD with the increasing knowledge of BD among 
clinicians and the changes that have occurred in the trends of prescribing 
medications to patients with BD. What medications, in which situation, and why 
the clinician prescribes are important to understand when educating clinicians.   
However, even if adequate treatment is prescribed, it is left to the patient to 
take the medicine. More than half of patients with BD either discontinue the 
treatments or do not take them regularly enough to get benefits of them. The first 
clinical problem is how to recognize nonadherence. As clinicians are reported to be 
poor at recognizing adherence problems, the use of other methods, like scales, 
electronic monitoring, and serum concentrations (see, e.g., Sajatovic et al. 
(Sajatovic et al., 2010)) to monitor adherence would be important. As problems 
exist with every method, it is advisable to use more than one method.  The second 
problem is how to help patients be more adherent. Psychosocial interventions 
(e.g., psychoeducation) have been shown to be efficient in fostering adherence 
among patients with BD and should be offered to patients with BD. The reasons 
and thus treatment for nonadherence differ for each individual and so must be 
customized for each patient. As the problem is especially high during depressive 
phases, attention should be given to evaluate and help patients with depression 
adhere to their treatments.  
Long-term work disability has been researched surprisingly seldom, 
especially when taking into account the tremendous burden of the disease on the 
patient and society as a whole. The factors affecting working disability are still 
poorly understood. Our study is the first prospective longitudinal study of the 
predictors of long-term working disability. As expected, a more severe course of 
the disease predicted long term working disability, as well as current depressive 
states. Care should be taken that these patients get individually tailored treatment 
 112 
 
 
with adequate acute and maintenance treatment, including psychosocial 
treatment, monitored for adherence and the course of the disease followed with a 
life chart, and have an easy access to care in case of worsening symptoms. We 
found that comorbidity with GAD or avoidant personality disorder predicted being 
granted a disability pension. The effect of treating these comorbidities on long-
term disability should be studied, especially if our findings can be replicated in 
other studies. We found that patients’ subjectively perceived disability at the acute 
phase was a surprisingly correct forecast of being granted a disability pension in 
the near future. So this simple question could be of help for the clinician to be used 
when assessing the patients’ risk of future long-term disability. 
BD has been proposed to be a neuroprogressive disease, but there is still not 
enough evidence for that claim. Many patients with BD experience a progressive 
decline of functioning, which may be the result of a slowly accumulating load of 
different elements (allostatic load) that in the end results in long-term disability. 
Also, some patients may be less capable of carrying this load, like those who have 
been abused in childhood, those who are less educated, and patients with 
comorbidities. It may also be that there are (genetically) different populations of 
BD, with different prognosis from the start. Accordingly, there may be a (genetic) 
subpopulation of patients with BD who have many of the factors associated with 
chronicity, like poor response to medications, increasing frequency of episodes, 
and cognitive deficits.  
As cognition has often been associated with functional disability, it would be 
important to investigate the role of cognition compared to other (clinical) factors 
affecting disability in different phases and especially longitudinally. Treatments 
like functional remediation may offer a better functional prognosis in cognitively 
disabled patients.  
More studies on the reasons for long-term disability are needed to help us 
find better ways to prevent functional decline. It has been reported that the 
functional prognosis of BD has not improved in the last decades despite the 
modern treatments, indicating that our treatments are not effective in preventing 
functional disability. 
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